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1.  Microwave Assisted Organic Synthesis: 
 
1.1 Introduction 
Synthesis of new chemical entities is major bottleneck in drug discovery. 
Conventional methods for various chemical synthesis is very well documented and 
practiced.1 The methods for synthesis (Heating process) of organic compounds has 
continuously modified from the decade. In 1855, Robert Bunsen invented the burner 
which acts as energy source for heating a reaction vessel, this was latter superseded 
by isomental, oil bath or hot plate, but the drawback of heating, though method 
remain the same. Microwave Assisted Organic Synthesis (MAOS), which has 
developed in recent years, has been considered superior to traditional heating. 
Microwave assisted organic synthesis2 (MAOS) has emerged as a new “lead” in 
organic synthesis. The technique offers simple, clean, fast, efficient, and economic for 
the synthesis of a large number of organic molecules. In the recent year microwave 
assisted organic reaction has emerged as new tool in organic synthesis. Important 
advantage of this technology include highly accelerated rate of the reaction, 
Reduction in reaction time with an improvement in the yield and quality of the 
product. Now day’s technique is considered as an important approach toward green 
chemistry, because this technique is more environmentally friendly. This technology 
is still under-used in the laboratory and has the potential to have a large impact on the 
fields of screening, combinatorial chemistry, medicinal chemistry and drug 
development. Conventional method of organic synthesis usually need longer heating 
time, tedious apparatus setup, which result in higher cost of process and the excessive 
use of solvents/ reagents lead to environmental pollution. This growth of green 
chemistry holds significant potential for a reduction of the by product, a reduction in 
waste production and a lowering of the energy costs. Due to its ability to couple 
directly with the reaction molecule and by passing thermal conductivity leading to a 
rapid rise in the temperature, microwave irradiation has been used to improve many 
organic syntheses. 
 
 
 
1.2 Microwave frequency 
Microwave heating refers the use of electromagnetic waves ranges from 0.01m to 1m 
wave length of certain frequency to generate heat in the material. These microwaves 
lie in the region of the electromagnetic spectrum between millimeter wave and radio 
wave i.e. between I.R and radio wave. They are defined as those waves with 
wavelengths between 0.01metre to 1meter, corresponding to frequency of 30GHz to 
0.3GHz. 
 
1.3 Principle 
The basic principle behind the heating in microwave oven is due to the interaction of 
charged particle of the reaction material with electro magnetic wavelength of 
particular frequency. The phenomena of producing heat by   electromagnetic 
irradiation are ether by collision or by conduction, some time by both.  
All the wave energy changes its polarity from positive to negative with each cycle of 
the wave. This cause rapid orientation and reorientation of molecule, which cause 
heating by collision. If the charge particles of material are free to travel through the 
material (e.g. Electron in a sample of carbon), a current will induce which will travel 
in phase with the field. If charge particle are bound within regions of the material, the 
electric field component will cause them to move until opposing force balancing the 
electric force.3-9  
1.4 Heating Mechanism 
In microwave oven, material may be heated with use of high frequency 
electromagnetic waves. The heating arises from the interaction of electric field 
component of the wave with charge particle in the material. Two basic principal 
mechanisms involve in the heating of material 
1.4.1 Dipolar Polarisation 
Dipolar polarisation is a process by which heat is generated in polar molecules. On 
exposure to an oscillating electromagnetic field of appropriate frequency, polar 
molecules try to follow the field and align themselves in phase with the field. 
However, owing to inter-molecular forces, polar molecules experience inertia and are 
unable to follow the field. This results in the random motion of particles, and this 
random interaction generates heat. Dipolar polarisation can generate heat by either 
one or both the following mechanisms:  
  
1.  Interaction between polar solvent molecules such as water, methanol and ethanol  
2.  Interaction between polar solute molecules such as ammonia and formic      acid  
  
The key requirement for dipolar polarisation is that the frequency range of the  
oscillating field should be appropriate to enable adequate inter -particle interaction. If 
the frequency range is very high, inter-molecular forces will stop the motion of a 
polar molecule before it tries to follow the field, resulting in inadequate inter-particle 
interaction. On the other hand, if the frequency range is low, the polar molecule gets 
sufficient time to align itself in phase with the field. Hence, no random interaction 
takes place between the adjoining particles. Microwave radiation has the appropriate 
frequency (0.3-30 GHz) to oscillate polar particles and enable enough inter-particle 
interaction. This makes it an ideal choice for heating polar solutions.  
In addition, the energy in a microwave photon (0.037 kcal/mol) is very low, relative 
to the typical energy required to break a molecular bond (80-120 kcal/mol). 
Therefore, microwave excitation of molecules does not affect the structure of an 
organic molecule, and the interaction is purely kinetic.   
  
1.4.1. a Interfacial Polarization 
Interfacial polarization is an effect, which is very difficult to treat in a simple manner, 
and easily viewed as combination of the conduction and dipolar polarization effects. 
This mechanism is important for system where a dielectric material is not 
homogenous, but consists of conducting inclusion of one dielectric in other.  
1.4.2. Conduction mechanism  
The conduction mechanism generates heat through resistance to an electric current. 
The oscillating electromagnetic field generates an oscillation of electrons or ions in a 
conductor, resulting in an electric current. This current faces internal resistance, which 
heats the conductor.   
  
The main limitation of this method is that it is not applicable for materials that have 
high conductivity, since such materials reflect most of the energy that falls on them.   
 
 
 
 
 
 
1.5. Effects of solvents 
 
Every solvent and reagent will absorb microwave energy differently. They each have 
a different degree of polarity within the molecule, and therefore, will be affected 
either more or less by the changing microwave field. A solvent that is more polar, for 
example, will have a stronger dipole to cause more rotational movement in an effort 
to align with the changing field. A compound that is less polar, however, will not be 
as disturbed by the changes of the field and, therefore, will not absorb as much 
microwave energy. Unfortunately, the polarity of the solvent is not the only factor in 
determining the true absorbance of microwave energy, but it does provide a good 
frame of reference. Most organic solvents can be broken into three different 
categories: low, medium, or high absorber, as shown in Figure 6. The low absorbers 
are generally hydrocarbons while the high absorbers are more polar compounds, such 
as most alcohols. 
 
Absorbance level Solvents 
High 
DMSO, EtOH, MeOH, Propanols, 
Nitobenzen, Formic Acid, Ethylene 
Glycol 
Medium 
Water, DMF, NMP, Butanol, 
Acetonitrile, HMPA, Methy Ethyl 
Ketone, Acetone, Nitromethane, 
Dichlorobenzene, 1,2-Dichloroethane, 
Acetic Acid, trifluoroacetic Acid, 
Low 
Chloroform, DCM, Carbon tetrachloride, 
1,4-Dioxane, Ethy Acetate, Pyridine, 
Triethyamine, Toluene, Benzene, 
Chlorobenzene, Pentane, Nexane and 
other hydrocarbons 
 
 
 
1.6 Conventional vs Microwave Heating 
Microwave heating is different from conventional heating in many respects. The 
mechanism behind microwave Synthesis is quite different from conventional 
synthesis. Points enlisted in Table 1, differ the microwave heating from conventional 
heating.10-26 
No CONVENTIONAL MICROWAVE 
1 
Reaction mixture heating proceeds 
from a surface usually inside surface of 
reaction vessels 
Reaction mixture heating proceeds 
directly inside mixture 
2 
The vessel should be in physical 
contact with surface source that is at a 
higher temperature source (e.g. mental, 
oil bath, steam bath etc.) 
No need of physical contact of 
reaction with the higher temperature 
source. While vessel is kept in 
microwave cavities. 
3 
By thermal or electric source heating 
take place. 
By electromagnetic wave heating take 
place. 
4 
Heating mechanism involve- 
conduction 
Heating mechanism involve- 
dielectric polarization and conduction 
5 
Transfer of energy occur from the wall, 
surface of vessel, to the mixture and 
eventually to reacting species 
The core mixture is heated directly 
while surface (vessel wall) is source 
of loss of heat 
6 
In conventional heating, the highest 
temperature (for a open vessels) that 
can be achieved is limited by boiling 
point of particular mixture. 
In microwave, the temperature of 
mixture can be raised more than its 
boiling point i.e. superheating take 
place 
7 
In the conventional heating all the 
compound in mixture are heated 
equally 
In microwave, specific component 
can be heated specifically. 
8 Heating rate is less Heating rate is several fold high 
 
 
1.7 Application of microwave in organic synthesis 
Following reactions have been performed through microwave heating.  
Sr. Reaction Ref. Sr Reaction Ref. 
1 Acetylation reaction 27 18 Diel’s-Alder reaction 44 
2 Addition reaction 28 19 Dimerization reaction 45 
3 Alkylation reaction 29 20 Elimination reaction 28 
4 Alkynes metathesis 30 21 Estrification reaction 46 
5 Allylation reaction 31 22 Enantioselective reaction 47 
6 Amination reaction 32 23 Halogenation reaction 48 
7 
Aromatic nucleophillic 
substitution reaction  
33 24 Hydrolysis reaction 59 
8 Arylation reaction 34 25 Mannich reaction 50 
9 Carbonylation reaction 35 26 Oxidation reaction 51 
10 Combinatorial reaction 36 27 Phosphorylation synthesis 52 
11 Condensation reaction 37 28 Polymerization reaction 53 
12 Coupling reaction 38 29 Rearrangement reaction 54 
13 Cyanation reaction 39 30 Reduction reaction 55 
14 Cyclization reaction 40 31 Ring closing synthesis 56 
15 Cyclo-addition reaction 41 32 Solvent free reaction 57 
16 Deacetylation reaction 42 33 Transestrification reaction 46 
17 Dehalogenation reaction 43 34 Transformation reaction 58 
 
           
Figure 1.2: General View of Monomode CEM Discover (left) and Multimode 
MILESTONE Start (right) Systems 
 
1.8 Studies on 2-Aminoimidazoles 
 
Much effort has been dedicated to the study of molecular architecture and its 
relationship to biological activity. From decades of high throughput screening of both 
natural and synthetic small molecules we have clued in on structural features that 
impart a high probability of biological efficacy.59 Recently natural products have 
enjoyed a renaissance in lead generation for discovery based research. This realization 
has further been folded into the concept of Biology-oriented synthesis (BIOS) which 
relies on the core structures of natural products as valuable pre-validated scaffolds.60  
These so-called “privileged” pharmacophores are often the basis of synthetic 
collections aimed at increasing the success rate of small molecule screening ventures. 
 
In particular, marine natural products derived from sponges have provided valuable 
leads for therapeutic small molecules.61-62 Surprisingly the large majority of these 
compounds have been isolated from organisms of the class Dermospongiae. In the 
mid 1980’s chemists noted that the other major sponge class, Calcarea, had rarely 
been subject to chemical investigations. A flurry of efforts through the mid-1990’s 
helped to establish biogenetic relationships among these sponges. Isolated to explore 
these interconnections and not necessarily for specific biological responses the 
activities of these natural products have remained largely uncovered. Since these 
initial investigations, an emerging structural class has recurrently been identified 
through bioassay guided isolation which contains the 2-aminoimidazole core. From 
the viewpoint of small molecule discovery this review will highlight alkaloids isolated 
from Leucetta sp. This small skeletal family has been shown to interrogate an 
incredibly diverse range of biological processes and thus represents an important 
discovery scaffold for both medicinal and discovery based research. 
 
In 1958, a nitrogen rich antibiotic, consequently named azomycin, was isolated from a 
presumptive Streptomyces sp.63 This new antibiotic displayed good antimicrobial 
activity against B. subtilis (6 μg/mL) and E. coli (25 μg/mL) and was relatively well 
tolerated  in mice (LD50 = 80 mg/kg). Eventually the structure of azomycin was 
revealed to be 2-nitroimidazole (2)64, which along with its synthetic derivative 
metronidiazole (3) have become clinically relevant antiprotozoal therapeutics (Fig. 
1.8.1).65 With the parallel observation that several microbes were able to oxidize 
aromatic amines, Lancini’s group showed some Streptomyces species are able to 
oxidize 2-aminoimidazole itself, along with a series of 4-alkyl-2-aminoimidazoles, to 
their corresponding 2-nitroimidazoles.66 This suggested that the 2-aminoimidazole 
might be the direct biosynthetic precursor to azomycin and in 1970 Okami’s group 
isolated the parent heterocycle (1) from  Streptomyces eurocidicus.67 This study also 
showed that supplementing the growth medium with L-Arg substantially increased the 
production of 1, suggesting that arginine catabolism is critical to its biosynthesis. It is 
unknown whether a similar pathway exists in marine organisms that produce more 
complex 2-aminoimidazoles, however 1 has been discovered in sponges of the family 
Halicondriidae.68 
L-Arg
N
NH
NH2
N
NH
NO2
N
N
Me
NO2
OH
1 2 3
2-Aminoimidazole Azomycin Metronidazole  
    Fig.1.8.1 Biosynthetic transformations of 2-aminoimidazole.  
 
Studies on azomycin’s (2) and metronidazole’s (3) mechanism of action have 
revealed that the nitro group is reduced in vivo to the nitroso radical which is 
responsible for its selective anaerobic antiprotozoal activity.69 Subsequent studies 
have shown that hypoxic conditions in tumors are also capable of reducing the 2-
nitorimidazole, prompting it to serve as an important prodrug for 2-aminoimidazoles 
in hypoxic environments.70-72 
The ambivalent reactivity of the key structural motif 2-amino-1H-imidazole (4) is 
responsible for the molecular diversity observed in this group of alkaloids. The 
electrophilic or nucleophilic reactivity at the same position C-4(5) is dependent on the 
tautomeric isomer involved (Scheme 1.8.1).73 
nucleophilic 
position
HN N
NH2
N N
NH
5
H H
1
2
3
4 5
N N
NH2
5
electrophilic 
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4
 
Scheme-1.8.1 The Tautomerism and Ambivalent Reactivity of 2-    
Aminoimidazole 
It is understood that the 2-aminoimidazole occupies an important region of chemical 
space as its hydrogen bond donor-acceptor pattern is capable of recreating that of the 
guanidine.74 More importantly, it occupies a unique pKa range between the more 
acidic 2-aminopyridinium ion75 and less acidic guanidinium ion76 (Fig.1.8.2). 
Furthermore, the pKa’s of 2-aminoimidazolium ions show a predictable trend with 
substitution, allowing it to be finely tuned for medicinal applications as illustrated in 
the examples below.77   
N NH2 N
H
N
NH2
2-Aminopyridine 2-aminobenzimidazole
pKa = 6.71 7.18
NHN
NH2
NHN
NH2
NHN
NH2
Me MeMe
pKa = 8.46 8.65 9.21
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Fig.1.8.2 pKa’s of common guanidine mimetics  
 
This dramatic difference in the pKa of 2-aminoimidazoles (~4 pKa units) with that of 
guanidine has led to some debate concerning the ability of the 2-aminoimidazole to 
directly mimic a guanidine. These arguments, based on a lowered pKa and electronic 
dissimilarity are, however, precisely what makes the 2-aminoimidazole a unique 
guanidine mimic for medicinal chemistry.-77-78 Most importantly, their pKa range 
(pKa ~7-9) allows a significant fraction of compound to be uncharged at 
physiological pH thus increasing the likelihood of cellular penetration. It also permits 
this unique heterocycle to cross the blood brain barrier and may decrease the 
susceptibility of these compounds to Pgp mediated efflux vide infra.79   
 
1.9 2-Aminoimidazole Alkaloids 
 
The 2-aminoimidazole framework is emerging as an important pharmacophore,80 and 
is widely found in numerous biologically active marine alkaloids. Over the last 25 
years, several hundreds of diverse 1-unsubstituted and 1-substituted 2-
aminoimidazoles have been characterized. 1-Unsubstituted 2-aminoimidazole 
alkaloids (Fig. 1.9.1) have been isolated essentially from various species of marine 
sponges (Phylum Porifera) of Caribbean and South Atlantic regions.81 Oroidin (1) and 
the dimeric sceptrin (3) are the most abundant members of the pyrrole-imidazole 
family. 
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Fig.1.9.1 Some representative 1-unsubstituted 2-aminoimidazoles from marine 
sponges.  
In turn, most of the 1-substituted 2-aminoimidazole alkaloids (Figure 1.9.2) have been 
isolated from the Calcarea group of the genera Leucetta and Clathrina from the Red 
Sea and the Indo-Pacific regions.82 
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Fig.1.9.2  Some representative 1-substituted 2-aminoimidazoles from 
marine sponges. 
 
Both classes of 1-substituted and 1-unsubstituted 2-aminoimidazoles possess 
interesting biological properties. Due to their high cytotoxicity many polysubstituted 
2-aminoimidazole alkaloids are involved in chemical defense of marine sponges 
against predators, in the prevention of the settlement of fouling and pathogenic 
microorganisms or in the suppression of epibiotic bacteria and spatial competition.  
 
 
Recently group of Erik83 described a novel, short and efficient synthesis of diverse 2-
aminoimidazoles from readily available polysubstituted secondary propargylamines 
and thioureas (Scheme-1.9.1). Both the guanylation and the cyclization steps can be 
carried out either in a stepwise manner with a carbodiimide activator and an AgI 
catalyst or in a one-pot process with a recoverable AgI salt as a promoter and catalyst. 
This protocol was successfully applied to the total synthesis of all trisubstituted 2-
aminoimidazole naamine alkaloids. Furthermore, we demonstrated the potential of 
polysubstituted 2-aminoimidazoles as inhibitors of bacterial biofilm formation.  
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Scheme 1.9.1 Short total synthesis of alkaloid of the naamine family 
Pierre Potier proposed biogenetic scheme, various hypothetical constituents can be 
predicted. It is clear that the above chemical pathway suggests that these compounds 
may be more widespread than presently known. The isolation and characterisation of 
new pyrrole-imidazole metabolites will certainly allow us to explore additional 
transformations which could support this hypothesis. As chemical diversity, 
enzymatic catalysis variation and mutagenesis are closely related, the ‘‘prebiotic 
chemistry’’ presented here can also provide strong evidence for a multifunctional 
enzyme-mediated biosynthesis. Such multiprotein systems would be particularly 
needed by the living fixed sponges for their adaptation to environmental influences, 
and for self-defence. 
 
 
 
Fig.1.9.3 Arrangement of all known oroidin alkaloids in structural groups. 
 
 
 
 
 
1.10 Methods for the preparation of 2-aminoimidazoles  
 
Several methods for the formation of 2-aminoimidazoles are known with widely 
differing degrees of synthetic utility, but no current method as of yet has a broad 
range of applicability in complex molecule synthesis. Harsh reaction conditions 
and/or synthetically difficult and labile precursors are often required for such task. 
The methods to prepare 2-aminoimidizoles may be categorized into four main classes: 
 
1) Condensation reactions,  
2) Ambivalent addition of 2-aminoimidazole,  
3) Direct formation of C-N bond. 
4) Heterocyclic exchange reactions.  
 
Functionalized 2-aminoimidazoles can show a wide range of stability issues, the free 
base of many substrates is susceptible to nucleophilic or base mediated degredation. 
This instability has thus far precluded a unified strategy to access this heterocycle, but 
the variety of methods can often lead to success in a complex molecule setting. 
 
1.10.1 Condensations   
 
 By far the most common way to prepare the 2-aminoimidazoles originates with the 
condensation of α-amino or α -haloketone with cyanamide or a guanidine derivative, 
respectively. This strategy was first disclosed by Norris and McKee who explored the 
condensation of α -aminoacetophenones with  N-cyanoguanidines (scheme-1.10.1).84 
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Scheme-1.10.1 Norris and McKee‘s condensation. 
 
Subsequently Lawson was able to show that aminoacetaldehyde diethylacetal can 
undergo acid catalyzed addition to cyanamide giving the masked guanidine 
acetaldehyde (Scheme-1.10.2).85 
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Scheme-1.10.2  Lawson’s synthesis. 
 
Kruetzberger found that condensation of 1,2-hydrazinedicarboxamidine with benzoin 
derivatives in alkali media will yield symmetrically substituted azoimidazoles after 
spontaneous oxidation of the  bis-imidazolhydrazine (Scheme-1.10.3).86 Reductive 
cleavage of the azo group by hydrogenolysis gives two mole equivalents of the 2-
aminoimidazole. This methodology is useful but limited to the preparation of 4,5-
diaryl substituted 2-aminoimidazoles. 
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Scheme-1.10.3 Kruetzberger’s condensation. 
 
In 1966, Lancini and Lazzari successfully expanded Lawson’s strategy to include α -
aminoketones, including the use of N-alkylamines (Scheme-1.10.4).87-88 They were 
the first to observe the strict pH dependence of this condensation. At very low pH the 
cyanamide is quickly converted to urea. At high pH, dimerization of the aminoketone 
to the piperazine competes with cyanamide condensation. Having established the 
optimum pH of the reaction to be ~4.5, these conditions are now routinely adopted. In 
1925 Pyman and Burtles had reported the reaction of α-bromoacetone and guanidine 
to give a mixture of uncharacterizable compounds, leading them to abandon this 
approach and develop their diazonium coupling described below.89 Seventy years 
later, Weber discovered that N-acetylguanidine smoothly undergoes displacement and 
condensation with α -haloketones and aldehydes.90 
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Scheme-1.10.4 Lancini and Lazzari’s expanded strategy 
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Scheme-1.10.5 Weber’s condensation with  N-acetylguanidine. 
 
In the late 1970’s Nishimura reported the condensation of substituted α-diketones 
with guanidine to yield a variety of useful products (Scheme-1.10.6).91 This report 
illuminates the variety of chemistry that is possible around this heterocyclic core. 
Treatment of a diketone with guanidine in dioxane and methanol yields the substituted 
bicyclic  bis-guanidine . Alternatively, aprotic reaction conditions can selectively 
deliver the 2-aminoimidizo-4-ol. This intermediate can undergo a base catalyzed 
pinacol-type rearrangement to form the 2-aminoimidizo-4-one. This same 
intermediate can give rise to the 4,5-diol upon exposure to aqueous hydrochloric acid. 
A similar hydration reaction with anhydrous HCl affords the di-methoxylated 
derivative. Hydrogenolysis of 2-aminoimidizo-4-ol cleanly gives the 4,5-dialkyl-2-
aminoimidazole. These laboratory transformations foreshadow potential biosynthetic 
relationships between the 2-aminoimidazole natural products isolated from marine 
sponges. 
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Scheme-1.10.6 Nishimura’s diketone condensation 
 
 
 
1.10.2 Ambi-valent Addition of 2-Aminoimidazole  
 
Depending on reaction conditions, the parent heterocycle, 2-aminoimidazole, can be 
influenced to react either at N-2 or C-4. In Potier’s synthesis of girolline, 2-
aminoimidizole was added directly to the α-chloroaldehyde. Under the influence of 
sodium carbonate, the imidazole adds preferentially through the 4-position (Scheme-
1.10.7 ).92 As revealed in Horne’s synthesis of stevensine, methanesulfonic acid was 
used to add the 2-aminoimidazole across an olefin.93-94 Horne has also shown that 
Friedel-Crafts type alkylation of the activated ethers can proceed with attack by C-4 
in the presence of methanesulfonic acid to give stevensine (Scheme-1.10.7). 
Alternatively, triflouroacetic acid persuades N-2 addition to give the N-alkylated 2-
aminoimidazole.  
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Scheme-1.10.7 Potier’s Ambi-valent additions of 2-aminoimidazole 
 
H
N
N
H2N
N
H
Br
Br
NH
MeO
Br
O
N
H
Br
Br
NH
O
N
HN
H2N
MsOH
90 oCTFA rt.
N
H
Br
Br NH
HN Br
O
N
HN
Stevensine
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1.10.3 Formation of C-N bond.  
 
It is now clear that, condensation reactions are applicable to the preparation of mono- 
and di-substituted 2-aminoimidazoles. To generate more highly substituted 2-amino 
imidazole cores, the direct introduction of N-2 on an appropriately substituted 
imidazole is frequently applied. The first method for forming 2-aminoimidazoles, in 
this manifold, was reported in 1925 by Burtles and Pyman who showed that azo-
bromoaniline and dimethylimidazole underwent aromatic substitution to form the 
hydrazone (Scheme-1.10.9).The aryl hydrazone was then readily reduced by Zn dust 
and aqueous acetic acid or stannous chloride and hydrochloric acid.  
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Scheme-1.10.9  Pyman’s synthesis. 
 
Hassner was the first to report the reaction of imidazole lithium with a vinyl azide, 
hydrolysis of the intermediate triazine gives the aminoimidazole.95 Since that report, 
Potier has popularized the use of lithiated imidazoles.96 Potier reported that lithiation 
with LDA followed by azide transfer from TsN3 efficiently generated the 2-
azidoimidazoles (Scheme-1.10.10). Hydrogenolysis of the azide proceeds smoothly to 
give the 2-aminoimidazole, exemplified in his synthesis of keramidine.97 
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Scheme-1.10.10 Potier’s method via lithiation.  
 
Lithiated imidazoles can also be trapped by disulfides to give the 2-thioimidazoles. 
Oxidation to either the sulfone or sulfoxide creates a leaving group capable of 
displacement with azide (Scheme-1.10.11).98 This strategy has been utilized by 
Weinreb in the synthesis of ageladine A.99-100 
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Scheme-1.10.11 Anderson’s method of synthesis. 
To avoid lithiation, Ohta has shown that 2-bromoimidazoles can undergo palladium 
catalyzed coupling with trimethylsilylazide (Scheme-1.10.12). Reduction again 
provides the 2-aminoimidazole. This strategy has been implemented by Ohta’s group 
to access several Leucetta alkaloids discussed below. Also, noteworthy, Ohta has 
shown that during reduction of the azide it can be directly protected as its 
benzylidenimine.101-102 
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  Scheme-1.10.12 Ohta’s palladium catalyzed synthesis. 
 
1.10.4 Heterocyclic Exchange Reactions  
  
The transformation of 3-amino-1,2,4-oxadiazoles to 2-aminoimidazoles can be carried 
out by reaction with fluorinated ß-dicarbonyls to give the ß-hemiaminal (Scheme-
1.10.13).103 This can undergo subsequent conversion to the 2-amidoimidazole through 
a Boulton-Katritzky Rearrangement. This intermediate can then be reduced to give 
Intermediate. The benzamide can also be removed via acid catalyzed hydrolysis to 
give the trifluoromethyl amino-imidazole. An interesting reaction, however the 
synthesis of the intermediate ß-enaminocarbonyl is low yielding and initial results 
suggest limited substituent scope, as the initial condensation requires the presence of 
the trifluoromethyl ketone. 
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Scheme-1.10.13 Boulton-Katritzky rearrangment of aminooxadiazoles. 
Another route to 4(5)-acyl-2-amino-1H-imidazoles is based on the recyclization of 5-
acyl-2-amino-1,3-oxazoles (Scheme-1.10.14).104 For example, 5-acetyl-2-amino-
oxazole gave upon heating in water solution with ammonia or aliphatic amines 2-
amino-1H-imidazoles in 32% (R = H) and 43-62% (R = alkyl or cycloalkyl) yields. 
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Methodology to prepare 2-aminoimidzoles has greatly advanced due to the rising 
demand in natural product synthesis and medicinal chemistry. However, the 
development of methods to succinctly generate a highly functionalized 2-
aminoimidazole core from stable precursors is warranted.   
 
1.11 The 2-Aminoimidazole as a Pharmacophore 
 
The 2-aminoimidazole has been utilized as a building block has led to the 
development of several medicinally relevant small molecules. 
1.11.1 Antibiotics Activity 
 
Researchers at Zeneca delivered a series of broad spectrum antibiotics a-c, inspired by 
the well studied cephalosporins.106-106 They were further able to show that substitution 
on N1 of the aminoimidazole led to inactive compounds, again suggesting that this 
motif may make an acid hydrogen bond contact (Fig. 1.11.1). Interestingly they were 
able to correlate the pKa of the 2-aminoimidazole with activity. Against Gram 
positive organisms they found that a slight elevation in the pKa led to a dramatic 
decrease in activity. For Gram-negative bacteria, there was little difference, 
suggesting pKa may alter the membrane permeability. 
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Fig-1.11.1 2-aminoimidazole modified cephalosporins. 
 
1.11.2 Sodium Hydrogen Exchanger-1 (NHE-1) Antagonists. 
 
Scientists at Bristol-Meyers Squibb have noted the ability of the 2-aminoimidazole to 
function as a bioisostere of acylguanidines.106 Looking to produce novel inhibitors of 
the sodium hydrogen exchanger-1 (NHE-1) they aimed at replacing the acylguanidine 
in their lead compounds (Fig. 1.11.2). They surveyed a number of heterocyclic 
analogues that would conserve the pKa of the acylguanidine as a cationic species, 
necessary for antagonism of the Na+ transporter. 
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Fig.- 1.11.2 NHE-1 antagonists. (NHE-1 Inhibition IC50 (µm)) 
 
1.11.3 Anti HIV Activity 
 
Much effort has been dedicated to the development of HIV protease (HIV PR) 
inhibitors for the treatment of AIDS. The protease is responsible for the processing of 
nascent polypeptides to mature proteins comprising the viral particle. Without the 
formation of the mature particle, viral replication of HIV has been shown to be 
inhibited. HIV PR has therefore been an active biochemical target for the 
development of small molecule therapeutics.   
 
Wilkerson and co-workers at DuPont-Merck had developed a cyclic urea-based HIV 
PR inhibitor scaffold which possessed an acceptable pharmacokinetic profile, but 
lacking the potency necessary to advance the candidate.107 Biochemical evaluation of 
this series of compounds against the HIV PR dimer revealed that a and b were 
extremely potent inhibitors  Ki  = 0.023 and 0.012 nM respectively. The compounds 
were also able to inhibit viral replication in vitro as measured by the ability of the 
compounds to inhibit RNA synthesis by 90% (a) IC90 = 13.2 nM; (b) IC90 = 26.2 nM). 
Interestingly, QSAR on this series of cyclic ureas suggested the optimum lipophilicity 
for protease inhibition (ClogP = 4.4) is different from the inhibition of viral 
replication (ClogP = 6.36) as revealed by the reversal of Ki and IC90 selectivities for 
(a) and (b). This makes it difficult to optimize both parameters within the same 
molecule, but suggests that while (a, b) display the same hydrogen bonding pattern at 
the terminal urea, the lipophilicity disparity between the 2-aminoimidazole and the 
benzimidazole has a significant effect on their pharmacokinetic profile.  With these 
results, (a) and (b) were advanced for pharmacokinetic studies in female Beagles. As 
seen in the pharmacokinetic profiles (Fig. 1.11.3) the decreased lipohilicity of (b) had 
a significant impact on the clearance (CL) and half-life (t1/2) of the compound, 
advancing its candidacy based on this improved PK profile. 
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      Fig.- 1.11.3 Unsymmetrical HIV PR inhibitors. 
 
Parameter a b 
Ki (nM) 0.023 0.012 
IC90 (nM) 13.2 26.2 
Dose (mg/kg) 5.0 5.0 
CL, L/h/kg 0.8 0.5 
Vss (L/Kg) 1.0 4.0 
T1/2 (h,iv) 0.9 5.6 
 
Table-1.13.1: Pharmacokinetic profiles of HIV PR inhibitors 
1.11.4 α-adrenoreceptor agonists. 
 
Agents that can stimulate α-andrenoceptors modulate a variety of physiological 
processes including the reduction of blood pressure, sedation and the inhibition of 
intestinal fluid secretion.108 Scientists at Allergan Pharmaceuticals targeted the α –
andrenoceptor to reduce intraocular pressure(IOP), a common condition in patients 
suffering from glaucoma.109 The challenge in designing such agents stems from the 
ability of  α –andrenoceptor subtypes to modulate different biological processes, most 
concerning are those in the central nervous system (CNS). One approach to 
minimizing CNS effect is topical application, minimizing access of the compound to 
the CNS. From the known α-andrenoceptor agonist clonidine,110 modifications to 
minimize CNS access generated the lead compounds p-aminoclonidine and AGN-
191103 (21) (Fig. 1.13.4). The The alternative approach is to discover compounds 
displaying enough selectivity between the α-andrenoceptor subtypes such that they 
exhibit an enhanced therapeutic index. This led to replacing the imidazolidin-imine 
with a 2-aminoimidazole. This compound (a) was selected for further evaluation. 
Binding assays demonstrated (a) bound to the α2A-receptor with a  Ki = 1.7 nM and 
was 1200-fold selective for the α2A –receptor over the α1-receptor, 50-fold selective 
for the α2A –receptor over the α2B –receptor, and 10- fold selective for the  α2A –
receptor over the  α2C –receptor. Compound (a) was found to be effective in vivo with 
an EC50 = 8.7 nM and importantly remained effective when administered 
intravenously, demonstrating its capability of crossing the blood-brain barrier. 
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1.11.5 Anti Cancer Activity 
Cancer has been the leading cause of death worldwide. Chemotherapy remains one of 
the major treatment options available for cancer, andmost of the currently used 
anticancer drugs are administered to patients via a parenteral infusion or bolus 
injection. Clinical complications with the parenteral administrations have been 
documented. Extra care is needed because of inappropriate patient compliances, and 
extra cost associated with hospitalization is necessary. Efforts in searching for orally 
active anticancer agents have been extensive, including the anticancer drug category 
of tubulin binding agents from which only injectable drugs are available such as 
taxanes and vinca alkaloids. Recently Chiung-Tong Chen111 reported the synthesis 
and biological functions of 2-amino-1-arylidenaminoimidazoles as orally active 
anticancer agents. Selective compounds had shown potent effects in the interference 
on the colchicines binding to tubulins, inhibition of tumor cell proliferation, and 
induction of human cancer cell apoptosis.  
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1.11.6 BACE-1 Inhibitors 
 
Alzheimer’s disease (AD) is the largest unmet medical need in neurobiology and 
accounts for the majority of dementia diagnosed in the elderly. AD is characterized by 
a progressively slow decline in cognitive function that leaves the end-stage patient 
dependent on custodial care with death occurring on the average of 9 years after 
diagnosis. The lack of an effective treatment for AD has stirred an intense search for 
novel therapies based on the amyloid hypothesis. This hypothesis states that a gradual 
and chronic imbalance between the production and clearance of Aß peptides results in 
their accumulation in the brain. These secreted peptides polymerize into neurotoxic 
oligomers that disrupt neuronal function and lead to cell death and memory loss that is 
phenotypical of AD. ß-secretase (BACE-1) is an as partyl protease representing the 
ratelimiting step in the generation of these Aß peptide fragments. Given the central 
role of Aß in AD pathology, inhibition of BACE-1 has become an attractive target for 
the treatment of Alzheimer’s disease. Vacca112 and Hills113 developed a series of 
aromatic heterocycles as BACE-1 inhibitors. The potency of the weak initial lead 
structure was dramatically enhanced using traditional medicinal chemistry. These 
inhibitors were shown to bind in a unique fashion that allowed for potent binding in a 
non-traditional fashion. 
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1.11.7 Anti Biofilm Activity 
 
Bacterial biofilms are defined as a surface attached community of  ignalling sms 
that are protected by an extracellular matrix of biomolecules. Within a biofilm state, 
bacteria are more resistant to antibiotics and are inherently insensitive to antiseptics 
and basic host immune responses. The NIH has estimated that 65-80% of all 
microbial infections are biofilm-based. Biofilm infections of indwelling medical 
devices are also of major concern, as once the device is colonized, infection is 
virtually impossible to eradicate. Bacterial biofilms114-116 underlie the persistent 
colonization of hospital facilities, which perpetuates nosocomial infections. Hospital-
acquired infections place a $10 billion burden on the U.S. healthcare system annually. 
Given the prominence of biofilms in infectious diseases, there has been an increasing 
effort toward the development of small molecules that will modulate bacterial biofilm 
development and maintenance. This, coupled with the spread of multi-drug antibiotic 
resistance across many of these bacteria, has put a tremendous burden on the scientific 
and medical community to alleviate biofilm-related problems. In this review, we will 
highlight the development of small molecules that inhibit and/or disperse bacterial 
biofilms through non-microbicidal mechanisms. The review will be segmented into 
providing a general overview of how bacteria develop into biofilm communities, why 
they are important, and the difficulties associated with their control. This will be 
followed by a discussion of the numerous approaches that have been applied to the 
discovery of lead small molecules that mediate biofilm development. These 
approaches are grouped into: 1) discovery/synthesis of molecules based upon 
naturally occurring bacterial  ignalling molecules, 2) chemical library screening, and 
3) discovery/synthesis of natural product and natural product analogues. 
 
Very recently the research group of Melander has been studying widely the ability of 
simple analogues of the marine natural products bromoageliferin and oroidin (Fig. 
1.11.6) to control biofilm development. Bromoageliferin is a sponge-derived alkaloid 
that was reported to inhibit the formation of bacterial biofilms from marine sources, 
presumably as a defense mechanism against biofouling.117 They reasoned that core 
structures derived from this complex molecule could be used as structural inspiration 
for the development of potent and synthetically accessible anti-biofilm agents. One of 
these scaffolds developed was based upon an aryl framework.118 From a medicinal 
chemistry stand point, this scaffold was deemed a promising platform to develop 
further functionalized 2-aminoimidazole (2-AI) derivatives as diversity could rapidly 
be introduced through manipulation of the benzene ring. They described the synthesis 
and anti-biofilm activity of these aryl 2-AI derivatives against three commonlystudied 
Gram-negative bacteria. 
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Fig. 1.11.6  2-Aminoimidazole-based anti-biofilm molecules. 
 
The research group of melander has recently developed several novel libraries of 2- 
aminoimidazole small molecules inspired by the marine alkaloids bromoageliferin  
and oroidin. These natural products were reviously reported to inhibit biofilm 
formation of the marine arotobacterium Rhodospirillum salexigens.119 TAGE and 
CAGE were the first documented 2-aminoimidazoles with anti-biofilm activity against 
Pseudomonas aeruginosa biofilms. 
 
Analogues of the structurally simpler alkaloid oroidin were also pursued to develop 
novel classes of small molecules with anti-biofilm activity. Recently, an oroidin 
inspired library was constructed utilizing click chemistry to generate a diverse library 
of 2-aminoimidazole/triazole conjugates (2-AIT).These compounds displayed the 
widest spectrum of anti-biofilm activity observed within the 2-aminoimidazole class 
(Fig. 1.11.7).120-121 
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Fig. 1.11.7   Representative 2-aminoimidazoles derived from the marine natural 
products bromoageliferin and oroidin. 
 
The synthetic approach to this 2-AIT derivatization is outlined in (Scheme 1.11.1). In 
their  previous synthesis of 2-AIT conjugates, they employed the alkyne-derived 2-AI 
as a precursor for the CuI-mediated[3+2] alkyne/azide cycloaddition (click reaction). 
Although this reaction worked well, purification of the resulting product was 
cumbersome, due to the need for copious amounts of ammonia saturated methanol for 
column chromatography. Therefore, they decided to revise the route by employing a 
Boc-protected 2-AI alkyne that would allow more traditional means of purification 
(i.e. methanol/dichloromethane columns). The Boc-protected scaffold was 
synthesized from oct-7-ynoic acid by treatment with oxayl chloride followed by 
diazomethane and quenching of the resulting α-diazo ketone with HBr to generate the 
intermediate a-bromo ketone. Cyclization with Boc-guanidine then delivered the 
target 2-AI alkyne.. 
 
a) i : (COCl)2,CH2Cl2, DMF (cat.), ii : CH2N2,Et2O/CH2Cl2, iii : HBr (82%) ; b) Boc-guanidine, DMF, RT
(59%) ; c) azide, CuSO4, Na ascorbate, EtOH, CH2Cl2,H2O; d) TFA, CH2Cl2 (58-94 % over two steps)
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Scheme-1.11.1  Melander’s 2-AI-T conjugate synthesis.  
 
It was explained by earlier work that once target 2-AI alkyne had been synthesized, 
assembled a diverse array of azido amides to employ in the click reaction to create 
pilot collection of 2-AIT conjugates. Briefly, 2-bromo-ethylamine was treated with 
sodium azide to deliver 2-azido-ethylamine, which following acylation (via the 
respective acid chloride) generated the azido amides for elaboration into the 2-AIT 
collection. Each azido amide was then subjected to the click reaction with target 2-AI 
alkyne. Boc-deprotection (TFA/CH2Cl2) followed by counterion exchange 
(trifluoroacetate for chloride) delivered the target 2-AIT compounds for antibiofilm 
screening. 
 
1.12 Introduction to Biofilm 
 
 Biofilms play a significant role in infection disease and account for up 
to 80% of microbial infections in the body.  
 Bacterial biofilms are defined as a surface-attached community of bacteria 
that are surrounded by a protective extracellular matrix.  
 On a global scale, biofilm related costs incur 6-10 billions of Euros to the 
agricultural, engineering, and medical sectors of economy.  
 Despite the focus of modern microbiology research on pure culture, 
planktonic bacteria, it is now recognized that most bacteria found in 
natural, clinical, and industrial settings persist in biofilms.  
 Within a biofilm, bacteria are upward of 1000-times more resistant to 
conventional antibiotic treatment  
 Biofilms grow virtually everywhere, in almost any environment where 
there is a combination of moisture, nutrients, and a surface.  
 
 
1.12.1 Properties of biofilms 
 
A biofilm community can be formed by a single bacterial species, but in nature 
biofilms almost always consist of rich mixtures of many species of bacteria, as well as 
fungi, algae, yeasts, protozoa, other microorganisms, debris and corrosion products. 
Biofilms are held together by sugary molecular strands, collectively termed 
"extracellular polymeric substances" or "EPS." The cells produce EPS and are held 
together by these strands, allowing them to develop complex, three-dimensional, 
resilient, attached communities. Biofilms cost the U.S. literally billions of dollars 
every year in energy losses, equipment damage, product contamination and medical 
infections. But biofilms also offer huge potential for bioremediating hazardous waste 
sites, biofiltering municipal and industrial water and wastewater, and forming 
biobarriers to protect soil and groundwater from contamination 
 
 
 
 
 
1.12.2 Biofilm Growth Cycle 
 
1)  Planktonic bacteria reversibly attach to a surface suitable for growth and 
Bacteria begin secretion of the extra cellular polymeric substances (EPS) and 
attachment becomes irreversible.  
2)  The maturing biofilm begins to take on a 3-dimensional shape. Biofilm 
communities can develop within hours.  
3)  The biofilm fully matures, and complex architecture is observed. Bacteria 
disperse from the biofilm to reinitiate biofilm colonization of a distal surface. 
 
1.12.3 Biofilm Drug Resistance  
 
The figure below shows a model of biofilm resistance to killing based on persister 
survival.  
Initial treatment with antibiotic kills normal cells (coloured green) in both planktonic 
and biofilm populations.  
The immune system kills planktonic persisters (coloured green), but the biofilm 
persister cells (coloured pink) are protected from the host defences by the exopolymer 
matrix. 
After the antibiotic concentration is reduced, persisters resuscitate and repopulate the 
biofilm and the infection relapses. 
 
Biofilm infections are highly recalcitrant to antibiotic treatment. However, planktonic 
cells that are derived from these biofilms are, in most cases, fully susceptible to 
antibiotics. Importantly, biofilms do not actually grow in the presence of elevated 
concentrations of antibiotics, therefore biofilms do not have increased resistance 
compared with planktonic cells.122 But if biofilms are not resistant to antibiotics, how 
do biofilm bacteria avoid being killed by antibiotic treatments? The resistance of 
biofilms to drug therapy has been one of the more elusive problems in microbiology, 
but the analysis of a simple dose-response experiment provided an unexpected insight 
into the puzzle.122-124 
 
Most of the cells in a biofilm are highly susceptible to bactericidal agents such as 
fluoroquinolone antibiotics or metal oxyanions, which can kill both rapidly dividing 
and slow- or non-growing cells.124-126 This is important, as cells in the biofilm are 
slow-growing, and many are probably in the stationary phase of growth. The 
experiment also revealed a small sub-population of cells that remain alive irrespective 
of the concentration of the antibiotic (persisters). The number of surviving persisters 
was greater in the non-growing stationary phase. In vitro, a stationary culture seems to 
be more tolerant than a biofilm to antibiotics. However, this situation is probably 
reversed in vivo. Antibiotic treatment will kill most biofilm and planktonic cells, 
leaving persisters alive. At this point, the similarity with an in vitro experiment 
probably ends. The immune system can mop up and kill remaining planktonic 
persisters, just as it eliminates nongrowing cells of a bacterial population that is 
treated with a bacteriostatic antibiotic. However, the biofilm exopolymer matrix 
protects against immune cells,127-129 and persisters that are contained in the biofilm 
can survive both the onslaught of antibiotic treatment and the immune system. When 
the concentration of antibiotic reduces, persisters can repopulate the biofilm, which 
will shed off new planktonic cells, producing the relapsing biofilm infection. The 
problem of biofilm resistance72 to killing by most therapeutics probably defaults to 
persisters. Interestingly, yeast biofilms also form tolerant persisters. 
 
1.13 Recent publications on 2-aminoimidazoles. 
 
The core structure 2-aminoimidazole has assumed importance in various synthesis 
related to heterocyclic in drug synthesis as appeared in Sci-finder search results on the 
basis of number of publications in medicinal and synthetic chemistry journals. 
 
 
Fig.1.10  Sci-finder search results by heating term 2-aminoimidazole. 
 
1.14 Conclusion 
 
Bacterial biofilms pose a serious threat to the healthcare system of our society as they 
are responsible for the morbidity and mortality of a myriad of diseases. The 
development of antibiotic resistance among many bacterial strains has put a 
tremendous pressure on the medical community to find alternative approaches for the 
treatment of biofilm-mediated diseases. In this present work of thesis a microwave 
assisted synthesis of small molecules which shows ability to controlling bacterial 
antibiofilm has been reported. 
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In the current chapter a library of  1-substituted 2-hydroxy-2-phenyl-2,3-dihydro-
imidazo[1,2-a]pyrimidinium salts and  2N-substituted 4(5)-phenyl-2-amino-1H-
imidazoles was synthesized via microwave assisted protocol and tested for the 
antagonistic effect against biofilm formation by Salmonella Typhimurium and 
Pseudomonas aeruginosa.   
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2.1  Introduction 
As described in chapter-1 the class of 2-aminoimidazoles has recently been given 
particular interest due to various biological properties of these compounds. 2-
Aminoimidazole alkaloids and their metabolites, isolated from the marine sponges 
Hymeniacidon sp., have been described as potent antagonists of serotonergic1 and 
histaminergic2 receptors. Naamine and isonaamine alkaloids from the marine sponges 
Leucetta sp. exhibit antiviral and anticancer activity.3,4 Because of these interesting 
biological activities, numerous synthetic routes to 1-substituted and 1-unsubstituted 2-
aminoimidazoles have been reported. Modern synthetic methods for accessing 1-
unsubstituted 2-amino-1H-imidazoles can be roughly classified as heterocyclization 
of substituted or protected guanidines with 1,2-dielectrophiles,5a-c heteroaromatic 
nucleophilic substitution5c,6 and recyclization of 2-aminooxazoles.7 Although different 
substituted guanidines are readily available and can be prepared in situ (e.g. from 
cyanamines8), the high basicity of guanidines together with non-regioselectivity often 
leads to multiple products.9 Protection by acetyl5a and Boc-groups5c requires, in turn, 
acidic deprotection conditions. Another procedure is the cyclocondensation of 
aldehydes and guanidine nitrate using sodium cyanide and supported aluminum oxide, 
which provides symmetric 2-aminoimidazoles.10 
 
Recently, we described two new approaches to the synthesis of substituted 2-amino-
1H-imidazoles. The first approach is based on the cleavage of imidazo[1,2-
a]pyrimidines11 with hydrazine12 In the second approach we reported microwave 
assisted one pot synthesis.(scheme-3)13 
 
 
 
 
 
 
 
 
 
 
 
 
2.2 Reaction scheme: 
2.2.1 2-amino pyramidine: (Scheme-1) 
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2.2.2 Synthesis of substituted 2-amino 1 H-imidazole. (Scheme-2) 
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2.2.3 One-Pot approach: (Scheme-3) 
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2.3 Proposed Mechanism: 
Regarding the mechanism of the transformation of 2-hydroxy-2,3-dihydro-1H-
imidazo[1,2-a]pyrimidinium salts into 2-amino-1H-imidazoles, we presume that the 
reaction proceeds via an unusual Dimroth-type rearrangement14-16 (Scheme-4). 
 
Scheme-4: Proposed Mechanism for the Dimroth-type Rearrangement of 2-
Hydroxy-2,3-dihydro-1H-imidazo[1,2-a]pyrimidinium Salts III-12 
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In the first step, the 2-hydroxy-2,3-dihydroimidazo[1,2-a]pyrimidinium salt (1) 
undergoes cleavage of the pyrimidine ring, resulting in the generation of pyrazole and 
2-amino-5-hydroxyimidazolidine (C), which is in equilibrium with the open form (D). 
This can cyclize again leading to the isomeric 2-amino-5(4)-hydroxyimidazolidines 
(E). Both isomers (C) and (E) were detected by mass-spectrometry. Final 
dehydratation upon microwave irradiation, results in the rearranged 2-amino-1H-
imidazoles 2. This dehydratation step, as judged by mass-spectrometry, was found to 
be the slowest step of the transformation. While some 2-amino-5(4)-
hydroxyimidazolidines (E) lost water spontaneously at room temperature, other 
required higher temperature upon microwave irradiation. Therefore all reactions were 
run at 100 °C, preventing the sequence from stopping after the first step. 
 
2.4 Results and discussion: 
Initially careful investigation of the formation and dehydratation of salt (3) resulting 
in the formation of salt (4) under conventional heating conditions as well as upon 
microwave irradiation has been studied. As a proof of concept, the condensation of 2-
methylaminopyrimidine (1, R1 = Me) and α-phenacylbromide (2, R2 = Ph) was 
studied (Table 1). A sealed vial containing a solution of the starting compounds in 
acetonitrile was conventionally heated with an oil bath (Table 1, No-1-6) or irradiated 
with microwaves (Table 1, No-7-12) at different temperatures for 30−60 min. The 
formation of the 2-hydroxy salt (3) was faster under microwave irradiation and this 
compound was obtained in 88% yield within 30 min. Further increase of the 
temperature up to 120 °C using conventional heating or microwave irradiation led to a 
mixture of salts (3) and (4) (Table 1). Interestingly, using microwave irradiation at 
120 °C for 60 min, we were able to drive the reaction completely to the formation of 
the imidazo[1,2-a]pyrimidinium salt (4) (Table 1, No-12). 
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No. Conditions Time (min) T (°C) 3 (yield %)b    4 (yield %)b 
1 
Conventional 
30 80 64 0 
2 60 80 77 0 
3 30 100 81 Traces 
4 60 100 85 Traces 
5 30 120 68 17 
6 60 120 53 28 
 
7 
Microwave 
30 80 88 0 
8 60 80 85 0 
9 30 100 48 33 
10 60 100 45 35 
11 30 120 12 79 
12 60 120 traces 84 
aAll reactions were carried out on a 1 mmol scale of 2-methylaminopyrimidine (1, R1 = Me) with 
1.35 equiv of α-phenacylbromide (2, R2 = Ph) in MeCN (5 Ml); bisolated yield after recrystallization 
from MeCN. 
Table-1: Investigation of the condensation under conventional heating and 
microwave irradiationa 
 
As the transformation of salts (3) into salts (4) is relatively rapid at the temperatures 
above 100 °C, the synthesis of salts 3 was conducted at 80 °C. Treatment of 
substituted 2-aminopyrimidines (1) with 15 mol % excess of α-bromoketones (2) in 
MeCN under microwave irradiation for 30 min generated the intermediate salts (3) 
which, in most cases, precipitated from the reaction mixture upon cooling (Table-2). 
Reaction progress was monitored by mass-spectrometry. In all cases examined, the 
reaction appeared to be complete after 30 min. The cleavage step was performed 
under microwave irradiation at 90 °C, using 7 equivalents of hydrazine hydrate. Based 
on the data given in (Table-2), the reaction appears to be compatible with both aryl 
and alkyl substitutions. All the reactions were clean, smooth, and provided the 
products in good and high yields. The compounds were purified by column 
chromatography using 5−10% MeOH in CH2Cl2 as the eluent. All the final 2-amino-
1H-imidazoles were characterized by 1H and 13C NMR spectroscopy. Their 
composition was also confirmed by HRMS. 
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No. 
Compound 
Code 
R1 R2 Yield 
1 BS-136* CH3 2,4-(di-OCH3) 48 
2 BS-137* (benzo[d][1,3]dioxol-6- naphthalen-1-yl 72 
yl)methyl 
3 BS-140* C3H7 3,4-(di-Cl) 70 
4 BS-141* cyclohexane 4-SO2Me 43 
5 BS-143* C8H17 4-Cl 43 
6 BS-146* C5H11 4-Cl 57 
7 BS-147* C6H13 4-F 61 
8 BS-148* 4-methoxyphenethyl 3-Br 44 
9 BS-154* cyclooctane 4-SO2Me 53 
10 BS-139* 2-methoxyethyl 4-CN 55 
11 BS-258 C8H17 4-OCH3 78 
12 BS-259 C8H17 4-F 69 
13 BS-260 C8H17 3,4-(di-Cl) 72 
14 BS-261 C8H17 3-Br 79 
15 BS-262 C8H17 naphthalen-1-yl 68 
16 BS-263 C8H17 4-NO2 66 
17 BS-264 C8H17 4-(4-NO2Ph) 75 
18 BS-265 C8H17 SO2Me 54 
19 BS-292 i-Bu 4-NO2 70 
20 BS-293 i-Bu H 71 
21 BS-294 i-Bu 4-Br 69 
22 BS-295 i-Bu 4-Cl 73 
*Compounds have been synthesized via One-pot protocol (Scheme-3). 
All compounds are either oily or amorphous solid. 
Table-2: Microwave assisted synthesis of substituted 2-amino-1H-imidazoles. 
2.5 Biofilm activity: 
Bacteria are able to switch between a planktonic life style and a biofilm mode of 
growth, in which they live as structured communities of bacterial cells enclosed in a 
self-produced polymeric matrix and adherent to an inert or living surface.17  As 
bacteria in biofilms are more resistant to challenges from predators, antibiotics, 
disinfectants and host immune systems,18-21  serious problems and high costs have 
been associated with biofilms, both in medicine and industrial settings.   According to 
the National Institutes of Health, more than 80% of microbial infections are related to 
biofilms.22  Especially the use of indwelling medical devices comprises a high risk for 
the development of biofilm related infections.19   This high prevalence of biofilm 
related infections is  particularly problematic given the fact that bacteria in biofilms 
can be up to 1000-fold more resistant to antibiotics.23  In industry, biofilms have been 
implicated e.g. in the contamination of installations in food industry, mild steel 
corrosion, decreased passage through pipelines by colonization of the interior of the 
pipes, and enhanced resistance of vessels by initiation of  “biofouling” on the vessel 
hulls.  The yearly economic loss caused by ‘biofouling’ in the marine industry is 
estimated at $ 6.5 billion.24  
One way to deal with this problem is the development of small molecules that are able 
to prevent or destroy biofilm formation25.  Only a few molecular scaffolds have been 
identified to date, among which the best-studied examples are (1) the halogenated 
furanones, which were originally isolated from the seaweed Delisea pulchra,26-27  (2) 
analogues of the homoserine lactone signalling molecules28 and (3) analogues of the 
sponge-derived marine natural alkaloids oroidin and bromoageliferin.29-36  A 
particularly valuable approach is the development of small molecules that specifically 
target the biofilm formation in a non-toxic manner, as it is expected that resistance 
against these compounds will emerge much slower than against classical 
microbiocidal compounds.   As a consequence, non-toxic biofilm inhibitors have the 
potential to be used in a preventive treatment of a wide diversity of industrial and 
medical surfaces.  Furthermore, the potential to co-dose biofilm inhibitors and 
classical antibiotics for the treatment of biofilm infections is also an attractive 
option.27   
Salmonella enterica serovar Typhimurium and Pseudomonas aeruginosa are two well 
studied organisms in terms of biofilm formation.  Salmonella enterica is worldwide 
one of the most important causes of foodborne infections.  Salmonella is able to form 
biofilms on a variety of both biotic surfaces (such as gallstones,37 plant surfaces,38-39 
and epithelial cell layers40) and abiotic surfaces (such as  concrete, plastics, glass, 
polystyrene, … )41-42.  These biofilms are an important survival strategy in all stages 
of infection, from transmission to chronic infection. Severe non-typhoid Salmonella 
infections are commonly treated with fluoroquinolones and third-generation 
cephalosporins. Unfortunately, there are alarming reports concerning the development 
of resistance against these antibiotics43, underlining the urgent need  of alternative 
anti-Salmonella strategies.  Given the importance of biofilms in the spread of 
Salmonella, the development of Salmonella biofilm inhibitors seems a promising 
approach.   P. aeruginosa is an opportunistic pathogen implicated in a myriad of 
infections.  Patients with compromised host defenses, such as burn patients,  HIV 
patients and cystic fibrosis patients (80% colonization rate of P. aeruginosa44) are 
particularly susceptible to P. aeruginosa infections.45 P. aeruginosa biofilms have 
been related to recurrent ear infections, chronical bacterial prostatitis and lung 
infections in CF patients,  the latter being extremely harmful as  P. aeruginosa 
colonization and chronic lung infection is the major causative agent of morbidity and 
mortality in CF patients.46  Moreover, P. aeruginosa can colonize as biofilms a 
variety of medical devices such as intravascular catheters and urinary catheters. 
Obviously there is an urgent need of agents that can prevent or eradicate P. 
aeruginosa biofilms on infected tissues and on medical devices.  
 
2.5.1 2N-substituted 2-aminopyrimidines 
 
Some members of the 2-aminopyrimidine class of compounds have previously been 
shown to possess antibacterial and antifungal activity.47-48 These molecules are the 
precursors of the N1-substituted diazo[1,2-a]pyrimidinium salts in our synthesis 
pathway (scheme-2). The availability of a broad array of 2-aminopyrimidines, 
substituted with n-alkyl, cyclo-alkyl and aromatic groups at the N2-position prompted 
us to investigate the potential of this class of compounds as biofilm inhibitors.  The 
influence of compounds on the biofilm formation of S. Typhimurium was tested at 
25°C.  Remarkably, none of the compounds does have an effect on the biofilm 
formation at 400 µM, which was the highest concentration tested.  
 
2.5.2 2-hydroxy-2,3-dihydro-imidazopyrimidinium salts 
 
A broad array of 1-substituted 2-hydroxy-2-phenyl-2,3-dihydro-imidazopyrimidinium 
salts were synthesized via previously established chemistry from our laboratory and 
their ability to prevent the biofilm formation of S. Typhimurium and P. aeruginosa 
was tested. These molecules differ in the substitution pattern of the 2-phenyl ring and 
in the nature of the substituent at the 1-position i.e. n-alkyl, iso-alkyl, cyclo-alkyl. 
 
2.5.2.1  n-Alkyl or iso-alkyl substituents at 1-position 
 
In first instance, a series of 2-hydroxy-2-phenyl-2,3-dihydro-imidazopyrimidinium 
salts with a broad variety of  n-alkyl or iso-alkyl substituents at the 1-position, with 
lengths ranging from 1 carbon atom to 14 carbon atoms was synthesized. The 2-
phenyl group of these salts is either unsubstituted, para-substituted with a chlorine 
atom, a nitro group, a fluorine atom, a bromine atom or a methoxy group, or 3,4-
disubstituted with chlorine atoms.  Each compound was assayed for the ability to 
inhibit S. Typhimurium ATCC14028 biofilm formation at 25 °C.  As depicted in 
figure 1A, a clear correlation was found between the length of the alkyl substituent 
and the biofilm inhibitory activity.  In general the activity of the molecules with a 
short alkyl chain was found to be very low (IC50 > 400 µM).  Within a series of 
molecules with the same substitution of the 2-phenyl ring, in general a gradual 
increase in biofilm inhibitory activity was observed by raising the length of the alkyl 
chain from 1 to 8 carbon atoms. The compounds with an octyl substituent show a 
maximal activity with IC50 values in the range of 6-11 µM.  By further raising the 
alkyl chain length from 8 to 14 carbon atoms, a gradual decrease in biofilm inhibitory 
activity was observed.  For the molecules with a heptyl, octyl, nonyl and decyl side 
chain (which are the most active molecules), the nature of the substituent of the 2-
phenyl group does not have a substantial effect on the biofilm inhibitory activity.  
Next the influence of a subset of the 2-hydroxy-2-phenyl-2,3-dihydro-
imidazopyrimidinium salts for their ability to prevent the biofilm formation of  P. 
aeruginosa was studied.  As represented in table-4 and figure-1B, a similar structure 
activity relationship was found as in the case of Salmonella biofilm inhibition. 
Compounds with short alkyl substituents (C1-6) in general only have a slight effect on 
the biofilm formation (IC50’s >80 µM), while compounds with medium length side 
chains (C7-C10) have IC50 values between 20-40 µM and compounds with long side 
chains (C11-C14) have IC50 values higher than 800 µM.  However, it should be 
mentioned that some of the compounds with long side chain do reduce the biofilm 
formation to a certain extent, but their dose response curves reach a steady state level 
of 25 to 45 % biofilm inhibition starting from concentrations between 25 and 50 µM.  
NN
N R1
OHBr
R2  
No. Code R2 R1 S. Typhimurium IC50 
P. aeruginosa 
IC50 
1 BS-289 H i-Bu 131.2 289.4 
2 BS-083 H n-Pen 278.2 565.4 
3 BS-058 H n-Hex 102.0 405.8 
4 BS-049 H n-Hep 23.4 25.5 
5 BS-052 H n-Oct 9.8 14.4 
6 BS-061 H n-Non 8.3 26.8 
7 BS-055 H n-Dec 15.0 29.9 
8 BS-064 H n-Und 24.6 >800 
9 BS-067 H n-Dod 27.5 >800 
10 BS-070 H n-Trd 81.6 >800 
11 BS-073 H n-Tet 179.6 >800 
12 BS-291 4-Cl i-Bu 31.4 83.4 
13 BS-099 4-Cl n-Pen 32.6 163.9 
14 BS-092 4-Cl n-Hex 13.7 79.8 
15 BS-089 4-Cl n-Hep 6.7 36.9 
16 BS-090 4-Cl n-Oct 7.0 15.7 
17 BS-093 4-Cl n-Non 18.3 20.2 
18 BS-091 4-Cl n-Dec 51.3 83.3 
19 BS-094 4-Cl n-Und 61.9 >800 
20 BS-095 4-Cl n-Dod 122.1 >800 
21 BS-096 4-Cl n-Trd 316.1 >800 
22 BS-097 4-Cl n-Tet >800 >800 
23 BS-288 4-NO2 i-Bu 322.5 191.7 
24 BS-290 4-Br i-Bu 5.2 6.3 
IC50: Concentration of inhibitor needed to inhibit biofilm formation by 50%. 
Table-4: Influence of 1-alkylated 2-hydroxy-2,3-dihydro-imidazo[1,2-
a]pyrimidinium salts on the biofilm formation of S. Typhimurium ATCC14028 and P. 
aeruginosa PA14 at 25°C. 
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Figure-1A: Effect of the length of the n-alkyl chain at the 1-position of 2-hydroxy-2-
phenyl-2,3-dihydro-imidazo[1,2-a]pyrimidinium salts, substituted with Cl and H at 
the para-position of the 2-phenyl ring, on the IC50 (µM) for inhibition of biofilm 
formation of S. Typhimurium ATCC14028. 
 
2.5.2.2  Further Modification in the most active core structure 
Since the compounds with a n-octyl chain substituted at the 1-position have the 
highest activity against Salmonella biofilms and also have a high activity against 
Pseudomonas biofilms, we decided to synthesize the additional 1-octyl-2-hydroxy-2-
phenyl-2,3-dihydro-imidazopyrimidinium salts with more variation in the substitution 
pattern of the 2-phenyl ring. As depicted in Table 5 these compounds generally inhibit 
biofilm formation of S. Typhimurium at low concentrations. However, no improved 
activity was observed in comparison with the previously described compounds (Table 
2). The effect of the n-octyl substituted compounds on the biofilm formation of P. 
aeruginosa  strongly depends on the substitution pattern of the 2-phenyl ring, as some 
of the compounds have low IC50 values (10-40 µM), while the other compounds only 
have a moderate activity (IC50 = 100-400 µM). 
N
N
N C8H17
OHBr
R  
SR CODE R 
S. Typhimurium 
IC50 
P. aeruginosa 
IC50 
1 BS-180 4-NO2 6.6 12.1 
2 BS-176 4-F 7.6 nd 
3 BS-175 4-OMe 10.5 nd 
4 BS-177 3,4-diCl 7.1 nd 
5 BS-187 4-SMe 13.2 36.5 
6 BS-179 Naphtyl 14.7 15.1 
7 BS-185 4-(4-NO2Ph) 31 215.2 
8 BS-186 4-SO2Me 60.3 99.9 
9 BS-188 4-([1,1’-biphenylyl]-4-yl) 52.8 336.1 
10 BS-178 3-Br 7.1 29 
 
Table-5: Influence of N1-octyl 2-hydroxy-2, 3-dihydro-imidazo[1,2-a]pyrimidinium 
salts on the biofilm formation of S. Typhimurium ATCC14028 and P. aeruginosa 
PA14 at 25°C. 
 
2.5.2.3  Cyclo-alkyl substituents at 1-position 
A series of 2-hydroxy-2-phenyl-2,3-dihydro-imidazopyrimidinium salts with a broad 
variety of  cyclo-alkyl substituents at the 1-position was synthesized with lengths 
ranging from 3 to 12 carbon atoms (Table 6). The 2-phenyl group of these salts was 
either unsubstantiated or para-substituted with a chlorine atom. Similarly to the 
structure-activity relationship delineated for the n-alkyl substituted salts, a gradual 
increase in the inhibitory activity against Salmonella biofilms was observed by rising 
the length of the cyclo-alkyl chain from 3 to 8 carbon atoms.  However, in contrast to 
the salts with  n-dodecyl chain at the 1-position, the salts with a cyclo-dodecyl chain 
do have a very strong effect against Salmonella biofilms (IC50 values < 6.25 µM).  By 
analogy with (1) the effect on Salmonella biofilms and (2) the activity of the n-alkyl 
substituted salts, we found that all the cyclo-alkyl substituted salts with a short side 
chain do only have a slight effect on the biofilm formation of P. aeruginosa (IC50’s 
>150 µM), while the compounds with a medium length side chain have a stronger 
biofilm inhibitory activity. The salts with a cyclo-dodecyl chain do drastically reduce 
the Pseudomonas biofilm formation (IC50’s ~7 µM), in sharp contrast to the 
compounds with  n-dodecyl side chain.   
 
N
N
N R1
OHBr
R2  
SR CODE R2 R1 
S. Typhimurium 
IC50 
P. aeruginosa 
IC50 
1 BS-079 H c-Bu 493.0 >400 
2 BS-076 H c-Hex 139.0 22.4 
3 BS-046 H c-Hep 84.2 191.3 
4 BS-043 H c-Oct 58.4 48.6 
5 BS-100 4-Cl c-Bu 120.8 371.5 
6 BS- 4-Cl c-Pen 41.8 41.9 
7 BS-098 4-Cl c- Hex 33.0 16.4 
8 BS-088 4-Cl c- Hep 27.9 76.2 
9 BS-087 4-Cl c-Oct 12.6 22.7 
10 BS-086 4-Cl c-Doc 5.6 6.8 
Table-6: Influence of 1-cyclo-alkyl-2-hydroxy-2,3-dihydro-imidazo[1,2-a] 
pyrimidinium salts on the biofilm formation of S. Typhimurium ATCC14028 and P. 
aeruginosa PA14 at 25°C. 
 
2.5.3 2N-substituted 2-aminoimidazoles 
In the present it was interesting to investigate whether introduction of n-alkyl, iso-
alkyl, cyclo-alkyl or aromatic group at the 2N-position of the 4(5)-phenyl-2-amino-
1H-imidazoles could also enhance their biofilm inhibitory activity. Therefore a broad 
range of 2N-substituted 4(5)-phenyl-2-amino-1H-imidazoles were synthesized. 
An array of 4(5)-phenyl-2-aminoimidazoles 2N-substituted with either a short n- or 
iso-alkyl chain (C1-C5) or n-octyl chain was synthesized. As depicted in table7, a 
broad diversity of (substituted) 4(5)-phenyl groups were included. The compounds 
with a iso-butyl substitution at the 2N-position were found to be in general more 
active than their 2N-unsubstituted counterparts, with respect to both the Salmonella 
and Pseudomonas biofilm formation. 
 
N
N
H
HN
R1
R2
 
SR R1 R2 
S. Typhimurium 
IC50 
P. aeruginosa 
IC50 
1 CH3 2,4-(di-OCH3) Nd Nd 
2 (benzo[d][1,3]dioxol-6-yl)methyl naphthalen-1-yl 261.0 10.5 
3 C3H7 3,4-(di-Cl) 10.9 27.7 
4 Cyclohexane 4-SO2Me Nd Nd 
5 C8H17 4-Cl >400 Nd 
6 C5H11 4-Cl >400 Nd 
7 C6H13 4-F >400 12.5 
8 C8H17 4-OCH3 >400 >800 
9 C8H17 4-F >400 Nd 
10 C8H17 3,4-(di-Cl) 118.3 >800 
11 C8H17 3-Br 44.6 >800 
12 C8H17 naphthalen-1-yl 238.4 >800 
13 C8H17 4-NO2 10.9 25.0 
14 C8H17 4-(4-NO2Ph) Nd Nd 
15 C8H17 SO2Me 41.8 Nd 
16 i-Bu 4-NO2 3.8 22.9 
17 i-Bu H 4.9 1.2 
18 i-Bu 4-Br 2.9 1.2 
19 i-Bu 4-Cl 2.0 0.9 
 
Table-7: Influence of 2N-alkylated 2-aminoimidazoles on the biofilm formation and 
the planktonic growth of S. Typhimurium ATCC14028 and P. aeruginosa PA14 at 
25°C. 
 
 
2.6 Conclusion 
 
In the present study, the potential of these 1-substituted 2-hydroxy-2,3-dihydro-
imidazopyrimidinium salts and 2N-subsituted 2-amino-1H-imidazoles as inhibitors of 
the biofilm formation by S. Typhimurium and P. aeruginosa was thoroughly 
investigated.  We found that 2-hydroxy-2,3-dihydro-imidazopyrimidinium salts with 
intermediate length n-alkyl chains (C7-C10) substituted at the 1-position in general 
prevent the biofilm formation of both species at low micromolar concentrations (IC50 
= 5-50 µM).   For these molecules, the nature of the substituent of the 2-phenyl group 
does not have a substantial effect on the biofilm inhibitory activity.  Salts with a 
shorter (C1-C5) or longer (C11-C14) n-alkyl chain at the 1-position were found to be 
much less potent.  Consistent with this, we observed that salts with an intermediate 
length cyclo-alkyl chain are much more active against biofilm formation of both 
species as compared to the salts with a short cyclo-alkyl chain.  However, remarkably 
salts with a long cyclo-dodecyl side chain were found to have even better activities 
than salts with an intermediate length cyclo-alkyl side chain. 
 
In the framework of the 2-aminoimidazoles, be the introduction of a butyl, pentyl or 
hexyl side chain at the 2N-position of the 2-aminoimdazoles results in an enhanced 
biofilm inhibitory activity against both species, while introduction of a shorter n-alkyl 
chain reduces the biofilm inhibitory activity.  The effect of introduction of longer n-
alkyl chains however seems to be strongly dependent on the substitution pattern of the 
5-phenyl ring and the bacterial species studied. 
 
In conclusion, the 2N-substituted 2-aminoimidazoles and 2-hydroxy-2-phenyl-2,3-
dihydro-imidazopyrimidinium salts of the present study are valuable candidates in the 
development of therapeutics and sanitizers for the combat of biofilm formation by S. 
Typhimurium, P. aeruginosa and possibly other pathogenic bacteria. 
 
 
 
 
 
2.7 Experimental 
2.7.1 General Methods 
All chemical reagents were used without further purification. Solvents for column 
chromatography and TLC were laboratory grade and distilled before use. For thin-
layer chromatography (TLC), analytical TLC plates (Alugram SIL G/UV254 (E. M. 
Merk) were used. Column chromatography was performed with flash silica gel (100-
200 mesh) or neutral alumina oxide (50-200 micron). 1H and 13C NMR spectra were 
recorded on a Bruker Avance 300 (300 MHz) or a Bruker AMX-400 (400 MHz) 
spectrometers. NMR samples were run in the indicated solvents and were referenced 
internally. Chemical shift values were quoted in ppm and coupling constants were 
quoted in Hz. Chemical shift multiplicities were reported as s = singlet, d = doublet, t 
= triplet, q = quartet, m = multiplet and br = broad. Low-resolution mass spectra were 
recorded on a HEWLETT-PACKARD instrument (CI or EI) and LCQ Advantage 
instrument (ESI). High-resolution mass spectra (EI) were recorded on a KRATOS 
MS50TC instrument. Melting points were determined using Reichert-Jung Thermovar 
apparatus and were uncorrected. 
 
2.7.2 Microwave Irradiation Experiments 
Microwave irradiation experiments were carried out in a dedicated CEM-Discover 
mono-mode microwave apparatus or Milestone MicroSYNTH multi-mode microwave 
reactor (Laboratory Microwave Systems). Microwave apparatuses were used in the 
standard configuration as delivered, operating at a frequency 2.45 GHz with 
continuous irradiation power from 0 to 400 W. The reactions were carried out in 10, 
20, 30 and 50 mL glass tubes. The temperature was measured with an IR sensor on 
the outer surface of the process vial or fibre optic sensor inside the process vial. After 
the irradiation period, the reaction vessel was cooled rapidly (2-5 min) to ambient 
temperature by air jet cooling. 
 
 
 
 
 
 
2.8 Biological assays 
2.8.1 Static peg assay for prevention of Salmonella Typhimurium and 
Pseudomonas aeruginosa biofilm formation 
 
The device used for biofilm formation is a platform carrying 96 polystyrene pegs 
(Nunc no. 445497) that fits as a microtiter plate lid with a peg hanging into each 
microtiter plate well (Nunc no. 269789).  Two-fold serial dilutions of the compounds 
in 100 µl liquid broth (Tryptic Soy Broth diluted 1/20 (TSB 1/20)) per well were 
prepared in the microtiter plate (2 or 3 repeats per compound).  Subsequently, an 
overnight culture of S. Typhimurium ATCC14028 (grown in Luria-Bertani medium)  
or P. aeruginosa (grown in TSB) was diluted 1:100 into the respective liquid broth 
and 100 µl (~106 cells) was added to each well of the microtiter plate, resulting in a 
total amount of 200 µl medium per well. The pegged lid was placed on the microtiter 
plate and the plate was incubated for 24 h at 25°C without shaking.  During this 
incubation period biofilms were formed on the surface of the pegs. After 24 h, the 
optical density at 600 nm (OD600) was measured for the planktonic cells in the 
microtiter plate using a VERSAmax microtiter plate reader (Molecular Devices). This 
gives a first indication of the effect of the compounds on the planktonic growth.  For 
quantification of biofilm formation, the pegs were washed once in 200 µl phosphate 
buffered saline (PBS). The remaining attached bacteria were stained for 30 min with 
200 μl 0.1% (w/v) crystal violet in an isopropanol/methanol/PBS solution (v/v 
1:1:18). Excess stain was rinsed off by placing the pegs in a 96-well plate filled with 
200 μl distilled water per well. After the pegs were air dried (30 min), the dye bound 
to the adherent cells was extracted with 30% glacial acetic acid (200 µl). The OD570 of 
each well was measured using a VERSAmax microtiter plate reader (Molecular 
Devices). The IC50 value for each compound was determined from the concentration 
gradient by using the GraphPad software of Prism. 
 
 
 
 
 
 
2.8.2 Bioscreen assay for measuring Salmonella Typhimurium and P. 
aeruginosa growth inhibition 
 
The Bioscreen device (Oy Growth Curves Ab Ltd) was used for measuring the 
influence of the chemical compounds on the planktonic growth of Salmonella 
Typhimurium and P. aeruginosa. The Bioscreen is a computer controlled 
incubator/reader/shaker that uses 10x10 well microtiter plates and measures light 
absorbance of each well at a specified wave length in function of time. An overnight 
culture of S. Typhimurium ATCC14028 (grown up in LB medium) or P. aeruginosa 
(grown up in TSB) was diluted 1:200 in liquid broth (TSB 1/20). 300 µl of the diluted 
overnight culture was added to each well of the 10x10 well microtiter plate.  
Subsequently, serial dilutions of the chemical compounds were prepared in DMSO or 
EtOH.  3 µl of each diluted stock solution was added to the wells (containing the 300 
µl bacterial culture) in 3-fold.  As a control 3 µl of the appropriate solvent was also 
added to the plate in 3- or 4-fold.  The microtiter plate was incubated in the Bioscreen 
device at 25°C for at least 24 h, with continuous medium shaking.  The absorbance of 
each well was measured at 600 nm each 15 min.  Excel was used to generate the 
growth curves for the treated wells and the untreated control wells.  
The effect of each compound concentration on the planktonic growth was classified 
into one of the following categories: 
1) The planktonic growth is not or only slightly affected, indicated by the symbol 
‘-‘.  
2) The planktonic growth is retarded, indicated by the symbol ‘+’.  
3) The planktonic growth is completely or almost completely inhibited, indicated 
by the symbol ‘o’.  
The following criterium was used to decide between the first and the second category: 
If the absorbance (measured at 600 nm) of the bacterial culture treated with the 
compound is at least 0.5 (for Salmonella) or 0.8 (for Pseudomonas) units lower 
than the absorbance of the untreated culture during 4 consecutive hours, then the 
effect on the planktonic growth is classified in category 2. 
 
 
 
2.9 Experimental protocol: 
2.9.1  General Procedure for the Preparation of Substituted 2-
Aminopyrimidines  
In a 50 mL microwave vial were successively dissolved in EtOH (20 mL) 2-
chloropyrimidine (3.43 g, 30 mmol), amine (39 mmol, 1.3 equiv) and triethylamine 
(6.2 mL, 45 mmol, 1.5 equiv). The reaction tube was sealed, and irradiated in the 
cavity of a Milestone MicroSYNTH microwave reactor at a ceiling temperature of 
120 °C at 100 W maximum power for 25 min. After the reaction mixture was cooled 
with an air flow for 15 min, it was diluted with water (100 mL), extracted with DCM 
(2×150 mL) and dried over Na2SO4. The solvent was evaporated in vacuo, and the 
crude mixture was purified by silica gel flash chromatography using 0-5% 
MeOH−DCM as the eluent. 
 
13 new substituted 2-aminopyrimidine derivatives were synthesized in similar 
manner. (Table-1) 
Table-1 Compound synthesized 
N
N
N
H
R
 
ENTRY CODE R Yield 
1 BS-021 cyclododecane 66 
2 BS -024 cyclooctane 60 
3 BS -025 cycloheptane 64 
4 BS -030 cyclobutane 61 
5 BS-029 C6H13 88 
6 BS -026 C7H15 87 
7 BS -027 C8H17 86 
8 BS -033 C9H19 86 
9 BS -028 C10H21 87 
10 BS -034 C11H23 88 
11 BS -035 C12H25 89 
12 BS -036 C13H27 88 
13 BS -037 C14H19 88 
 
2.9.2 General Procedure for the Preparation of Salts. 
To a solution of 2-substituted aminopyrimidine (6 mmol) and α-bromoacetophenone 
(7.2 mmol, 1.2 equiv) in acetonitrile (12 mL) was added 4-dimethylaminopyridine (6 
mg, 0.05 mmol). After being stirred at 85 °C for 5 h, the reaction mixture was diluted 
with acetone (20 mL) and the precipitate was filtered and washed with acetone (2×20 
mL), ether (2×20 mL) and dried over P2O5 to give salt as a white solid. 
10 new compounds were synthesized in similar manner. 
 
2.9.3 General Procedure for the Preparation of Salts. (Microwave) 
In a 50 mL microwave vial were successively dissolved 2-substituted 
aminopyrimidine (6 mmol) and α-bromoacetophenone (7.2 mmol, 1.2 equiv) in 
acetonitrile (12 mL) was added 4-dimethylaminopyridine (6 mg, 0.05 mmol). The 
reaction tube was sealed, and irradiated in the cavity of a Milestone MicroSYNTH 
microwave reactor at a ceiling temperature of 80 °C at 100 W maximum power for 30 
min. After the reaction mixture was cooled with an air flow for 15 min, the reaction 
mixture was diluted with acetone (20 mL) and the precipitate was filtered and washed 
with acetone (2×20 mL), ether (2×20 mL) and dried over P2O5 to give salt as a white 
solid. 34 new compounds were synthesized in similar manner. 
 
2.9.4 General Procedure for the Preparation of 2-Amino-1H-imidazoles.  
To a suspension of salt (2 mmol) in MeCN (5 mL) hydrazine hydrate (0.7 mL, 14 
mmol of a 64% solution, 7 equiv) was added, and the mixture was irradiated in the 
sealed Milestone MicroSYNTH microwave reactor for 10 min at a ceiling 
temperature of 100 °C at 150 W maximum power. After cooling down hydrazine 
hydrate was evaporated with toluene (3×20 mL). The resulting residue was purified 
by column chromatography (silica gel; MeOH−DCM 1:4 v/v with 5% of 6M NH3 in 
MeOH) to afford 2-amino-1H-imidazole as an amorphous material. 
12 new compounds were synthesized in similar manner. 
 
2.9.5 General procedure for the one-pot two-step microwave-assisted synthesis 
of 2-amino-1H-imidazoles. 
In a microwave vial (10 mL) were successively dissolved in dry MeCN (3 mL) the 
corresponding 2-aminopyrimidine (4 mmol) and α-bromoketone (4.6 mmol). The 
reaction tube was sealed and irradiated in a microwave reactor at a ceiling 
temperature of 80 °C and a maximum power of 50 W for 30 min. After the reaction 
mixture was cooled with an air flow for 15 min, hydrazine hydrate (0.9 mL, 28 mmol 
of a 64% solution, 7 equiv) was added, and the mixture was irradiated at a ceiling 
temperature of 90 °C and a maximum power of 50 W for another 10 min. After the 
reaction mixture was cooled, hydrazine hydrate was removed by distillation with 
toluene (3×20 mL). The resulting residue was purified by column chromatography 
(silica gel; MeOH-DCM 1:9 v/v with 0.5 % of 6N ammonia in MeOH) to afford 2-
amino-1H-imidazole as amorphous solid. 
10 new compounds were synthesized in similar manner. 
 
2.10 Spectral Characterization 
N-Cyclooctylpyrimidin-2-amine (BS-024) 
N
N
N
H  
Yield: 60%. 1H NMR (300 MHz, CDCl3): δ = 8.25 (d, J = 4.77 Hz, 2H), 6.46 (t, J = 
4.8 Hz, 1H), 5.07 (br s, 1H), 4.04 (m, 1H), 1.93 (m, 2H), 1.63 (m, 12H). 13C NMR 
(75.5 MHz, CDCl3): δ =161.6, 158.0 (×2), 110.0, 50.6, 31.7 (×2), 27.5 (×2), 25.3, 
23.5 (×2). HRMS (EI): C12H19N3, calcd 205.2994, found: 205.2982. 
 
 
N –Cycloheptylpyrimidin-2-amine (BS-025) 
N
N
N
H  
Yield: 64%. 1H NMR (300 MHz, CDCl3): δ = 8.26 (d, J = 4.77 Hz, 2H), 6.47 (t, J = 
4.77 Hz, 1H), 5.09 (br s, 1H), 4.01 (m, 1H), 2.02 (m, 2H), 1.55 (m, 10H). 13C NMR 
(75.5 MHz, CDCl3): δ =161.6, 158.0 (×2), 110.0, 51.6, 35.0 (×2), 28.2 (×2), 23.9 
(×2). HRMS (EI): C11H17N3, calcd 191.2728, found: 191.2742. 
N –Heptylpyrimidin-2-amine (BS-026) 
N
N
N
H
C7H15
 
Yield: 87%. 1H NMR (300 MHz, CDCl3): δ = 8.27 (d, J = 4.8 Hz, 2H), 6.50 (t, J = 4.8 
Hz, 1H), 5.07 (br s, 1H), 3.40 (m, 2H), 1.61 (m, 2H), 1.31 (m, 8H), 0.85 (m 3H). 13C 
NMR (75.5 MHz, CDCl3): δ =162.5, 157.9 (×2), 110.1, 41.5, 31.8, 29.6, 29.0, 26.9, 
22.6, 14.0. HRMS (EI): C11H19N3, calcd 193.2887, found: 193.2894.  
N –Octylpyrimidin-2-amine (BS-027) 
N
N
N
H
C8H17
 
Yield: 86%. 1H NMR (300 MHz, CDCl3): δ = 8.27 (d, J = 4.74 Hz, 2H), 6.49 (t, J = 
4.77 Hz, 1H), 5.11 (br s, 1H), 3.40 (m, 2H), 1.60 (m, 2H), 1.27 (m, 10H), 0.87 (m 
3H). 13C NMR (75.5 MHz, CDCl3): δ =162.4, 158.0 (×2), 110.1, 41.5, 31.8, 29.6, 
29.3, 29.2, 26.9, 22.6, 14.1. HRMS (EI): C12H21N3, calcd 207.3152, found: 207.3131. 
N –Decylpyrimidin-2-amine (BS-028) 
N
N
N
H
C10H21
 
Yield: 87%. 1H NMR (300 MHz, CDCl3): δ = 8.27 (d, J = 4.8 Hz, 2H), 6.50 (t, J = 4.8 
Hz, 1H), 5.07 (br s, 1H), 3.38 (m, 2H), 1.60 (m, 2H), 1.26 (m, 14H), 0.87 (t, J = 6.93, 
3H). 13C NMR (75.5 MHz, CDCl3): δ =162.4, 158.0 (×2), 110.1, 41.5, 31.8, 29.6 (×2), 
29.5, 29.3 (×2), 26.9, 22.6, 14.1. HRMS (EI): C14H25N3, calcd 235.3684, found: 
235.3670. 
N –Cyclobutylpyrimidin-2-amine (BS-030) 
N
N
N
H  
Yield: 61%. 1H NMR (300 MHz, CDCl3): δ = 8.27 (m, 2H), 6.51 (t, J = 4.77 Hz, 1H), 
5.29 (br s, 1H), 4.46 (m, 1H), 2.42 (m, 2H), 1.89 (m, 2H), 1.76 (m, 2H). 13C NMR 
(75.5 MHz, CDCl3): δ =161.6, 158.0 (×2), 110.4, 46.3, 31.5 (×2), 15.0. HRMS (EI): 
C8H11N3, calcd 149.1930, found: 149.1917 
N –Nonylpyrimidin-2-amine (BS-033) 
N
N
N
H
C9H19
 
Yield: 86%. 1H NMR (300 MHz, CDCl3): δ = 8.27 (d, J = 4.71 Hz, 2H), 6.50 (t, J = 
4.77 Hz, 1H), 5.07 (br s, 1H), 3.40 (m, 2H), 1.61 (m, 2H), 1.26 (m, 12H), 0.87 (t, J = 
6.9, 3H). 13C NMR (75.5 MHz, CDCl3): δ =162.5, 158.0 (×2), 110.1, 41.5, 31.8, 29.6, 
29.5,29.4, 29.2, 27.0, 22.6, 14.1. HRMS (EI): C13H23N3, calcd 221.3418, found: 
221.3400. 
N –Undecylpyrimidin-2-amine (BS-034) 
N
N
N
H
C11H23
 
Yield: 88%. 1H NMR (300 MHz, CDCl3): δ = 8.27 (d, J = 4.62 Hz, 2H), 6.50 (t, J = 
4.77 Hz, 1H), 5.07 (br s, 1H), 3.40 (m, 2H), 1.60 (m, 2H), 1.25 (m, 16H), 0.87 (t, J = 
6.87, 3H). 13C NMR (75.5 MHz, CDCl3): δ = 162.5, 158.0 (×2), 110.2, 41.5, 31.9, 
29.6 (×4), 29.3 (×2), 26.9, 22.6, 14.1. HRMS (EI): C15H27N3, calcd 249.3950, found: 
249.3938. 
 
N –Dodecylpyrimidin-2-amine (BS-035) 
N
N
N
H
C12H25
 
Yield: 89%. 1H NMR (300 MHz, CDCl3): δ = 8.27 (d, J = 4.41 Hz, 2H), 6.50 (t, J = 
4.74 Hz, 1H), 5.07 (br s, 1H), 3.40 (m, 2H), 1.61 (m, 2H), 1.25 (m, 18H), 0.88 (t, J = 
6.84, 3H). 13C NMR (75.5 MHz, CDCl3): δ = 162.4, 158.0 (×2), 110.2, 41.5, 31.9, 
29.6 (×5), 29.3 (×2), 26.9, 22.6, 14.1. HRMS (EI): C16H29N3, calcd 263.4216, found: 
263.4202. 
N –Tridecylpyrimidin-2-amine (BS-036) 
N
N
N
H
C13H27
 
Yield: 88%. 1H NMR (300 MHz, CDCl3): δ = 8.27 (d, J = 4.77 Hz, 2H), 6.50 (t, J = 
4.8 Hz, 1H), 5.07 (br s, 1H), 3.38 (m, 2H), 1.60 (m, 2H), 1.25 (m, 20H), 0.88 (t, J = 
6.9, 3H). 13C NMR (75.5 MHz, CDCl3): δ = 162.4, 158.0 (×2), 110.1, 41.5, 31.9, 29.6 
(×6), 29.3 (×2), 27.0, 22.7, 14.1. HRMS (EI): C17H31N3, calcd 277.4481, found: 
277.4491. 
N –Tetradecylpyrimidin-2-amine (BS-037) 
N
N
N
H
C14H29
 
Yield: 88%. 1H NMR (300 MHz, CDCl3): δ = 8.27 (d, J = 4.77 Hz, 2H), 6.50 (t, J = 
4.8 Hz, 1H), 5.07 (br s, 1H), 3.38 (m, 2H), 1.60 (m, 2H), 1.25 (m, 22H), 0.88 (t, J = 
6.9, 3H). 13C NMR (75.5 MHz, CDCl3): δ = 162.4, 158.0 (×2), 110.2, 41.5, 31.9, 29.6 
(×7), 29.3 (×2), 26.9, 22.7, 14.1. HRMS (EI): C18H33N3, calcd 291.4747, found: 
291.4723. 
 
 
1-Heptyl-2-hydroxy-2-phenyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-4-ium 
bromide amine (BS-049) 
N
N
N C7H15
OH
Br
 
Yield: 75 %. 1H NMR (300 MHz, CDCl3): δ = 9.03 (m, 1H), 8.85 (m, 1H), 7.80 (s, 
1H), 7.77 (m, 2H), 7.49 (m, 3H), 7.31 (m, 1H), 4.82 (s, 2H). 3.17 (m, 2H), 1.36 (m, 
2H), 1.09 (m, 8H), 0.80 (t, J = 6.84 Hz, 3H). 
2-Hydroxy-1-octyl-2-phenyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-4-ium 
bromide (BS-052) 
N
N
N C8H17
OH
Br
 
Yield: 73 %. 1H NMR (300 MHz, CDCl3): δ = 9.03 (m, 1H), 8.86 (m, 1H), 7.80 (s, 
1H), 7.75 (m, 2H), 7.47 (m, 3H), 7.31 (t, J = 5.49 Hz, 1H), 4.83 (s, 2H). 3.17 (m, 2H), 
1.36 (m, 2H), 1.09 (m, 10H), 0.83 (t, J = 6.72 Hz, 3H). 
1-Decyl-2-hydroxy-2-phenyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-4-ium 
bromide (BS-055) 
N
N
N C10H21
OH
Br
 
Yield: 78 %. 1H NMR (300 MHz, CDCl3): δ = 9.03 (d, J = 4.62 Hz, 1H), 8.87 (d, J = 
6.18 Hz, 1H), 7.81 (s, 1H), 7.74 (m, 2H), 7.47 (m, 3H), 7.31 (m, 1H), 4.83 (s, 2H). 
3.17 (m, 2H), 1.09 (m, 16H), 0.85 (t, J = 6.51 Hz, 3H). 13C NMR (75.5 MHz, CDCl3): 
δ =167.5, 154.5, 148.2, 138.2, 129.2, 128.3 (×2), 126.9 (×2), 111.1, 90.6, 62.6, 40.7, 
31.2, 28.7, 28.6, 28.5, 28.2, 27.3, 25.8, 22.0, 13.9.  
1-Hexyl-2-hydroxy-2-phenyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-4-ium 
bromide (BS-058) 
N
N
N C6H13
OH
Br
 
Yield:  80 %. 1H NMR (300 MHz, CDCl3): δ = 9.03 (m, 1H), 8.87 (m, 1H), 7.81 (s, 
1H), 7.74 (m, 2H), 7.47 (m, 3H), 7.31 (m 1H), 4.83 (s, 2H). 3.17 (m, 2H), 1.34 (m, 
2H), 1.09 (m, 6H), 0.78 (t, J = 6.48 Hz, 3H). 
2-Hydroxy-1-nonyl-2-phenyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-4-ium 
bromide (BS-061) 
N
N
N C9H19
OH
Br
 
Yield: 75 %. 1H NMR (300 MHz, CDCl3): δ = 9.03 (m, 1H), 8.87 (m, 1H), 7.80 (s, 
1H), 7.74 (m, 2H), 7.47 (m, 3H), 7.31 (t, J = 6.21 Hz, 1H), 4.83 (s, 2H). 3.17 (m, 2H), 
1.09 (m, 14H), 0.84 (t, J = 6.63 Hz, 3H). 13C NMR (75.5 MHz, CDCl3): δ =167.5, 
154.5, 148.2, 138.2, 129.2, 128.3 (×2), 126.9 (×2), 111.1, 90.6, 62.6, 40.7, 31.1, 28.5, 
28.4, 28.2, 27.3, 25.8, 22.0, 13.9.  
2-Hydroxy-2-phenyl-1-undecyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-4-ium 
bromide (BS-064) 
N
N
N C11H23
OH
Br
 
Yield: 80 %. 1H NMR (300 MHz, CDCl3): δ = 9.03 (d of d, J = 1.89, 4.68 Hz, 1H), 
8.87 (d, J = 6.06 Hz, 1H), 7.80 (s, 1H), 7.75 (m, 2H), 7.47 (m, 3H), 7.31 (m 1H), 4.83 
(s, 2H). 3.17 (m, 2H), 1.09 (m, 18H), 0.85 (t, J = 6.42 Hz, 3H). 
1-Dodecyl-2-hydroxy-2-phenyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-4-ium 
bromide (BS-067) 
N
N
N C12H25
OH
Br
 
 
Yield: 78 %. 1H NMR (300 MHz, CDCl3): δ = 9.03 (m, 1H), 8.87 (m, 1H), 7.81 (s, 
1H), 7.74 (m, 2H), 7.46 (m, 3H), 7.31 (m, 1H), 4.84 (s, 2H). 3.17 (m, 2H), 1.22 (m, 
20H), 0.85 (t, J = 6.24 Hz, 3H). 13C NMR (75.5 MHz, CDCl3): δ =167.5, 154.5, 
148.2, 138.2, 129.2, 128.3 (×2), 126.9 (×2), 111.1, 90.6, 62.6, 40.7, 31.2, 28.9 (×2), 
28.8, 28.6 (×2), 28.2, 27.3, 25.8, 22.0, 13.9.  
2-Hydroxy-2-phenyl-1-tridecyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-4-ium 
bromide (BS-070) 
N
N
N C13H27
OH
Br
 
Yield: 79 %. 1H NMR (300 MHz, CDCl3): δ = 9.03 (m, 1H), 8.87 (m, 1H), 7.80 (s, 
1H), 7.76 (m, 2H), 7.46 (m, 3H), 7.31 (m 1H), 4.83 (s, 2H). 3.17 (m, 2H), 1.22 (m, 
22H), 0.85 (m, 3H). 
 
 
 
2-Hydroxy-2-phenyl-1-tetradecyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-4-ium 
bromide (BS-073) 
NN
N C14H29
OH
Br
 
Yield: 72 %. 1H NMR (300 MHz, CDCl3): δ = 9.03 (d, J = 4.65 Hz, 1H), 8.87 (d, J = 
6.27 Hz, 1H), 7.81 (s, 1H), 7.77 (m, 2H), 7.46 (m, 3H), 7.32 (m 1H), 4.84 (s, 2H). 
3.17 (m, 2H), 1.23 (m, 24H), 0.85 (m, 3H). 
1-Cyclobutyl-2-hydroxy-2-phenyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-4-
ium bromide (BS-079) 
N
N
N
OH
Br
 
Yield: 77 %. 1H NMR (300 MHz, CDCl3): δ = 9.03 (m, 1H), 8.83 (m, 1H), 7.86 (s, 
1H), 7.65(m, 2H), 7.46(m, 3H), 7.34 (m 1H), 4.76 (s, 2H). 3.90 (m, 1H), 2.76 (m, 
2H), 1.88 (m, 2H), 1.69 (m, 2H). 
2-Hydroxy-1-pentyl-2-phenyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-4-ium 
bromide (BS-083) 
N
N
N C5H11
OH
Br
 
Yield: 74 %. 1H NMR (300 MHz, CDCl3): δ = 9.03 (m, 1H), 8.86 (m, 1H), 7.82 (s, 
1H), 7.77 (m, 2H), 7.47 (m, 3H), 7.31 (m 1H), 4.83 (s, 2H). 3.17 (m, 2H), 1.36, (m, 
2H), 1.09 (m, 4H), 0.73 (t, J = 6.72 Hz, 3H). 
2-(4-Chlorophenyl)-1-cycloheptyl-2-hydroxy-2,3-dihydro-1H-imidazo[1,2-
a]pyrimidin-4-ium bromide (BS-088) 
N
N
N
OH
Br
Cl  
Yield: 90 %. 1H NMR (300 MHz, CDCl3): δ = 9.00 (d of d, J = 1.92, 4.65 Hz, 1H), 
8.85 (m, 1H), 7.92 (s, 1H), 7.79 (d, J = 8.64 Hz, 2H), 7.56 (d, J = 8.58 Hz, 2H), 7.28 
(m, 1H), 4.74 (m, 2H). 3.10 (m, 1H), 2.19 (m, 2H), 1.40 (m, 10H). 
2-(4-Chlorophenyl)-1-heptyl-2-hydroxy-2,3-dihydro-1H-imidazo[1,2-
a]pyrimidin-4-ium bromide (BS-089) 
N
N
N C7H15
OH
Br
Cl  
Yield: 91 %. 1H NMR (300 MHz, CDCl3): δ = 9.04 (d, J = 4.65 Hz, 1H), 8.87 (d, J = 
5.85 Hz, 1H), 7.90 (s, 1H), 7.78 (d, J = 8.61 Hz, 2H), 7.55 (d, J = 8.58 Hz, 2H), 7.32 
(m, 1H), 4.82 (s, 2H). 3.17 (m, 2H), 1.09 (m, 10H), 0.81 (t, J = 7.17 Hz, 3H). 
2-(4-Chlorophenyl)-2-hydroxy-1-octyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-
4-ium bromide (BS-090) 
N
N
N C8H17
OH
Br
Cl  
Yield: 71 %. 1H NMR (300 MHz, CDCl3): δ = 9.05 (d, J = 6.51 Hz, 1H), 8.90 (d, J = 
6.24 Hz, 1H), 7.90 (s, 1H), 7.78 (d, J = 8.61 Hz, 2H), 7.55 (d, J = 8.58 Hz, 2H), 7.32 
(m, 1H), 4.82 (m, 2H). 3.17 (m, 2H), 1.09 (m, 12H), 0.83 (t, J = 6.75 Hz, 3H). 
2-(4-Chlorophenyl)-1-decyl-2-hydroxy-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-
4-ium bromide (BS-091) 
N
N
N C10H21
OH
Br
Cl  
Yield: 86 %. 1H NMR (300 MHz, CDCl3): δ = 9.04 (d, J = 3.33 Hz, 1H), 8.86 (d, J = 
6.0 Hz, 1H), 7.89 (s, 1H), 7.81 (d, J = 8.37 Hz, 2H), 7.55 (d, J = 8.4 Hz, 2H), 7.32 (m, 
1H), 4.82 (m, 2H). 3.17 (m, 2H), 1.09 (m, 16H), 0.85 (t, J = 6.51 Hz, 3H). 13C NMR 
(75.5 MHz, CDCl3): δ = 167.7, 154.6, 148.2, 137.3, 134.1, 129.0 (×2), 126.3 (×2), 
111.1, 90.2, 62.5, 40.7, 31.2, 28.8, 28.6 (×2), 28.2, 27.2, 25.8, 22.0, 13.9.  
2-(4-Chlorophenyl)-1-hexyl-2-hydroxy-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-
4-ium bromide (BS-092) 
N
N
N C6H13
OH
Br
Cl  
Yield: 83 %. 1H NMR (300 MHz, CDCl3): δ = 9.04 (d, J = 4.47 Hz, 1H), 8.87 (d, J = 
6.3 Hz, 1H), 7.90 (s, 1H), 7.78 (d, J = 8.55 Hz, 2H), 7.56 (m, 2H), 7.33 (t, J = 5.0 Hz, 
1H), 4.82 (m, 2H). 3.17 (m, 2H), 1.05 (m, 8H), 0.79 (t, J = 6.30 Hz, 3H). 
 
 
 
2-(4-Chlorophenyl)-2-hydroxy-1-nonyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-
4-ium bromide (BS-093) 
N
N
N C9H19
OH
Br
Cl  
Yield: 82 %. 1H NMR (300 MHz, CDCl3): δ = 9.03 (d of d, J = 1.86, 4.62 Hz, 1H), 
8.86 (m, 1H), 7.89 (s, 1H), 7.78 (d, J = 8.64 Hz, 2H), 7.55 (d, J = 8.58 Hz, 2H), 7.32 
(m, 1H), 4.82 (m, 2H). 3.17 (m, 2H), 1.09 (m, 14H), 0.84 (t, J = 6.63 Hz, 3H).  
2-(4-Chlorophenyl)-2-hydroxy-1-undecyl-2,3-dihydro-1H-imidazo[1,2-
a]pyrimidin-4-ium bromide (BS-094) 
N
N
N C11H23
OH
Br
Cl  
Yield: 83 %. 1H NMR (300 MHz, CDCl3): δ = 9.03 (d, J = 4.56 Hz, 1H), 8.87 (d, J = 
6.3 Hz, 1H), 7.89 (s, 1H), 7.78 (d, J = 8.49 Hz, 2H), 7.55 (d, J = 8.49 Hz, 2H), 7.32 
(m, 1H), 4.82 (m, 2H). 3.17 (m, 2H), 1.22 (m, 18H), 0.85 (t, J = 6. 3 Hz, 3H). 13C 
NMR (75.5 MHz, CDCl3): δ = 167.5, 154.6, 148.2, 137.3, 134.1, 129.0 (×2), 128.3 
(×2), 111.1, 90.2, 62.5, 40.7, 31.2, 28.9, 28.8, 28.6 (×2), 28.2, 27.2, 25.8, 22.0, 13.9.  
2-(4-Chlorophenyl)-1-dodecyl-2-hydroxy-2,3-dihydro-1H-imidazo[1,2-
a]pyrimidin-4-ium bromide (BS-095) 
N
N
N C12H25
OH
Br
Cl  
Yield: 90 %. 1H NMR (300 MHz, CDCl3): δ = 9.03 (d of d, J = 1.83, 4.59 Hz, 1H), 
8.87 (d, J = 6.06 Hz, 1H), 7.90 (s, 1H), 7.78 (d, J = 8.64 Hz, 2H), 7.55 (d, J = 8.61 
Hz, 2H), 7.32 (m, 1H), 4.82 (m, 2H). 3.17 (m, 2H), 1.22 (m, 20H), 0.85 (t, J = 6. 33 
Hz, 3H). 
2-(4-Chlorophenyl)-2-hydroxy-1-tridecyl-2,3-dihydro-1H-imidazo[1,2-
a]pyrimidin-4-ium bromide (BS-096) 
N
N
N C13H27
OH
Br
Cl  
Yield: 95 %. 1H NMR (300 MHz, CDCl3): δ = 9.03 (d of d, J = 1.83, 4.65 Hz, 1H), 
8.87 (d of d, J = 1.77, 6.27 Hz, 1H), 7.90 (s, 1H), 7.78 (d, J = 8.61 Hz, 2H), 7.55 (d, J 
= 8.61 Hz, 2H), 7.32 (m, 1H), 4.82 (m, 2H). 3.17 (m, 2H), 1.23 (m, 22H), 0.85 (t, J = 
6. 33 Hz, 3H). 13C NMR (75.5 MHz, CDCl3): δ = 167.5, 154.6, 148.2, 137.2, 134.1, 
129.0 (×2), 128.3 (×2), 111.2, 90.2, 62.5, 40.7, 31.2, 28.9 (×3), 28.8, 28.6 (×2), 28.2, 
27.2, 25.8, 22.0, 13.9.  
2-(4-Chlorophenyl)-2-hydroxy-1-tetradecyl-2,3-dihydro-1H-imidazo[1,2-
a]pyrimidin-4-ium bromide (BS-097) 
NN
N C14H29
OH
Br
Cl  
Yield: 90 %. 1H NMR (300 MHz, CDCl3): δ = 9.03 (d, J = 4.56 Hz, 1H), 8.87 (d J = 
6.12 Hz, 1H), 7.90 (s, 1H), 7.78 (d, J = 8.55 Hz, 2H), 7.55 (d, J = 8.55 Hz, 2H), 7.32 
(t, J = 4.95 Hz, 1H), 4.82 (m, 2H). 3.17 (m, 2H), 1.23 (m, 24H), 0.85 (t, J = 6. 09 Hz, 
3H). 
 
2-(4-Chlorophenyl)-1-cyclohexyl-2-hydroxy-2,3-dihydro-1H-imidazo[1,2-
a]pyrimidin-4-ium bromide (BS-098) 
N
N
N
OH
Br
Cl  
Yield: 84 %. 1H NMR (300 MHz, CDCl3): δ = 9.01 (d of d, J = 1.86, 4.68 Hz, 1H), 
8.84 (d of d, J = 1.83, 6.39 Hz, 1H), 7.96 (s, 1H), 7.78 (d, J = 8.64 Hz, 2H), 7.56 (d, J 
= 8.58 Hz, 2H), 7.30 (m, 1H), 4.72 (m, 2H). 3.02 (m, 1H), 2.13 (m, 2H), 0.75 (m, 8H). 
2-(4-Chlorophenyl)-2-hydroxy-1-pentyl-2,3-dihydro-1H-imidazo[1,2-
a]pyrimidin-4-ium bromide (BS-099) 
N
N
N C5H11
OH
Br
Cl  
Yield: 78 %. 1H NMR (300 MHz, CDCl3): δ = 9.04 (d of d, J = 1.8, 4.56 Hz, 1H), 
8.87 (d of d,  J = 1.65, 6.27 Hz, 1H), 7.90 (s, 1H), 7.78 (d, J = 8.64 Hz, 2H), 7.56 (d, J 
= 8.61 Hz, 2H), 7.32 (m, 1H), 4.81 (m, 2H). 3.17 (m, 2H), 1.10 (m, 6H), 0.75 (t, J = 6. 
81 Hz, 3H). 
2-(4-Chlorophenyl)-1-cyclobutyl-2-hydroxy-2,3-dihydro-1H-imidazo[1,2-
a]pyrimidin-4-ium (BS-100) 
NN
N
OH
Br
Cl  
Yield: 81 %. 1H NMR (300 MHz, CDCl3): δ = 9.06 (d, J = 4.11 Hz, 1H), 8.84 (d, J = 
6.21 Hz, 1H), 7.95 (s, 1H), 7.69 (d, J = 8.58 Hz, 2H), 7.55 (d, J = 8.55 Hz, 2H), 7.35 
(t, J = 5.22 Hz, 1H), 4.64 (m, 2H), 3.89 (m, 1H), 2.73 (m, 2H), 1.91 (m, 2H), 1.66 (m, 
2H). 
2-Hydroxy-2-(4-methoxyphenyl)-1-octyl-2,3-dihydro-1H-imidazo[1,2-
a]pyrimidin-4-ium bromide (BS-175) 
N
N
N C8H17
OH
Br
OMe  
Yield: 77 %. 1H NMR (300 MHz, CDCl3): δ = 9.02 (m, 1H), 8.84 (d, J = 6.3 Hz, 1H), 
7.71 (s, 1H), 7.65 (d, J = 8.79 Hz, 2H), 7.30 (m, 2H), 7.01 (d, J = 8.79 Hz, 1H), 4.79 
(s, 2H). 3.79 (s, 3H), 3.17 (m, 2H), 1.10 (m, 12H), 0.83 (t, J = 6.66 Hz, 3H). 13C NMR 
(75.5 MHz, CDCl3): δ = 167.4, 159.7, 154.4, 148.2, 129.8, 128.4 (×2), 113.5 (×2), 
111.0, 90.5, 62.5, 55.2, 40.5, 31.0, 28.2 (×2), 27.3, 25.8, 22.0, 13.8.  
2-(4-Fluorophenyl)-2-hydroxy-1-octyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-
4-ium bromide (BS-176) 
N
N
N C8H17
OH
Br
F  
Yield: 68 %. 1H NMR (300 MHz, CDCl3): δ = 9.03 (d of d, J = 1.92, 4.71 Hz, 1H), 
8.84 (d of d, J = 1.65, 6.3 Hz, 1H), 7.86 (s, 1H), 7.82 (m, 2H), 7.33 (m, 3H), 4.82 (s, 
2H). 3.17 (m, 2H), 1.10 (m, 12H), 0.83 (t, J = 6.72 Hz, 3H). 13C NMR (75.5 MHz, 
CDCl3): δ = 167.4, 164.1, 160.8, 154.5, 134.5 (×2), 129.5 (d), 115.3 (d), 111.2, 90.2, 
62.5, 40.6, 31.0, 28.2 (×2), 27.3, 25.8, 21.9, 13.8.  
 2-(3,4-Dichlorophenyl)-2-hydroxy-1-octyl-2,3-dihydro-1H-imidazo[1,2-
a]pyrimidin-4-ium bromide (BS-177) 
N
N
N C8H17
OH
Br
Cl
Cl
 
 
Yield: 82 %. 1H NMR (300 MHz, CDCl3): δ = 9.05 (d of d, J = 1.86, 4.62 Hz, 1H), 
8.88 (d of d, J = 1.74, 6.27 Hz, 1H), 8.07 (s, 1H), 8.02 (s, 1H), 7.78 (s, 2H), 7.33 (m, 
1H), 4.83 (m, 2H). 3.23 (m, 2H), 1.11 (m, 12H), 0.83 (t, J = 6.75 Hz, 3H). 13C NMR 
(75.5 MHz, CDCl3): δ = 167.4, 154.6, 148.0, 139.4, 132.1, 131.2, 130.4, 129.4, 127.3, 
111.3, 89.6, 62.3, 40.6, 31.0, 28.2 (×2), 27.2, 25.7, 21.9, 13.8.  
2-(3-Bromophenyl)-2-hydroxy-1-octyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-
4-ium bromide (BS-178) 
N
N
N C8H17
OH
Br
Br
 
Yield: 53  %. 1H NMR (300 MHz, CDCl3): δ = 9.04 (d of d, J = 1.86, 4.68 Hz, 1H), 
8.87 (d of d, J = 1.62, 6.27 Hz, 1H), 8.01 (s, 1H), 7.93 (s, 1H), 7.77 (d, J = 7.86 Hz, 
1H), 7.66 (d, J = 8.4 Hz, 1H), 7.46 (t, J = 7.92 Hz, 1H)  7.33 (m, 1H), 4.82 (m, 2H). 
3.22 (m, 2H), 1.36 (m, 2H), 1.11 (m, 10H), 0.83 (t, J = 6.72 Hz, 3H). 13C NMR (75.5 
MHz, CDCl3): δ = 167.4, 154.6, 148.1, 140.9, 132.1, 130.4, 129.9, 126.0, 121.7, 
111.2, 89.8, 62.5, 40.6, 31.0, 28.2 (×2), 27.2, 25.7, 21.9, 13.8.  
 
 
2-Hydroxy-2-(naphthalen-1-yl)-1-octyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-
4-ium bromide (BS-179) 
NN
N C8H17
OH
Br
 
Yield: 82 %. 1H NMR (300 MHz, CDCl3): δ = 9.08 (d, J = 4.11 Hz, 1H), 9.00 (d, J = 
5.25 Hz, 1H), 8.38 (s, 1H), 8.02 (m, 4H), 7.86 (d, J = 7. 61 Hz, 1H), 7.60 (m, 2H), 
7.38 (t, J = 5.64 Hz, 1H), 4.99 (s, 2H). 3.26 (m, 2H), 1.39 (m, 2H), 1.00 (m, 10H), 
0.76 (t, J = 6.6 Hz, 3H). 13C NMR (75.5 MHz, CDCl3): δ = 167.4, 154.7, 148.3, 
135.4, 132.9, 132.1, 128.4, 128.1, 127.5, 127.0, 126.6 (×2), 124.2, 111.2, 90.8, 62.5, 
40.7, 30.9, 28.2 (×2), 27.3, 25.8, 21.9, 13.8. 
2-Hydroxy-2-(4-nitrophenyl)-1-octyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-4-
ium bromide (BS-180) 
N
N
N C8H17
OH
Br
NO2  
Yield: 75 %. 1H NMR (300 MHz, CDCl3): δ = 9.06 (m, 1H), 8.89 (m, 1H), 8.37 (d, J 
= 8.7 Hz, 2H), 8.12 (s, 1H), 8.05 (d, J = 8.76 Hz, 2H), 7.36 (m, 1H), 4.86 (m, 2H). 
3.22 (m, 2H), 1.39 (m, 2H), 1.09 (m 10H), 0.81 (t, J = 6.66 Hz, 3H). 13C NMR (75.5 
MHz, CDCl3): δ = 167.5, 154.7, 148.2, 147.9, 145.2, 128.7 (×2), 123.0 (×2), 111.4, 
90.0, 62.3, 40.8, 30.9, 28.2 (×2), 27.2, 25.7, 21.9, 13.8.  
 
 
 
2-Hydroxy-2-(4’-nitrobiphenyl-4-yl)-1-octyl-2,3-dihydro-1H-imidazo[1,2-
a]pyrimidin-4-ium bromide (BS-185) 
NN
N C8H17
OH
Br
NO2  
Yield: 49 %. 1H NMR (300 MHz, CDCl3): δ = 9.05 (d, J = 4.11 Hz, 1H), 8.88 (d, J = 
6.2 Hz, 1H), 8.32 (d, J = 8.7 Hz, 2H), 8.03 (d, J = 8.76 Hz, 2H), 7.94 (m, 5H), 7.34 (t, 
J = 4.98 Hz, 1H), 4.87 (s, 2H). 3.24 (m, 2H), 1.43 (m, 2H), 1.10 (m 10H), 0.76 (t, J = 
6.45 Hz, 3H). 13C NMR (75.5 MHz, CDCl3): δ = 167.5, 154.6, 148.2, 146.9, 145.5, 
138.9, 138.4, 127.9 (×3), 127.2 (×2), 124.1 (×3), 111.2, 90.5, 62.6, 40.8, 31.0, 28.2 
(×2), 27.3, 25.8, 21.9, 13.8.  
2-Hydroxy-2-(4-(methylsulfonyl)phenyl)-1-octyl-2,3-dihydro-1H-imidazo[1,2-
a]pyrimidin-4-ium bromide (BS-186) 
N
N
N C8H17
OH
Br
SO2Me  
Yield: 48 %. 1H NMR (300 MHz, CDCl3): δ = 9.06 (d of d J = 1.65, 4.47 Hz, 1H), 
8.94 (d of d, J = 1.56, 6.21 Hz, 1H), 8.08 (s, 1H), 8.05 (s, 4H), 7.36 (m, 1H), 4.87 (m, 
2H). 3.27 (s, 3H), 3.24 (m, 2H), 1.40 (m, 2H), 1.11 (m, 10H), 0.82 (t, J = 6.66 Hz, 
3H). 13C NMR (75.5 MHz, CDCl3): δ = 167.4, 154.7, 148.2, 143.7 (×2), 141.6, 128.1 
(×2), 127.0, 111.4, 90.3, 62.5, 43.3, 40.9, 31.0, 28.2 (×2), 27.4, 25.9, 21.9, 13.8.  
 
 
2-Hydroxy-2-(4-(methylthio)phenyl)-1-octyl-2,3-dihydro-1H-imidazo[1,2-
a]pyrimidin-4-ium bromide (BS-187) 
NN
N C8H17
OH
Br
SMe  
Yield: 49 %. 1H NMR (300 MHz, CDCl3): δ = 9.02 (m, 1H), 8.85 (m, 1H), 7.78 (s, 
1H), 7.66 (d, J = 8.52 Hz, 2H), 7.33 (m, 3H), 4.79 (m, 2H). 3.33 (s, 3H), 3.22 (m, 
2H), 1.39 (m, 2H), 1.10 (m, 10H), 0.83 (t, J = 6.66 Hz, 3H). 13C NMR (75.5 MHz, 
CDCl3): δ = 167.4, 154.7, 148.2, 143.7 (×2), 141.6, 128.1 (×2), 127.0, 111.4, 90.3, 
62.5, 43.3, 40.9, 31.0, 28.2 (×2), 27.4, 25.9, 21.9, 13.8.  
5-(2,4-Dimethoxyphenyl)-N-methy-1H-imidazol-2-amine (BS-136) 
N
N
H
HN
O
O
 
Yield : 48 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.63 (br, 1H), 7.43 (d, J = 3.0 
Hz, 1H), 7.07 (s, 1H), 6.90 (d, J = 8.8 Hz, 1H), 6.63 (d of d, J = 3.1, 3.1 Hz, 1H), 5.73 
(q, J = 5.1 Hz, 1H), 3.80 (s, 3H). 3.71 (s, 3H), 2.77 (d, J= 5.1 Hz, 3H). 13C NMR  
(75.5 MHz, DMSO-d6):  δ =153.1, 151.0, 149.5, 129.3, 123.4, 114.8, 111.8, 111.2, 
110.1, 55.5, 55.2, 29.8. HRMS (EI) C12H15N3O2, calcd 233.1164, found : 233.1173.  
N-((Benzol[d][1,3]dioxol-6-yl)-5-(naphthalene-3-yl)-1H-imidazol-2-amine (BS-
137) 
N
N
H
HN
O
O
 
Yield : 72 %.  1H NMR (300 MHz, DMSO-d6) δ = 10.61 (br, 1H), 8.06 (s, 1H), 7.83-
7.79 (m, 4H), 7.44-7.37 (m, 2H), 7.19 (s, 1H), 6.99 (s, 1H), 6.87-6.86 (m, 2H), 6.32 (t, 
J = 6.4 Hz, 1H), 5.96 (s, 2H), 4.34 (d, J = 6.4 Hz, 2H).  13C NMR  (75.5 MHz, 
DMSO-d6)  δ =151.2, 147.0, 145.8, 134.6, 133.5, 131.3, 127.5 (x 2), 127.4, 127.3, 
126.0,125.6, 124.6, 123.2, 120.4, 108.0 (x 2),107.8, 100.6 (x 2), 46.1. HRMS EI 
C21H17N3O2, calcd 343.1321 , found : 343.1340. 
5-(3,4-Dichlorophenyl)-N-propyl-1H-imidazol-2-amine(BS-140) 
NN
H
HN
C3H7
Cl
Cl
 
Yield : 70 %. 1H NMR (300 MHz, DMSO-d6) δ = 10.55 (br, 1H), 7.82 (s, 1H), 7.58 
(s, 1H), 7.50 (d, J = 8.2 Hz, 1H), 7.22 (s, 1H), 5.83 (t, J = 6.0 Hz, 1H), 3.10 (q, J = 8.2 
Hz, 2H), 1.54 (m, 2H), 0.90 (t, J = 7.35 Hz, 3H). 13C NMR  (75.5 MHz, DMSO-d6)  δ 
=151.6, 130.9 (x 2), 130.3 (x 2), 126.3, 124.6, 123.4, 104.2, 44.7, 22.6, 11.4. HRMS 
EI C12H13Cl2N3, calcd 269.0487, found : 269.0480. 
N-Cyclohexyl-5-(4-(methylsulfonyl)phenyl)-1H-imidazol-2-amine (BS-141) 
N
N
H
HN
S O
O  
Yield : 43 %. 1H NMR (300 MHz, DMSO-d6) δ = 10.54 (br, 1H), 7.83-7.76 (m, 4H), 
7.31 (s, 1H), 5.75 (d, J = 8.4 Hz, 1H), 3.16 (s, 3H), 2.49 (s, 1H), 1.90 (s, 2H), 1.70 (m, 
2H), 1.20 (m, 6H). 13C NMR  (75.5 MHz, DMSO-d6)  δ =151.1, 140.1, 136.1, 127.2(x 
4), 123.4 (x 2), 104.2, 51.1, 43.7, 33.0(x 2), 25.4, 24.6(x 2). HRMS EI C16H21N3O2S, 
calcd 319.1354. , found : 319.1337. 
5-(4-Chlorophenyl)-N-octyl-1H-imidazol-2-amine (BS-143) 
N
N
H
HN
C8H17
Cl  
Yield : 43%. 1H NMR (300 MHz, DMSO-d6) δ = 10.43 (br, 1H), 7.63 (d, J = 8.3 Hz, 
2H), 7.31 (d, J = 8.4 Hz,  2H), 7.09 (s, 1H), 5.71 (t, J = 4.9 Hz, 1H), 3.12 (m, 2H), 
1.48-1.51 (m, 2H), 1.25 (m, 10H), 0.85 (t, J = 4.2 Hz, 3H). 13C NMR  (75.5 MHz, 
DMSO-d6)  δ =151.5, 128.8 (x 2), 128.1 (x 3), 124.9 (x 2), 100.7, 42.9, 31.2, 29.4, 
28.8, 28.7, 26.4, 22.0, 13.9. HRMS EI C17H24ClN3, calcd 305.1659, found : 305.1646. 
5-(4-Chlorophenyl)-N-pentyl-1H-imidazol-2-amine (BS-146) 
N
N
H
HN
C5H11
Cl  
Yield: 57 %.  1H NMR (300 MHz, DMSO-d6) δ = 10.44 (br, 1H), 7.65 (d, J  = 7.3 Hz, 
2H), 7.31 (d, J = 8.3 Hz, 2H), 7.09 (s, 1H), 5.71 (t, J = 5.1 Hz, 1H), 3.12 (m, 2H), 
1.51 (t, J = 1.7 Hz,  2H), 1.30 (m, 4H), 0.88 (t, J = 6.7 Hz,  3H).13C NMR  (75.5 MHz, 
DMSO-d6)  δ =151.5, 128.9 (x 2), 128.1 (x 3), 124.9 (x 2), 104.1, 42.8, 29.1, 28.6, 
21.9, 13.9.HRMS EI C14H18ClN3, calcd 263.1189. , found: 263.1180. 
5-(4-Fluorophenyl)-N-hexyl-1H-imidazol-2-amine (BS-147) 
N
N
H
HN
C6H13
F  
Yield: 61 %.  1H NMR (300 MHz, DMSO-d6) δ = 10.38 (br, 1H), 7.62 (m, 2H), 7.09 
(t, J = 8.8 Hz,  2H), 6.99 (s, 1H), 5.66 (m, 1H), 3.13-3.10 (m, 2H), 1.51 (m, 2H), 1.28 
(m, 6H), 0.87 (t, J = 6.4 Hz,  3H).13C NMR  (75.5 MHz, DMSO-d6)  δ =161.6, 158.5, 
151.4, 125.0, 124.9, 115.0, 114.7, 104.1 (x 2), 42.9, 31.0, 29.4, 26.1, 22.1, 13.8., 
HRMS EI C15H20FN3, calcd 261.1641. , found: 261.1631. 
N-(4-Methoxyphenethyl)-5-(3-bromophenyl)-1H-imidazol-2-amine(BS-148) 
N
N
H
HN
Br
O
 
Yield : 44 %. 1H NMR (300 MHz, DMSO-d6) δ = 10.56 (br, 1H), 7.82 (s, 1H), 7.65 
(d, J = 6.5 Hz, 2H), 7.24-7.16 (m, 5H), 6.88 (d, J = 8.4 Hz, 2H), 5.77 (m, 1H), 3.72 (s, 
3H), 3.35 (s, 2H), 2.77 (t, J = 7.6 Hz, 2H). 13C NMR  (75.5 MHz, DMSO-d6)  δ 
=157.5, 151.3, 131.6 (x 2), 130.3, 129.6 (x 3), 127.3, 125.7, 122.1, 121.9,  113.6 (x 3), 
54.9, 44.8, 34.6.,HRMS EI C18H18BrN3O, calcd 371.0633. , found : 371.0658. 
N-Cyclooctyl-5-(4-(methylsulfonyl)phenyl)-1H-imidazol-2-amine (BS-154) 
N
N
H
HN
SO2Me  
Yield : 53 %.  1H NMR (300 MHz, DMSO-d6) δ = 10.49 (br, 1H), 7.86 (d, J = 8.5 Hz, 
2H), 7.79 (d, J = 8.5 Hz, 2H), 7.31 (d, J = 1.5 Hz, 1H), 5.74 (d, J = 8.4 Hz, 1H), 3.64 
(s, 1H), 3.16 (s, 3H), 1.80 (m, 2H), 1.53 (m, 12H). 13C NMR  (75.5 MHz, CDCl3)  δ = 
151.5, 138.8, 136.2, 127.7 (x 3), 124.0 (x 2), 105.1,  53.7, 44.6, 32.3 (x 2), 27.2 (x 2), 
25.2, 23.4 ( x 2). HRMS EI C18H25N3O2S, calcd 344.1667. , found : 344.1644. 
4-(2-(2-Methoxyethylamino)-1H-imidazole-5-yl)benzonitrile(BS-139) 
N
N
HNH
O
N
 
Yield 85 %. 1H NMR (300 MHz, DMSO d6) δ = 10.6 (br, 1H), 7.7 (m 4H), 7.3 (s 1H), 
5.8 (s 1H), 3.5 (t 2H), 3.4 (m 2H), 3.2 (s 3H). 13C NMR  (300 MHz, DMSO d6)  δ 
=151.3, 140.1, 134.2, 132.2(x 2), 123.8, 119.5, 110.8, 106.4, 104.1, 70.9, 57.9, 54.8, 
43.3. HRMS EI C13H14N4O, calcd 242.1168 , found : 242.1167. 
5-(4-Methoxyphenyl)-N-octyl-1H-imidazol-2-amine (BS-258 )  
N
N
H
N
H
C8H17
O  
Yield : 78 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.91 (br s, 1H), 7.51 (d, J = 8.57 
Hz, 2H), 6.95 (s, 1H), 6.87 (d, J = 8.75 Hz, 2H), 6.05 (m, 1H), 3.74 (s, 3H), 3.16 (m, 
2H), 1.51 (m, 2H), 1.28 (m, 10H), 0.85 (t, J = 6.75 Hz, 3H). 13C NMR (75.5 MHz, 
CDCl3): δ =149.2, 131.1, 129.5, 129.3 (×2), 128.8 (×2), 128.2, 123.4, 43.1, 31.6, 29.5, 
29.0, 28.9, 26.4, 22.2, 14.0. HRMS (EI): C18H27N3O, calcd 301.2154, found: 
301.2142. 
 5-(4-Fluorophenyl)-N-octyl-1H-imidazol-2-amine (BS-259) 
N
N
H
N
H
C8H17
F  
Yield :  69% .  1H NMR (300 MHz, DMSO-d6): δ = 10.44 (br s, 1H), 7.61 (t, J = 5.85 
Hz, 2H), 7.08 (t, J = 8.78 Hz, 2H), 6.99 (s, 1H), 5.67 (t, J = 6.03 Hz, 1H), 3.10 (m, 
2H), 1.51 (m, 2H), 1.25 (m, 10H), 0.83 (m, 3H). 13C NMR (75.5 MHz, CDCl3): δ 
=163.8, 160.5, 148.7, 130.2, 128.4, 127.0, 122.9, 115.5, 104.7, 43.0, 31.6, 29.5, 29.0, 
28.9, 26.4, 22.5, 14.0. HRMS (EI): C17H24FN3, calcd 289.1954, found:. 289.1964. 
5-(3,4-Dichlorophenyl)-N-octyl-1H-imidazol-2-amine (BS-260) 
N
N
H
N
H
C8H17
Cl
Cl
 
Yield : 72 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.52 (br s, 1H), 7.82 (s, 1H), 
7.58 (m, 1H), 7.50 (d, J = 8.13 Hz, 1H), 7.22 (s, 1H), 5.78 (m, 1H), 3.11 (m, 2H), 1.51 
(m, 2H), 1.28 (m, 10H), 0.85 (t, J = 6.94 Hz, 3H). 13C NMR (75.5 MHz, CDCl3): δ 
=149.6, 132.8, 131.1, 131.0, 130.6, 129.5, 127.1, 127.0, 124.2, 43.3, 31.6, 29.5, 29.0, 
28.9, 26.4, 22.5, 14.0. HRMS (EI): C17H23Cl2N3, calcd 339.1269, found:. 339.1279. 
5-(3-Bromophenyl)-N-octyl-1H-imidazol-2-amine (BS-261) 
N
N
H
N
H
C8H17
Br
 
Yield :  79 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.49 (br s, 1H), 7.79 (s, 1H), 
7.59 (s, 1H), 7.22 (m, 1H), 7.14 (s, 1H), 5.73 (t, J = 5.66 Hz, 1H), 3.11 (m, 2H), 1.51 
(m, 2H), 1.25 (m, 10H), 0.84 (t, J = 6.69 Hz, 3H). 13C NMR (75.5 MHz, CDCl3): δ 
=149.2, 133.0, 130.8, 130.1 (×2), 128.0, 126.5, 123.8, 122.6, 43.2, 31.6, 29.5, 29.0, 
28.9, 26.4, 22.5, 14.0. HRMS (EI): C17H24BrN3, calcd 349.1154, found:. 249.1138. 
5-(Naphthalen-1-yl)-N-octyl-1H-imidazol-2-amine (BS-262) 
N
N
H
N
H
C8H17
 
Yield :  68 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.53 (br s, 1H), 8.05 (s, 1H), 
7.80 (m, 3H), 7.39 (m, 3H), 7.17 (s, 1H), 5.73 (m, 1H), 3.16 (m, 2H), 1.54 (m, 2H), 
1.26 (m, 10H), 0.83 (t, J = 6.86 Hz, 3H). 13C NMR (75.5 MHz, CDCl3): δ =149.1, 
133.4, 132.4, 129.5, 128.3, 128.2, 127.9, 127.7, 126.6, 126.4 (×2), 126.0, 123.0, 43.3, 
31.6, 29.5, 29.0, 28.9, 26.4, 22.5, 14.0. HRMS (EI): C21H27N3, calcd 321.4592, 
found:. 321.4578. 
5-(4-Nitrophenyl)-N-octyl-1H-imidazol-2-amine (BS-263) 
N
N
H
N
H
C8H17
NO2  
Yield : 66 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.74 (br s, 1H), 8.12 (d, J = 8.92 
Hz, 2H), 7.84 (d, J = 8.92 Hz, 2H), 7.43 (s.1H), 5.91 (t, J = 5.54 Hz, 1H), 3.16 (m, 
2H), 1.52 (m, 2H), 1.25 (m, 10H), 0.85 (t, J = 6.75 Hz, 3H). 13C NMR (75.5 MHz, 
CDCl3): δ =163.8, 160.5, 148.7, 130.2, 128.4, 127.0, 122.9, 115.5, 104.7, 43.0, 31.6, 
29.5, 29.0, 28.9, 26.4, 22.5, 14.0. HRMS (EI): C17H24N4O2, calcd 316.1899, 
found:.316.1909. 
5-(4’-Nitrobiphenyl-4-yl)-N-octyl-1H-imidazol-2-amine (BS-264) 
N
N
H
N
H
C8H17
NO2  
Yield : 75 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.53 (br s, 1H), 8.27 (d, J = 8.71 
Hz, 2H), 7.96 (d, J = 8.71 Hz, 2H), 7.75 (s.4H), 7.18 (s. 1H), 5.76 (t, J = 5.88 Hz, 
1H), 3.16 (m, 2H), 1.53 (m, 2H), 1.26 (m, 10H), 0.86 (t, J = 6.75 Hz, 3H).  13C NMR 
(75.5 MHz, CDCl3): δ =163.8, 160.5, 148.7, 130.2, 128.4, 127.0, 122.9, 115.5, 104.7, 
43.0, 31.6, 29.5, 29.0, 28.9, 26.4, 22.5, 14.0. HRMS (EI): C23H28N4O2, calcd 
392.2212, found:.392.2201. 
5-(4-(Methylsulfonyl)phenyl)-N-octyl-1H-imidazol-2-amine (BS-265) 
N
N
H
N
H
C8H17
S
O
O
 
Yield : 54 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.62 (br s, 1H), 7.84 (d, J = 8.55 
Hz, 2H), 7.76 (d, J = 8.35 Hz, 2H), 7.32 (s.1H), 5.83 (t, J = 5.97 Hz, 1H), 3.16 (m, 
5H), 1.52 (m, 2H), 1.25 (m, 10H), 0.85 (t, J = 6. 56 Hz, 3H). 13C NMR (75.5 MHz, 
CDCl3): δ =150.7, 138.1, 136.6, 127.9 (×2), 127.6, 127.4 (×2), 126.0, 44.5, 43.6, 31.6, 
29.6, 29.0, 28.9, 26.5, 22.5, 14.0. HRMS (EI): C18H27N3O2S, calcd 349.4909, 
found:.249.4918. 
N-Isobutyl-5-(4-nitrophenyl)-1H-imidazol-2-amine (BS-292) 
N
N
H
N
H NO2  
Yield : 70 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.69 (br s, 1H), 8.12 (d, J = 9.02 
Hz, 2H), 7.84 (d, J = 8.50 Hz, 2H), 7.42 (s, 1H),  5.99 (t, J = 5.93 Hz, 1H), 2.99 (t, J = 
6.44 Hz, 2H), 1.83 (m, 1H), 0.89 (d, J = 6.70 Hz, 6H). 13C NMR (75.5 MHz, DMSO-
d6): δ =152.2 (×2), 143.8, 141.6, 123.9 (×2), 123.3, 104.1 (×2), 50.4, 27.9, 20.1 (×2). 
HRMS (EI): C13H16N4O2, calcd 260.1273, found: 260.1287 
N-Isobutyl-5-phenyl-1H-imidazol-2-amine (BS-293) 
N
N
H
N
H
 
Yield : 71 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.52 (br s, 1H), 7.59 (d, J = 7.47 
Hz, 2H), 7.28 (t, J = 7.47 Hz, 2H), 7.09 (t, J = 7.25 Hz,1H), 7.04 (s,1H),  5.92 (t, J = 
5.71 Hz, 1H), 2.98 (t, J = 6.37 Hz, 2H), 1.82 (m, 1H), 0.89 (d, J = 6.59 Hz, 6H). 13C 
NMR (75.5 MHz, DMSO-d6): δ =151.2, 134.0, 133.1, 128.2 (×2), 125.1, 123.4(×2), 
104.1, 50.5, 27.9, 20.1 (×2). HRMS (EI): C13H17N3, calcd 215.1422, found:215.1411. 
 
 
5-(4-Bromophenyl)-N-isobutyl-1H-imidazol-2-amine (BS-294) 
N
N
H
N
H Br  
Yield : 69 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.46 (br s, 1H), 7.55 (d, J = 8.25 
Hz, 2H), 7.42 (d, J = 8.25 Hz, 2H), 7.08 (s, 1H),  5.80 (t, J = 5.75 Hz, 1H), 2.97 (t, J = 
6.25 Hz, 2H), 1.82 (m, 1H), 0.89 (d, J = 6.50 Hz, 6H). 13C NMR (75.5 MHz, DMSO-
d6): δ =151.6, 134.1, 133.0 (×3), 125.3 (×2), 117.2, 104.1, 50.6, 27.9, 20.1 (×2). 
HRMS (EI): C13H16BrN3, calcd 293.0528, found:293.0529. 
5-(4-Chlorophenyl)-N-isobutyl-1H-imidazol-2-amine (BS-295) 
N
N
H
N
H Cl  
Yield : 73 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.46 (br s, 1H), 7.60 (d, J = 8.35 
Hz, 2H), 7.29 (d, J = 8.35 Hz, 2H), 7.07 (s, 1H),  5.81 (t, J = 5.96 Hz, 1H), 2.97 (t, J = 
6.20 Hz, 2H), 1.82 (m, 1H), 0.89 (d, J = 6.68 Hz, 6H). 13C NMR (75.5 MHz, DMSO-
d6): δ =151.5, 133.6, 133.2, 128.9, 128.0 (×2), 124.9 (×2), 104.1, 50.5, 27.9, 20.1 
(×2). HRMS (EI): C13H16ClN3, calcd 249.1033, found:249.1047. 
 
 
 
 
 
 
 
 
 
 
2.11 Representative NMR spectra    
2.11.1 1H and 13C NMR spectra of bs-026 
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2.11.2 1H and 13C NMR spectra of bs-091 
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2.11.3 1H and 13C NMR spectra of bs-143 
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Structure Activity Relationship of N1-Substituted 2-Aminoimidazoles 
as Inhibitors of Biofilm Formation by Salmonella Typhimurium and 
Pseudomonas aeruginosa 
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A library of N1-substituted 4(5)-phenyl-2-aminoimidazoles was synthesized and 
tested for the antagonistic effect against biofilm formation by Salmonella 
Typhimurium and Pseudomonas aeruginosa. The substitution pattern of the 4(5)-
phenyl group and the nature of the N1-substituent were found to have a major effect 
on the biofilm inhibitory activity. The most active compounds of this series were 
shown to inhibit the biofilm formation at low micromolar concentrations.   
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3.1 Introduction 
 
In previous chapter-2 the dimorth rearrangement was performed to generate 
substituted 2-aminoimidazoles. The 2-aminoimidazole (2-AI) ring structure is of 
particular interest especially within the realms of medicinal chemistry.  For example, 
several classes of marine natural products  possessing  this  structure  were  recently 
discovered  and  identified.l  Many  of  these  compounds display  a broad range of 
biological properties  including antibacterial, anti-inflammatory, anticancer, and 
antiviral activity.  Synthetic 2-AI derivatives, including 2-amino-histamine have been 
shown to have HI- and H2-receptor agonist and antagonist activity.2  Other unrelated 
2-AI derivatives  are  selective  5-HT3  receptor  antagonists, which  may  be  
potentially  useful  in  the  treatment  of chemotherapy induced emesis3. Novel 
cephalosporins with incorporated 2-AI rings display both Gram-positive and Gram-
negative antibacterial activity as well as good ß-lactamase stability4.  In addition, 2-AI 
can serve as an important starting material in the preparation of 2-nitroimidazole 
(azomycin) a naturally occurring antibiotic5. Other synthetic analogs of 2-
nitroimidazole have been found to be cytotoxic toward hypoxic tumor cells and act as 
hypoxic cell radiosensitizers.6 
 
The methods reported to prepare imidazoles are numerous, although only a limited 
number describe the direct synthesis of the corresponding 2-amino derivatives. The  
preparation of 2-AI was accomplished by the intramolecular cyclization of N-(2,2-
diethoxyethyl)guanidine upon acid hydrolysis.7,8 The  reaction of α-amino aldehydes 
or ketones with cyanamide appears to be the most commonly  used direct approach.8,9 
However, this  reaction  is pH  sensitive  and can  lead  to different products.  In one 
case the formation of  lH-imidazo[l,2-a]imidazoles was  observed.8  The dimerization  
and cyclization of a-amino aldehydes or ketones to symmetrical pyrazines is also a 
common problem associated with this method.9a,10  A classical, although indirect 
approach to 2-AI's relies upon the formation of 2-arylazo derivatives via diazonium 
coupling, followed by reduction.2a,7,11 The synthesis of 2-amino-4,5-diarylimidazoles 
was accomplished by the reduction of symmetrical 2,2'-azoimidazoles.13 A  more  
recent procedure was reported where 2-AI's were formed by the reaction of α -
diketones  with  guanidine,  followed  by catalytic hydrogenation.14 Other indirect 
approaches to 2-AI's involve ipso type substitutions of appropriate C-2 substituted 
imidazoles, where the addition of a suitable nitrogen nucleophile is followed by the 
elimination of an activated  leaving  group  such  as  a  halogen  or  alkyl sulfoxide or 
sulfone. This method has been applied with limited success to electron-poor 
imidazoles or when fluorine is the leaving group.4,15 An interesting synthetic route to 
functionalized 2-AI's, which were difficult to obtain by other methods, has been 
achieved using a base catalyzed rearrangement of 3-amino-1,2,4-oxadiazoles.16 
Another type of heterocyclic rearrangement involves the reaction of 2-aminooxazoles 
with ammonia or  formamide.17 Most recently, the synthesis of 2-amino-4(5)-(α-
hydroxyalkyl)imidazoles has been demonstrated where 2-AI was reacted with  
aldehydes  under neutral  conditions.18 
 
The microwave-assisted procedure for the synthesis of 1,4,5-substituted 2-
aminoimidazoles (Scheme-1) is two-step protocol based on the cyclocondensation of 
2-aminopyrimidines and bromocarbonyl compounds at 130-150 °C, followed by the 
cleavage of the intermediary imidazo[1,2-a]pyrimidin-1-ium salts with an excess of 
hydrazine. 
 
3.2 Reaction Scheme 
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3.3 Proposed Mechanism 
 
A possible mechanism for the pyrimidine ring cleavage upon reaction of salts (1) with 
amines, which involves the formation of azabutadienes (Scheme 2), Initially, the 
imidazo[1,2-a]pyrimidinium salt (1) undergoes a nucleophilic attack at its C-5 
position by a first molecule of amine. After rearrangement of the intermediate (A) and 
isomerisation of the resulting (B), (E, E)-azabutadiene (2) is formed. Initiated by 
protonation, the azabutadiene intermediate (C) in turn undergoes 1,4-addition with a 
second molecule of amine, finally resulting in the formation of 2-aminoimidazole (3) 
together with diazapentadienium salt (4) (Scheme-2). 
 
Consistent with this mechanism, the corresponding imidazo[1,2-a]pyrimidinium salts 
(1) can directly be cleaved to 2-aminoimidazoles (3) upon stirring with a large excess 
of secondary amine (6 or more equiv) at room temperature, while the isolated 
azabutadienes (2) appeared to be stable to 20 and more equivalents of piperidine in 
refluxing acetonitrile for 1 h. In contrary, azabutadienes (2) were quantitatively 
cleaved to 2-aminoimidazoles (3) in the presence of 1.5 equiv triethylamine 
hydrochloride salt (Scheme-3.5). 
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3.4 Result and Discussion  
 
It was found that the cyclocondensation of 2-alkylaminopyrimidines with α-
bromoacetophenones at 80 °C first led to stable 2-hydroxy-2,3-dihydroimidazo[1,2-
a]pyrimidinium bromides. The bicyclic nature of the structures clearly followed from 
1H NMR data, indicating the doublet of doublets of the methylene fragments, as well 
as from 13C NMR spectra. 
 
The 2-hydroxy-2,3-dihydroimidazo[1,2-a]pyrimidinium salts were obtained in good 
yields, and only for sterically hindered 2-alkylaminopyrimidines the yields slightly 
decreased. Dehydration of the 2-hydroxy-2,3-dihydroimidazo[1,2-a]pyrimidinium 
salts was successfully achieved by short (15 min) heating in polyphosphoric acid 
(PPA) at 150 °C. The corresponding imidazo[1,2-a]pyrimidinium salts were isolated 
and characterized as perchlorates, and in most cases the yields were almost 
quantitative. The structures of aromatic salts were completely consistent with their 1H, 
and 13C NMR data. 
 
The cleavage step was performed under microwave irradiation at 100 °C, using 7 
equivalents of hydrazine hydrate. Resulting 2-amino-1H-imidazoles were obtained in 
high yields. Using this protocol we have synthesized library of substituted 2-
aminoimidazole (Table-1) 
 
N
NH2N
R1
R2
 
 
 
No. 
Compound 
Code 
R1 R2 Yield % m.p. oC 
1 BS-042 cyclododecane H 53 228-230 
2 BS-045 cyclooctane H 53 152-154 
3 BS-048 cycloheptane H 54 180-182 
4 BS-078 cyclohexane H 64 153-155 
5 BS-081 cyclobutane H 47 77-79 
6 BS-085 C5H11 H 53 123-125 
7 BS-060 C6H13 H 53 - 
8 BS-051 C7H15 H 61 - 
9 BS-054 C8H17 H 55 - 
10 BS-063 C9H19 H 58 - 
11 BS-057 C10H21 H 53 - 
12 BS-066 C11H23 H 52 - 
13 BS-069 C12H25 H 52 - 
14 BS-072 C13H27 H 58 44-46 
15 BS-075 C14H19 H 64 44-46 
16 BS-116 cyclododecane Cl 42 221-223 
17 BS-117 cyclooctane Cl 55 207-209 
18 BS-118 cycloheptane Cl 51 180-182 
19 BS-128 cyclohexane Cl 37 179-181 
20 BS-130 cyclobutane Cl 40 156-158 
21 BS-129 C5H11 Cl 38 96-98 
22 BS-122 C6H13 Cl 53 76-78 
23 BS-119 C7H15 Cl 54 80-82 
24 BS-120 C8H17 Cl 57 76-78 
25 BS-123 C9H19 Cl 50 76-78 
26 BS-121 C10H21 Cl 52 89-91 
27 BS-124 C11H23 Cl 57 78-80 
28 BS-125 C12H25 Cl 57 79-81 
29 BS-126 C13H27 Cl 56 83-85 
30 BS-127 C14H19 Cl 51 82-83 
Yields are isolated yields over 2 steps. 
Table-1: compound library of substituted 2-aminoimidazole 
 
 
 
 
 
NNH2N
C8H17
R1
 
No. 
Compound 
Code 
R1 Yield % 
1 BS-199 4-OCH3 56 
2 BS-200 4-F 71 
3 BS-201 3,4-di Cl 64 
4 BS-202 3-Br 68 
5 BS-203 Naphthalen-1-yl 59 
6 BS-204 4-NO2 66 
7 BS-205 4-(4-NO2-Ph) 52 
8 BS-206 4-SO2Me 61 
9 BS-207 4-SMe 40 
10 BS-208 4-(4-biphenyl)_ 31 
Yields are isolated yields over 2 steps. 
Table -2:  2-aminoimidazole with octyl substitution at N-1 position 
 
3.5 Biofilm Activity 
 
The preliminary results from our lab the basic compound (A) with a non-substituted 
phenyl group at the C(5) position of the imidazole ring shows a moderate biofilm 
inhibitory activity (IC50 = 130 µM).  Interestingly, substitution of the para- position of 
the phenyl ring with a chlorine (B) atom enhances the biofilm inhibitory activity 
about ten times (IC50 = 16 µM).    
N
N
H
H2N
Cl
N
N
H
H2N
A B  
 
In an attempt to improve their biofilm inhibitory activity, we substituted the N1-
position of some of the para-substituted 4(5)-phenyl-2-aminoimidazoles with n-alkyl 
and cyclo-alkyl groups by using our previously established chemistry.  
 
3.5.1 N1-alkyl 2-aminoimidazoles 
 
In first instance a broad variety of  alkyl groups, with lengths ranging from one carbon 
atom to 14 carbon atoms, were introduced at the N1-position of the 4(5)-
monosubstituted 2-aminoimidazoles (A) and (B)  resulting in compounds A-1 to A-
14, and B-1 to B-13 respectively (Table-3).  Each compound was assayed for the 
ability to inhibit S. Typhimurium ATCC14028 biofilm formation at 25 °C.  As 
depicted in figure 1, a clear correlation was found between the length of the alkyl 
substituent and the biofilm inhibitory activity.  In general, compounds with a short 
alkyl chain substitution (C1, C2, C3) on the N1-position have a lower activity as 
compared to their respective unsubstituted counterparts.  This effect is most 
pronounced for the methyl substituent, which causes a reduction in the activity of at 
least 4 times.  To a lesser extent, ethyl and isopropyl substituents also cause a 
reduction in activity. Substitution with a butyl group does not have an unequivocal 
effect. In the case of compound A-4, the activity is enhanced three-fold, while in the 
other cases the activity is reduced.  Remarkably, all the compounds substituted with 
an alkyl group with an intermediate length between 5 and 10 carbon atoms are very 
active biofilm inhibitors, with IC50 values in general below 12 µM. The effect of 
substitution with a longer alkyl chain drastically depends on the nature of the 
substituent on the C5-position of the ring (phenyl or p-chlorophenyl). Indeed, 
replacement of the N1-hydrogen of compound (A) (phenyl on C5 of the ring) by a 
long alkyl chain (C11-C14) raises the activity drastically, from an IC50 of 130 µM for 
compound (A) to values below 8 µM for the substituted compounds (A-11 to A-14).  
In the case of compound (B) (p-chlorophenyl on C5 of the ring), substitution with an 
undecyl (B-10) and dodecyl (B-11) group results in very active compounds IC50 
values below 5 µM), while introduction of a tridecyl group (B-12) does not have a 
clear effect on the biofilm inhibitory activity and introduction of a tetradecyl (B-13) 
group drastically reduces the activity (IC50 = 453 µM).  Subsequently, we investigated 
the influence of some of the most active representatives of this class of compounds on 
the planktonic growth curve of S. Typhimurium at 25°C.  Most compounds only show 
a very small concentration range with a specific effect on biofilm formation and no 
effect on the planktonic growth (Table-3). Therefore we cannot exclude the possibility 
that the biofilm inhibitory effect of these compounds (at the higher concentrations) is 
partially due to a reduction of the planktonic growth of the bacteria in the growth 
medium used in the set-up to monitor biofilm formation. Interestingly, compound A-
14 with a long alkyl chain, does not follow this general trend as no effect on the 
growth was observed at 80 µM while the biofilm formation was inhibited at 9 µM. 
 
As depicted in table-3 and figure 1, a similar structure activity relationship was found 
for the inhibition of P. aeruginosa biofilm formation at 25°C.  Again, introduction of 
a short alkyl chain at the N1-position generally results in a decreased activity (except 
for compound (A-2), while all the compounds with an intermediate alkyl chain length 
show very strong activities. The effect of substitution with a long alkyl chain is in this 
case also dependent on the nature of the C5-subsitutent. In the case of compound (A), 
substitution with a long alkyl chain results in very active compounds (A-10 to A-14), 
The activity of compound (B) is also decreased after introduction of a long N1-alkyl 
chain, (compounds B-9 to B-13).  Interestingly, growth curve analysis revealed that 
these compounds are much less toxic to P. aeruginosa than to S. Typhimurium.  Most 
compounds show a broad concentration range with only biofilm inhibition and no 
effect on the planktonic growth (table -3). 
 
N
NH2N
R1
R2
 
No. 
Compound 
Code 
R1 R2 
S. Typhimurium 
IC50 
P. aeruginosa 
IC50 
1 A-1 Me H 431.5 95.1 
2 A-2 Et H 206.0 20.6 
3 A-3 i-pr H 175.5 4.5 
4 A-4 n-Bu H 51.9 2.1 
5 A-5 n-Pen H 48.3 2.0 
6 A-6 n-Hex H 39.6 19.1 
7 A-7 n-Hep H 12.2 6.8 
8 A-8 n-Oct H 11.8 18.5 
9 A-9 n-Non H 5.9 8.3 
10 A-10 n-Dec H 6.1 15.0 
11 A-11 n-Und H 7.1 16.2 
12 A-12 n-Dod H 7.1 12.8 
13 A-13 n-Trd H 5.9 27.2 
14 A-14 n-Tet H 8.6 9.7 
15 B-1 Me Cl 108.1 111.8 
16 B-2 Et Cl 53.1 11.3 
17 B-3 n-Bu Cl 57.8 16.9 
18 B-4 n-Pen Cl 8.0 6.0 
19 B-5 n-Hex Cl 4.9 5.3 
20 B-6 n-Hep Cl 9.3 2.6 
21 B-7 n-Oct Cl 5.8 3.9 
22 B-8 n-Non Cl 3.9 8.0 
23 B-9 n-Dec Cl 4.0 22.3 
24 B-10 n-Und Cl 4.0 42.9 
25 B-11 n-Dod Cl 6.1 49.7 
26 B-12 n-Trd Cl 19.5 33.8 
27 B-13 n-Tet Cl 453.3 19.0 
 
IC50: concentration of inhibitor needed to inhibit biofilm formation by 50%. 
Explanation Note: Number of compound code is also corresponding to the number of 
carbon chain at R1 position. (ie. A-1 is Methyl substituted ) 
Table-3: Influence of N1-alkylated 2-aminoimidazoles on the biofilm formation and 
the planktonic growth of S. Typhimurium ATCC14028 and P. aeruginosa PA14 at 
25°C.  
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Figure-1 Effect of introduction of alkyl chains with different lengths (1-14 C-
atoms; at the N1-postion of compound A (Blue) and B (Red) on the IC50 (µM) for 
inhibition of the biofilm formation of S. Typhimurium ATCC14028 at 25°C in TSB 
1/20.   
 
3.5.2 Further Modification in the most active core structure 
 
The introduction of a n-octyl side chain at the N1-position of compounds (A) and (B) 
does result in very active inhibitors of both the Salmonella and Pseudomonas biofilm 
formation, we also decided to introduce an n-octyl chain at the N1-position of some 
other 4(5)-phenyl-2-amino-1H-imidazoles and evaluate the biofilm inhibitory activity 
of the substituted compounds (table 4).  All the compounds (C8-1 to C8-10) are 
active inhibitors of both the S. Typhimurium and P. aeruginosa biofilm formation at 
25°C, except for compounds C8-7 and C8-10.  These compounds have very bulky 
C5-substituents, which could diminish the solubility of the compounds in the growth 
medium, reduce the uptake into the cell or cause steric hindrance in the putative 
receptor binding pocket. Growth curve analysis confirmed the previously described 
finding that the N1-alkylated 2-aminoimidazoles in general show a broad 
concentration range in which they specifically inhibit the biofilm formation of P. 
aeruginosa, without reducing the planktonic growth of the bacteria, while this 
concentration range is smaller in the case of S. Typhimurium.  Compounds C8-7 and 
C8-10 are exceptions to this rule as we found them to slow down the planktonic 
growth of P. aeruginosa at the IC50 for biofilm inhibition. 
N
NH2N
C8H17
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Sr. 
Compound 
Code 
R1 
S. 
Typhimurium 
IC50 
P. aeruginosa 
IC50 
1 C8-1 4-OCH3 8.5 1.2 
2 C8-2 4-F 10.7 4.8 
3 C8-3 3,4-di Cl 3.7 - 
4 C8-4 3-Br 11.1 40.6 
5 C8-5 Naphthalen-1-yl 6.5 17.6 
6 C8-6 4-NO2 35.4 - 
7 C8-7 4-(4-NO2-Ph) 116.6 >800 
8 C8-8 4-SO2Me 29.1 4.9 
9 C8-9 4-SMe 6.6 2.7 
10 C8-10 4-(4-biphenyl) >800 >800 
 
IC50: concentration of inhibitor needed to inhibit biofilm formation by 50%. 
Table-4: Influence of N1-octyl-2-aminoimidazoles on the biofilm formation and the 
planktonic growth of  S. Typhimurium ATCC14028 and P. aeruginosa PA14 at 25°C. 
 
 
 
 
 
3.5.3 Cyclo-alkyl 2-aminoimidazoles 
 
To determine whether the introduction of an intermediate or long cyclo-alkyl chain 
could also enhance the activity of the compounds, a broad variety of cyclo-alkyl 
groups, with lengths ranging from 4 to 12 carbon atoms, were introduced at the N1-
position of the 4(5)-monosubstituted 2-aminoimidazoles (A) and (B) (table 5). The 
compounds were tested against biofilm formation of S. Typhimurium and P. 
aeruginosa at 25°C.  As depicted introduction of an intermediate cyclo-alkyl chain 
does improve the biofilm inhibitory activity of compound (A) against S. Typhimurium 
and even more drastically against P. aeruginosa.  In the case of Salmonella, 
introduction of a cyclo-heptyl chain yields the most active compound (compound A-
Cy-5) with an IC50 of 27 µM, as compared to 130 µM for compound (A).  In the case 
of Pseudomonas, cyclo-hexyl and cyclo-octyl are the best substituents as introduction 
of these groups improves the activity drastically from an IC50 of 73 µM.  All 
compounds derived from (B) by introduction of an intermediate length side chain are 
very strong inhibitors of the Salmonella and Pseudomonas biofilm formation (table 
5), although their activity is not markedly better than the activity of the unsubstituted 
compounds.  Introduction of a dodecyl side chain abolishes the activity of all three 
compounds against P. aeruginosa biofilm formation, while the effect of a cyclo-
dodecyl substituent on the Salmonella biofilm inhibition depends on the nature of the 
C5-group.  Indeed, compound A-Cy-7, derived from (A) by introduction of a cyclo-
dodecyl group, is a very strong biofilm inhibitor, while compound B-Cy-6, derived 
from (B), is a moderate biofilm inhibitor.   As in the case of the n-alkyl substituents, 
growth curve analysis revealed that most compounds with cyclo-alkyl substituents 
only possess a very small concentration range with a selective effect on the 
Salmonella biofilm formation and no effect on the planktonic growth.  An exception 
is compound A-Cy-7, with a cyclo-dodecyl side chain, which does not affect the 
planktonic growth of Salmonella at 80 µM (the highest concentration tested), while 
the IC50 for biofilm inhibition is 15 µM.  Interestingly, the concentration range 
between biofilm inhibition and growth inhibition is much broader in the case of P. 
aeruginosa (table-5).  
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No. 
Compound 
Code 
R1 R2 
S. Typhimurium 
IC50 
P. aeruginosa 
IC50 
1 A-Cy-1 c-Pr H 89.6 35.0 
2 A-Cy-2 c-Bu H 116.3 19.9 
3 A-Cy-3 c-Pen H 70.7 12.6 
4 A-Cy-4 c-Hex H 85.1 4.6 
5 A-Cy-5 c-Hep H 26.8 14.2 
6 A-Cy-6 c-Oct H 40.4 4.5 
7 A-Cy-7 c-Dod H 14.5 >800 
8 B-Cy-1 c-Pr Cl 54.8 13.0 
9 B-Cy-2 c-Bu Cl 11.5 6.0 
10 B-Cy-3 c-Hex Cl 33.2 11.2 
11 B-Cy-4 c-Hep Cl 15.6 4.0 
12 B-Cy-5 c-Oct Cl 12.8 48.6 
13 B-Cy-6 c-Dod Cl 120.2 >800 
 
IC50: concentration of inhibitor needed to inhibit biofilm formation by 50%. 
Explanation Note: Number of compound code is also corresponding to the ring size of 
cyclic substitution at R1 position. (ie. A-Cy-1 is Cyclopropyl substituted ) 
 
Table-5: Influence of N1-cyclo-alkyl-2-aminoimidazoles on the biofilm formation 
and the planktonic growth of S. Typhimurium and P. aeruginosa PA14 at 25°C. 
 
 
 
 
 
 
 
3.6. Conclusion 
 
In the present study, we investigated the effect of the different substitution on 2-
aminoimidazoles on the biofilm formation of S. Typhimurium and P. aeruginosa.  We 
found that our simplest 2-aminoimidazole structure, 4(5)-phenyl-2-amino-1H-
imidazole (A), showed a moderate biofilm inhibitory activity both against S. 
Typhimurium and P. aeruginosa. Substitution of the para-position of the 4(5)-phenyl 
ring with a chlorine atom (B) enhanced the biofilm inhibitory activity about ten times. 
We were able to delineate a relationship between the length of the N1-alkyl or N1-
cyclo-alkyl chain of the N1-substituted 2-aminoimidazoles and their biofilm 
inhibitory activity.  In general, introduction of a short alkyl chain at the N1-position 
resulted in a decreased activity against S. Typhimurium and P. aeruginosa biofilm 
formation, while all compounds with an intermediate alkyl or cyclo-alkyl chain length 
showed very strong activities in both test systems. The introduction of a long alkyl or 
cylco-alkyl chain could either drastically enhance the activity or totally abolish the 
activity, depending on the nature of the C5-subsitutent and the bacterial species tested. 
Growth curve analysis revealed that the N1-(cyclo-)alkylated 2-aminoimidazoles 
show a broad concentration range in which they specifically inhibit the biofilm 
formation of P. aeruginosa, without retarding the planktonic growth of the bacteria.  
However, these compounds were much more toxic to S. Typhimurium. Therefore, we 
cannot exclude the possibility that a part of the inhibitory effect against Salmonella 
biofilms (at the higher concentrations) is due to a reduction of the planktonic growth 
of the bacteria in the growth medium surrounding the surface on which the biofilms 
are formed.   
In conclusion, the 2-aminoimidazoles and the imidazopyrimidinium salts of the 
present study are valuable candidates in the development of therapeutics and 
sanitizers for the combat of biofilm formation by S. Typhimurium, P. aeruginosa and 
possibly other pathogenic bacteria. 
 
 
 
 
 
3.7 Experimental 
3.7.1 General Methods 
 
All chemical reagents were used without further purification. Solvents for column 
chromatography and TLC were laboratory grade and distilled before use. For thin-
layer chromatography (TLC), analytical TLC plates (Alugram SIL G/UV254 (E. M. 
Merk) were used. Column chromatography was performed with flash silica gel (100-
200 mesh) or neutral alumina oxide (50-200 micron). 1H and 13C NMR spectra were 
recorded on a Bruker Avance 300 (300 MHz) or a Bruker AMX-400 (400 MHz) 
spectrometers. NMR samples were run in the indicated solvents and were referenced 
internally. Chemical shift values were quoted in ppm and coupling constants were 
quoted in Hz. Chemical shift multiplicities were reported as s = singlet, d = doublet, t 
= triplet, q = quartet, m = multiplet and br = broad. Low-resolution mass spectra were 
recorded on a HEWLETT-PACKARD instrument (CI or EI) and LCQ Advantage 
instrument (ESI). High-resolution mass spectra (EI) were recorded on a KRATOS 
MS50TC instrument. Melting points were determined using Reichert-Jung Thermovar 
apparatus and were uncorrected. 
 
3.7.2 Microwave Irradiation Experiments 
Microwave irradiation experiments were carried out in a dedicated CEM-Discover 
mono-mode microwave apparatus or Milestone MicroSYNTH multi-mode microwave 
reactor (Laboratory Microwave Systems). Microwave apparatuses were used in the 
standard configuration as delivered, operating at a frequency 2.45 GHz with 
continuous irradiation power from 0 to 400 W. The reactions were carried out in 10, 
20, 30 and 50 mL glass tubes. The temperature was measured with an IR sensor on 
the outer surface of the process vial or fibre optic sensor inside the process vial. After 
the irradiation period, the reaction vessel was cooled rapidly (2-5 min) to ambient 
temperature by air jet cooling. 
 
 
 
 
3.8. Experimental protocols 
 
3.8.1 General Procedure for the Preparation of hydroxy Salts. (Microwave) 
According to process described in chapeter-2  40 new hydrocy salts were 
synthesized 
 
3.8.2  General Procedure for the Preparation of HClO4 Salts.  
A mixture of 84% polyphosphoric acid (3 g) and hydroxy salts (3 mmol) was heated 
in 50 ml beaker upon intensive stirring at 150 °C for 15 min.  After cooling to the 
room temperature the resulting viscous mass was dissolved in 30 ml of water and 1 ml 
(10 mmol) of 70% HClO4 was added dropwise upon mild stirring. The white 
precipitate was washed with distilled water (3×10 mL), ether (2×10 mL) until a 
neutral reaction of the pH paper and then dried over P2O5 to give salt as fine white 
crystals. 
In similar manner 40 new compounds were synthesized. 
3.8.3 General Procedure for the Microwave-Assisted Synthesis of 2-
aminoimidazoles. 
 
To a suspension of HClO4 salt (2 mmol) in MeCN (5 mL) hydrazine hydrate (0.7 mL, 
14 mmol of a 64% solution, 7 equiv) was added, and the mixture was irradiated in the 
sealed Milestone MicroSYNTH microwave reactor for 10 min at a ceiling 
temperature of 100 °C at 150 W maximum power. After cooling down the reaction 
was worked up by diluting with DCM (300 mL), washing with sat. NH4Cl solution 
(150 mL), brine (150 mL) and water (2×150 mL) and drying over anhydrous Na2SO4. 
After filtration and concentration the resulting residue was purified by column 
chromatography (silica gel; DCM−MeOH, 9:1 v/v with 3% TEA) to afford the 
product as a colourless solid. 
40 new compounds were synthesized In similar manner. 
 
 
 
 
 
 
3.9 Spectral Characterization 
 
1-Cyclododecyl-5-phenyl-1H-imidazol-2-amine (BS-042) 
N
NH2N
 
Yield: 42 %. Mp: 228-230 °C. 1H NMR (300 MHz, CDCl3): δ = 7.38 (m, 5H), 6.59 (s, 
1H), 4.16 (m, 1H), 3.98 (br, 2H), 1.88 (m, 5H), 1.22(m, 14H), 0.90 (m, 3H). 13C NMR 
(75.5 MHz, CDCl3): δ =148.4, 131.4, 131.2, 129.8 (× 2), 128.3 (×2), 127.5, 122.1, 
50.0, 29.1(×2), 24.0 (×2), 23.9 (×2), 22.6 (×2), 21.9 (×2), 21.5. HRMS (EI):C21H31N3, 
calcd 325.2518, found: 325.2511. 
 
1-Cyclooctyl-5-phenyl-1H-imidazol-2-amine (BS-045) 
N
NH2N
 
Yield: 53 %. Mp: 152-154 °C. 1H NMR (300 MHz, CDCl3): δ = 7.43-7.28 (m, 5H), 
6.60 (s, 1H), 4.24 (m, 1H), 3.98 (br, 2H), 2.11 (m, 2H), 1.87 (m, 4H), 1.50 (m, 7H), 
1.25 (m, 1H). 13C NMR (75.5 MHz, CDCl3): δ =148.1, 131.2, 129.5, 129.0 (×2), 
128.4 (×2), 127.3, 122.7, 54.5, 33.1(×2), 26.2, 25.8 (×2), 25.3 (×2). HRMS (EI): 
C17H23N3, calcd 269.1892, found: 269.1893. 
 
1-Cycloheptyl-5-phenyl-1H-imidazol-2-amine (BS-048) 
N
NH2N
 
Yield: 54 %. Mp: 180-182 °C. 1H NMR (300 MHz, CDCl3): δ = 7.43-7.29 (m, 5H), 
6.59 (s, 1H), 4.09 (m, 3H), 2.13 (m, 2H), 1.95 (m, 2H), 1.73 (m, 2H), 1.54 (m, 6H). 
13C NMR (75.5 MHz, CDCl3): δ =148.2, 131.1, 129.6, 128.9 (×2), 128.5 (×2), 127.3, 
122.6, 54.6, 33.3(×2), 27.3 (×2), 25.7 (×2). HRMS (EI): C16H21N3, calcd 255.1735, 
found: 255.1759.  
 
1-Heptyl-5-phenyl-1H-imidazol-2-amine (BS-051) 
N
NH2N
C7H15  
Yield: 61 %. 1H NMR (300 MHz, CDCl3): δ = 7.43-7.31 (m, 5H), 6.67 (s, 1H), 3.95 
(br, 2H), 3.75(t, J = 7.5 Hz, 2H), 1.59 (m, 2H), 1.17 (m, 8H), 0.84 (t, J = 6.5 Hz, 3H). 
13C NMR (75.5 MHz, CDCl3): δ =149.0, 131.0, 129.4, 128.6 (×2), 128.2 (×2), 127.2, 
122.6, 43.1, 31.5, 29.5, 28.6, 26.4, 22.4, 14.0. HRMS (EI): C16H23N3, calcd 257.1892, 
found: 257.1908. 
 
1-Octyl-5-phenyl-1H-imidazol-2-amine (BS-054) 
N
NH2N
C8H17  
Yield: 55 %. 1H NMR (300 MHz, CDCl3): δ = 7.40-7.31 (m, 5H), 6.67 (s, 1H), 4.02 
(br, 2H), 3.75(t, J = 7.3 Hz, 2H), 1.59 (m, 2H), 1.17 (m, 10H), 0.85 (t, J = 6.6 Hz, 
3H). 13C NMR (75.5 MHz, CDCl3): δ =149.1, 131.0, 129.4, 128.6 (×2), 128.2 (×2), 
127.2, 122.6, 43.1, 31.6, 29.5, 29.0, 28.9, 26.4, 22.2, 14.0. HRMS (EI): C17H25N3, 
calcd 271.2048, found: 271.2035.  
 
1-Decyl-5-phenyl-1H-imidazol-2-amine (BS-057) 
N
NH2N
C10H21  
Yield: 53 %. 1H NMR (300 MHz, CDCl3): δ = 7.41-7.29 (m, 5H), 6.67 (s, 1H), 4.15 
(br, 2H), 3.75(t, J = 7.3 Hz, 2H), 1.58 (m, 2H), 1.21 (m, 14H), 0.87 (t, J = 6.5 Hz, 
3H). 13C NMR (75.5 MHz, CDCl3): δ =148.9, 131.0, 129.4, 128.6 (×2), 128.3 (×2), 
127.2, 122.6, 43.1, 31.8, 29.5, 29.4, 28.3, 29.2, 28.9, 26.4, 22.2, 14.1. HRMS (EI): 
C19H29N3, calcd 299.2361, found: 299.2365. 
 
 
1-Hexyl-5-phenyl-1H-imidazol-2-amine (BS-060) 
N
NH2N
C6H13  
Yield: 53 %. 1H NMR (300 MHz, CDCl3): δ = 7.41-7.30 (m, 5H), 6.67 (s, 1H), 3.98 
(br, 2H), 3.75(t, J = 7.4 Hz, 2H), 1.59 (m, 2H), 1.18 (m, 6H), 0.82 (t, J = 6.4 Hz, 3H). 
13C NMR (75.5 MHz, CDCl3): δ =149.0, 131.0, 129.4, 128.6 (×2), 128.2 (×2), 127.2, 
122.8, 43.1, 31.1, 29.5, 26.1, 22.4, 13.8. HRMS (EI): C15H21N3, calcd 243.1735, 
found: 243.1730. 
 
1-Nonyl-5-phenyl-1H-imidazol-2-amine (BS-063) 
N
NH2N
C9H19  
Yield: 58 %. 1H NMR (300 MHz, CDCl3): δ = 7.31 (m, 5H), 6.67 (s, 1H), 3.95 (br, 
2H), 3.75(t, J = 7.5 Hz, 2H), 1.58 (m, 2H), 1.17 (m, 12H), 0.86 (t, J = 6.6 Hz, 3H). 
13C NMR (75.5 MHz, CDCl3): δ =152.6, 134.6, 132.9, 132.1 (× 2), 131.7 (× 2), 130.7, 
126.4, 46.6, 35.3, 33.0, 32.8, 32.6, 32.5, 30.0, 26.1, 17.6. HRMS (EI): C18H27N3, calcd 
285.2205, found: 285.2222. 
 
5-Phenyl-1-undecyl-1H-imidazol-2-amine (BS-066)  
N
NH2N
C11H23  
Yield: 52 %. 1H NMR (300 MHz, CDCl3): δ = 7.42-7.31 (m, 5H), 6.67 (s, 1H), 3.99 
(br, 2H), 3.75 (t, J = 7.0 Hz, 2H), 1.59 (m, 2H), 1.17 (m, 16H), 0.87 (t, J = 6.4 Hz, 
3H). 13C NMR (75.5 MHz, CDCl3): δ =149.1, 131.0, 129.4, 128.6 (×2), 128.2 (×2), 
127.1, 122.9, 43.1, 31.8, 29.5 (× 2), 29.4, 29.3, 29.2, 28.9, 26.4, 22.6, 14.1. HRMS 
(EI): C20H31N3, calcd 313.2518, found: 313.2512. 
 
1-Dodecyl-5-phenyl-1H-imidazol-2-amine (BS-069) 
N
NH2N
C12H25  
Yield: 52 %. 1H NMR (300 MHz, CDCl3): δ = 7.39-7.30 (m, 5H), 6.67 (s, 1H), 3.99 
(br, 2H), 3.75 (t, J = 7.2 Hz, 2H), 1.58 (m, 2H), 1.17 (m, 18H), 0.88 (t, J = 6.4 Hz, 
3H). 13C NMR (75.5 MHz, CDCl3): δ =149.0, 131.1, 129.4, 128.6 (×2), 128.2 (×2), 
127.1, 123.0, 43.1, 31.9, 29.5 (× 3), 29.4, 29.3(× 2), 28.9, 26.4, 22.6, 14.1. HRMS 
(EI): C21H33N3, calcd 327.2674, found: 327.2663. 
 
5-Phenyl-1-tridecyl-1H-imidazol-2-amine (BS-072) 
N
NH2N
C13H27  
Yield: 58 %. Mp: 44-46 °C. 1H NMR (300 MHz, CDCl3): δ = 7.40-7.31 (m, 5H), 6.67 
(s, 1H), 3.99 (br, 2H), 3.75 (t, J = 7.3 Hz, 2H), 1.58 (m, 2H), 1.17 (m, 20H), 0.88 (t, J 
= 6.4 Hz, 3H). 13C NMR (75.5 MHz, CDCl3): δ =148.9, 131.0, 129.4, 128.6 (×2), 
128.2 (×2), 127.1, 122.7, 43.1, 31.9, 29.5 (× 7), 28.9, 26.4, 22.6, 14.1. HRMS (EI): 
C22H35N3, calcd 341.2831, found: 341.2827. 
 
5-Phenyl-1-tetradecyl-1H-imidazol-2-amine (BS-075) 
N
NH2N
C14H29  
Yield: 64 %. Mp: 44-46 °C. 1H NMR (300 MHz, CDCl3): δ = 7.41-7.30 (m, 5H), 6.67 
(s, 1H), 4.00 (br, 2H), 3.75 (t, J = 7.4 Hz, 2H), 1.58 (m, 2H), 1.17 (m, 22H), 0.88 (t, J 
= 6.3 Hz, 3H). 13C NMR (75.5 MHz, CDCl3): δ =148.8, 131.0, 129.5, 128.6 (×2), 
128.3 (×2), 127.2, 122.8, 43.1, 31.9, 29.6 (× 8), 28.9, 26.4, 22.6, 14.1. HRMS (EI): 
C23H37N3, calcd 355.2987, found: 355.3016. 
 
1-Cyclohexyl-5-phenyl-1H-imidazol-2-amine (BS-078) 
N
NH2N
 
Yield: 64 %. Mp: 153-155 °C. 1H NMR (300 MHz, CDCl3): δ = 7.42-7.28 (m, 5H), 
6.60 (s, 1H), 3.89 (m, 3H), 1.88 (m, 6H), 1.64 (m, 1H), 1.18 (m, 3H). 13C NMR (75.5 
MHz, CDCl3): δ =148.4, 131.2, 130.0, 129.0 (×2), 128.5 (×2), 127.3, 122.6, 55.1, 
31.2(×2), 25.9 (×2), 25.1. HRMS (EI): C15H19N3, calcd 241.1579, found: 241.1589.  
 
1-Cyclobutyl-5-phenyl-1H-imidazol-2-amine (BS-081) 
N
NH2N
 
Yield: 47%. Mp: 77-79 °C. 1H NMR (300 MHz, CDCl3): δ = 7.41-7.28 (m, 5H), 6.58 
(s, 1H), 4.61 (m, 1H), 4.07 (br, 2H), 2.51 (m, 2H), 2.27 (m, 2H), 1.75 (m, 2H). 13C 
NMR (75.5 MHz, CDCl3): δ =149.1, 131.3, 129.7, 128.6 (×2), 128.3 (×2), 127.1, 
122.9, 49.2, 29.5 (×2), 15.0. HRMS (EI): C13H15N3, calcd 213.1266, found: 213.1268. 
 
1-Pentyl-5-phenyl-1H-imidazol-2-amine (BS-085) 
N
NH2N
C5H11  
Yield: 53 %. Mp: 123-125 °C. 1H NMR (300 MHz, CDCl3): δ = 7.46-7.29 (m, 5H), 
6.67 (s, 1H), 4.00 (br, 2H), 3.75 (t, J = 7.5 Hz, 2H), 1.59 (m, 2H), 1.19 (m, 4H), 0.81 
(t, J = 6.7 Hz, 3H). 13C NMR (75.5 MHz, CDCl3): δ =149.0, 131.0, 129.4, 128.6 (×2), 
128.2 (×2), 127.2, 122.8, 43.1, 29.2, 28.6, 22.0, 13.8. HRMS (EI): C14H19N3, calcd 
229.1579, found: 229.1594.  
 
5-(4-Chlorophenyl)-1-cyclododecyl-1H-imidazol-2-amine (BS-116) 
N
NH2N
Cl
 
Yield: 42 %. Mp: 221-223 °C 1H NMR (300 MHz, CDCl3): δ = 7.38 (m, 5H), 6.59 (s, 
1H), 4.16 (m, 1H), 3.98 (br, 2H), 1.88 (m, 5H), 1.22(m, 14H), 0.90 (m, 3H). 13C NMR 
(75.5 MHz, CDCl3): δ =148.4, 131.4, 131.2, 129.8 (×2), 128.3 (×2), 127.5, 122.1, 
50.0, 29.1(×2), 24.0 (×2), 23.9 (×2), 22.6 (×2), 21.9 (×2), 21.5. HRMS (EI):C21H31N3, 
calcd 325.2518, found: 325.2118.  
5-(4-Chlorophenyl)-1-cyclooctyl-1H-imidazol-2-amine (BS-117) 
N
NH2N
Cl
 
Yield: 55 %. Mp: 207-209 °C.  1H NMR (300 MHz, CDCl3): δ = 7.37 (d, J = 8.4 Hz, 
2H), 7.20 (d, J = 8.4 Hz, 2H), 6.59 (s, 1H), 4.18 (m, 1H), 4.02 (br, 2H), 2.12 (m, 2H), 
1.85 (m, 4H), 1.50 (m, 7H), 1.25 (m, 1H). 13C NMR (75.5 MHz, CDCl3): δ =148.6, 
131.1, 130.0 (× 2), 129.7, 128.7 (×2), 128.3, 123.4, 56.7, 33.3(×2), 27.2 (×3), 25.7 
(×2). HRMS (EI): C17H22ClN3, calcd 303.1502, found: 303.1519.  
 
5-(4-Chlorophenyl)-1-cycloheptyl-1H-imidazol-2-amine (BS-118) 
N
NH2N
Cl
 
Yield: 51 %. Mp: 180-182 °C. 1H NMR (300 MHz, CDCl3): δ = 7.36 (d, J = 8.4 Hz, 
2H), 7.18 (d, J = 8.4 Hz, 2H), 6.59 (s, 1H), 4.00 (m, 3H), 2.12 (m, 2H), 1.92 (m, 2H), 
1.75 (m, 2H), 1.55 (m, 6H). 13C NMR (75.5 MHz, CDCl3): δ =148.6, 131.1, 130.0 
(×2), 129.7, 128.7 (×2), 128.3, 123.4, 56.7, 33.3(×2), 27.2 (×2), 25.7 (×2). HRMS 
(EI): C16H20ClN3, calcd 289.1346, found: 289.1364.  
 
5-(4-Chlorophenyl)-1-heptyl-1H-imidazol-2-amine (BS-119) 
N
NH2N
C7H15
Cl
 
Yield: 54 %. Mp: 80-82 °C. 1H NMR (300 MHz, CDCl3): δ = 7.35 (d, J = 8.4 Hz, 2H), 
7.23 (d, J = 8.4 Hz, 2H), 6.66 (s, 1H), 4.02 (br, 2H), 3.72(t, J = 7.5 Hz, 2H), 1.57 (m, 
2H), 1.18 (m, 8H), 0.84 (t, J = 6.5 Hz, 3H). 13C NMR (75.5 MHz, CDCl3): δ =149.4, 
133.0, 129.6, 129.3 (×2), 128.8 (×2), 128.1, 123.5, 43.1, 31.5, 29.5, 28.6, 26.4, 22.5, 
14.2. HRMS (EI): C16H22ClN3, calcd 291.1502, found: 291.1507.  
 
 
5-(4-Chlorophenyl)-1-octyl-1H-imidazol-2-amine (BS-120) 
N
NH2N
C8H17
Cl
 
Yield: 57 %. Mp: 76-78 °C. 1H NMR (300 MHz, CDCl3): δ = 7.35 (d, J = 8.4 Hz, 2H), 
7.23 (d, J = 9.3 Hz, 2H), 6.67 (s, 1H), 3.95 (br, 2H), 3.73(t, J = 7.2 Hz, 2H), 1.57 (m, 
2H), 1.18 (m, 10H), 0.86 (t, J = 6.6 Hz, 3H). 13C NMR (75.5 MHz, CDCl3): δ =149.2, 
131.1, 129.5, 129.3 (×2), 128.8 (×2), 128.2, 123.4, 43.1, 31.6, 29.5, 29.0, 28.9, 26.4, 
22.2, 14.0. HRMS (EI): C17H24ClN3, calcd 305.1659, found: 305.1649. 
 
5-(4-Chlorophenyl)-1-decyl-1H-imidazol-2-amine (BS-121) 
N
NH2N
C10H21
Cl
 
Yield: 52 %. Mp: 89-91 °C. 1H NMR (300 MHz, CDCl3): δ = 7.35 (d, J = 8.4 Hz, 2H), 
7.33 (d, J = 9.0 Hz, 2H), 6.67 (s, 1H), 3.97 (br, 2H), 3.72 (t, J = 7.4 Hz, 2H), 1.57 (m, 
2H), 1.18 (m, 14H), 0.87 (t, J = 6.5 Hz, 3H). 13C NMR (75.5 MHz, CDCl3): δ =148.3, 
133.0, 129.5, 129.3 (×2), 128.8 (×2), 128.2, 123.5, 43.1, 31.8, 29.5, 29.4 (×2), 29.2, 
28.9, 26.4, 22.6, 14.1. HRMS (EI): C19H28ClN3, calcd 333.1972, found: 333.1999. 
 
5-(4-Chlorophenyl)-1-hexyl-1H-imidazol-2-amine (BS-122) 
N
NH2N
C6H13
Cl
 
Yield: 53 %. Mp: 76-78 °C. 1H NMR (300 MHz, CDCl3): δ = 7.35 (d, J = 8.4 Hz, 2H), 
7.23 (d, J = 8.4 Hz, 2H), 6.67 (s, 1H), 3.97 (br, 2H), 3.37 (t, J = 7.9 Hz, 2H), 1.57 (m, 
2H), 1.18 (m, 6H), 0.83 (t, J = 6.4 Hz, 3H). 13C NMR (75.5 MHz, CDCl3): δ =149.3, 
133.0, 129.5, 129.3 (×2), 128.8 (×2), 128.2, 123.5, 43.1, 31.1, 29.5, 26.1, 22.4, 13.9. 
HRMS (EI): C15H20N3, calcd 277.1346, found: 277.1353. 
5-(4-Chlorophenyl)-1-nonyl-1H-imidazol-2-amine (BS-123) 
N
NH2N
C9H19
Cl
 
Yield: 50 %. Mp: 76-78 °C. 1H NMR (300 MHz, CDCl3): δ = 7.35 (d, J = 8.5 Hz, 2H), 
7.23 (d, J = 8.9 Hz, 2H), 6.67 (s, 1H), 4.00 (br, 2H), 3.73 (t, J = 7.3 Hz, 2H), 1.57 (m, 
2H), 1.18 (m, 12H), 0.87 (t, J = 6.6 Hz, 3H). 13C NMR (75.5 MHz, CDCl3): δ =152.2, 
133.1, 129.5, 129.3 (× 2), 128.8 (× 2), 128.2, 123.6, 43.1, 31.7, 29.6, 29.3, 29.1, 28.9, 
26.4, 22.6, 14.0. HRMS (EI): C18H26ClN3, calcd 319.1815, found: 319.1808. 
 
5-(4-Chlorophenyl)-1-undecyl-1H-imidazol-2-amine (BS-124)  
N
NH2N
C11H23
Cl
 
Yield: 57 %. Mp: 78-80 °C. 1H NMR (300 MHz, CDCl3): δ = 7.35 (d, J = 8.4 Hz, 2H), 
7.23 (d, J = 9.1 Hz, 2H), 6.66 (s, 1H), 4.00 (br, 2H), 3.72 (t, J = 7.3 Hz, 2H), 1.57 (m, 
2H), 1.18 (m, 16H), 0.88 (t, J = 6.4 Hz, 3H). 13C NMR (75.5 MHz, CDCl3): δ =149.2, 
133.1, 129.5, 129.3 (×2), 128.8 (×2), 128.2, 123.6, 43.1, 31.8, 29.6, 29.5, 29.4 (×2), 
29.3, 28.9, 26.4, 22.6, 14.1. HRMS (EI): C20H30ClN3, calcd 347.2128, found: 
347.2136. 
 
5-(4-Chlorophenyl)-1-dodecyl-1H-imidazol-2-amine (BS-125) 
N
NH2N
C12H25
Cl
 
Yield: 57 %. Mp: 79-91 °C. 1H NMR (300 MHz, CDCl3): δ = 7.35 (d, J = 8.4 Hz, 2H), 
7.23 (d, J = 8.9 Hz, 2H), 6.67 (s, 1H), 3.99 (br, 2H), 3.72 (m, 2H), 1.58 (m, 2H), 1.17 
(m, 18H), 0.88 (m, 3H). 13C NMR (75.5 MHz, CDCl3): δ =149.1, 133.1, 129.5, 129.3 
(×2), 128.8 (×2), 128.2, 123.6, 43.1, 31.9, 29.6 (× 3), 29.4 (× 2), 29.3, 28.9, 26.4, 
22.6, 14.1. HRMS (EI): C21H32ClN3, calcd 361.2285, found: 361.2281. 
 
5-(4-Chlorophenyl)-1-tridecyl-1H-imidazol-2-amine (BS-126) 
N
NH2N
C13H27
Cl
 
Yield: 56 %. Mp: 83-85 °C. 1H NMR (300 MHz, CDCl3): δ = 7.35 (d, J = 8.5 Hz, 2H), 
7.23 (d, J = 9.3 Hz, 2H), 6.67 (s, 1H), 3.99 (br, 2H), 3.72 (t, J = 7.3 Hz, 2H), 1.57 (m, 
2H), 1.17 (m, 20H), 0.88 (t, J = 6.3 Hz, 3H). 13C NMR (75.5 MHz, CDCl3): δ =149.1, 
133.1, 129.5, 129.3 (×2), 128.8 (×2), 128.2, 123.6, 43.1, 31.9, 29.6 (×4), 29.5, 29.4, 
29.3, 28.9, 26.4, 22.6, 14.1. HRMS (EI): C22H34ClN3, calcd 375.2441, found: 
375.2446. 
 
5-(4-Chlorophenyl)-1-tetradecyl-1H-imidazol-2-amine (BS-127) 
N
NH2N
C14H29
Cl
 
Yield: 51 %. Mp: 82-83 °C. 1H NMR (300 MHz, CDCl3): δ = 7.35 (d, J = 8.5 Hz, 2H), 
7.23 (d, J = 8.7 Hz, 2H), 6.67 (s, 1H), 4.00 (br, 2H), 3.72 (t, J = 7.3 Hz, 2H), 1.55 (m, 
2H), 1.17 (m, 22H), 0.87 (m, 3H). 13C NMR (75.5 MHz, CDCl3): δ =149.1, 133.1, 
129.5, 129.3 (×2), 128.8 (×2), 128.2, 123.6, 43.1, 31.9, 29.6 (×5), 29.5, 29.4 (×2), 
29.0, 26.4, 22.7, 14.1. HRMS (EI): C23H36ClN3, calcd 389.2598, found: 389.2602. 
 
5-(4-Chlorophenyl)-1-cyclohexyl-1H-imidazol-2-amine (BS-128) 
N
NH2N
Cl
 
Yield: 37 %. Mp: 179-181 °C. 1H NMR (300 MHz, CDCl3): δ = 7.35 (d, J = 8.4 Hz, 
2H), 7.18 (d, J = 8.4 Hz, 2H), 6.60 (s, 1H), 4.00 (br, 2H), 3.81 (m, 1H), 1.87 (m, 6H), 
1.66 (m, 1H), 1.23 (m, 3H). 13C NMR (75.5 MHz, CDCl3): δ =148.8, 133.2, 130.2 
(×2), 129.8, 128.9, 128.7 (×2), 123.7, 55.2, 31.2(×2), 25.9 (×2), 25.1. HRMS (EI): 
C15H18ClN3, calcd 275.1189, found: 275.1187.  
 
5-(4-Chlorophenyl)-1-pentyl-1H-imidazol-2-amine (BS-129) 
N
NH2N
C5H11
Cl
 
Yield: 38 %. Mp: 96-98 °C. 1H NMR (300 MHz, CDCl3): δ = 7.35 (d, J = 8.4 Hz, 2H), 
7.23 (d, J = 8.8 Hz, 2H), 6.67 (s, 1H), 4.08 (br, 2H), 3.73 (t, J = 7.3 Hz, 2H), 1.58 (m, 
2H), 1.22 (m, 4H), 0.82 (t, J = 6.6 Hz, 3H). 13C NMR (75.5 MHz, CDCl3): δ =149.3, 
133.0, 129.5, 129.3 (×2), 128.8 (×2), 128.2, 123.4, 43.2, 29.3, 28.6, 22.1, 13.8. HRMS 
(EI): C14H18ClN3, calcd 263.1189, found: 263.1185. 
 5-(4-Chlorophenyl)-1-cyclobutyl-1H-imidazol-2-amine (BS-130) 
N
NH2N
Cl
 
Yield: 40%. Mp: 156-159 °C. 1H NMR (300 MHz, CDCl3): δ = 7.33 (d, J = 8.4 Hz, 
2H), 7.19 (d, J = 8.5 Hz, 2H), 6.57 (s, 1H), 4.55 (m, 1H), 4.00 (br, 2H), 2.47 (m, 2H), 
2.27 (m, 2H), 1.76 (m, 2H). 13C NMR (75.5 MHz, CDCl3): δ =149.4, 133.0, 129.8, 
129.7 (×2), 128.6 (×2), 128.4, 123.5, 49.2, 29.5 (×2), 15.0. HRMS (EI): C13H14ClN3, 
calcd 247.0876, found: 247.0874. 
 
5-(4-Methoxyphenyl)-1-octyl-1H-imidazol-2-amine (BS-199) 
N
NH2N
C8H17
O
 
Yield: 56 %. 1H NMR (300 MHz, CDCl3): δ = 7.25 (m, 2H), 6.95 (d, J = 8.7 Hz, 2H), 
6.60 (s, 1H), 3.97 (br s, 2H), 3.84 (s, 3H), 3.70 (t, J = 7.8 Hz, 2H), 1.56 (m, 2H), 1.17 
(m, 10H), 0.86 (t, J = 7.05 Hz, 3H). 13C NMR (75.5 MHz, CDCl3): δ =149.2, 131.1, 
129.5, 129.3 (×2), 128.8 (×2), 128.2, 123.4, 43.1, 31.6, 29.5, 29.0, 28.9, 26.4, 22.2, 
14.0. HRMS (EI): C18H27N3O, calcd 301.4265, found: 301.4271. 
 
5-(4-Fluorophenyl)-1-octyl-1H-imidazol-2-amine (BS-200) 
N
NH2N
C8H17
F
 
Yield: 71 %. 1H NMR (300 MHz, CDCl3): δ = 7.27 (m, 2H), 7.09 (m, 2H), 6.63 (s, 
1H), 3.96 (br s, 2H), 3.70 (t, J = 6.8 Hz, 2H), 1.56 (m, 2H), 1.17 (m, 10H), 0.86 (t, J = 
7.05 Hz, 3H). 13C NMR (75.5 MHz, CDCl3): δ =163.8, 160.5, 148.7, 130.2, 128.4, 
127.0, 122.9, 115.5, 104.7, 43.0, 31.6, 29.5, 29.0, 28.9, 26.4, 22.5, 14.0. HRMS (EI): 
C17H24FN3, calcd 289.3910, found: 289.3901. 
 
 
5-(3,4-Dichlorophenyl)-1-octyl-1H-imidazol-2-amine (BS-201) 
NNH2N
C8H17
Cl
Cl
 
Yield: 64 %. 1H NMR (300 MHz, CDCl3): δ = 7.47 (d, J = 8.3 Hz, 1H), 7.40 (d, J = 
7.98 Hz, 1H), 7.16 (d of d, J = 2.0, 6.2 Hz, 1H), 6.71 (s, 1H), 4.05 (br s, 2H), 3.73 (t, J 
= 7.68 Hz, 2H), 1.59 (m, 2H), 1.19 (m, 10H), 0.86 (t, J = 7.05 Hz, 3H). 13C NMR 
(75.5 MHz, CDCl3): δ =149.6, 132.8, 131.1, 131.0, 130.6, 129.5, 127.1, 127.0, 124.2, 
43.3, 31.6, 29.5, 29.0, 28.9, 26.4, 22.5, 14.0. HRMS (EI): C17H23Cl2N3, calcd 
340.2906, found: 240.2918. 
 
5-(3-Bromophenyl)-1-octyl-1H-imidazol-2-amine (BS-202) 
N
NH2N
C8H17
Br
 
Yield: 68 %. 1H NMR (300 MHz, CDCl3): δ = 7.45 (m, 2H), 7.25 (m, 2H), 6.70 (s, 
1H), 4.02 (br s, 2H), 3.74 (t, J = 7.71 Hz, 2H), 1.59 (m, 2H), 1.19 (m, 10H), 0.86 (t, J 
= 6.08 Hz, 3H). 13C NMR (75.5 MHz, CDCl3): δ =149.2, 133.0, 130.8, 130.1 (×2), 
128.0, 126.5, 123.8, 122.6, 43.2, 31.6, 29.5, 29.0, 28.9, 26.4, 22.5, 14.0. HRMS (EI): 
C17H24BrN3, calcd 350.2966, found:250.2978. 
 
5-(Naphthalen-1-yl)-1-octyl-1H-imidazol-2-amine (BS-202) 
N
NH2N
C8H17  
Yield: 68 %. 1H NMR (300 MHz, CDCl3): δ = 7.85 (m, 4H), 7.46 (m, 3H), 6.78 (s, 
1H), 4.04 (br s, 2H), 3.83 (t, J = 7.62 Hz, 2H), 1.62 (m, 2H), 1.15 (m, 10H), 0.82 (t, J 
= 6.99 Hz, 3H). 13C NMR (75.5 MHz, CDCl3): δ =149.1, 133.4, 132.4, 129.5, 128.3, 
128.2, 127.9, 127.7, 126.6, 126.4 (×2), 126.0, 123.0, 43.3, 31.6, 29.5, 29.0, 28.9, 26.4, 
22.5, 14.0. HRMS (EI): C21H27N3, calcd 321.4592, found: 321.4576. 
5-(4-Nitrophenyl)-1-octyl-1H-imidazol-2-amine (BS-204) 
N
NH2N
C8H17
NO2  
Yield: 66%. 1H NMR (300 MHz, CDCl3): δ = 8.27 (d, J = 8.7 Hz, 2H), 7.47 (t, J = 8.7 
Hz, 2H), 6.89 (s, 1H), 4.13 (br s, 2H), 3.82 (t, J = 7.8 Hz, 2H), 1.63 (m, 2H), 1.21 (m, 
10H), 0.85 (t, J = 6.96 Hz, 3H). 13C NMR (75.5 MHz, CDCl3): δ =163.8, 160.5, 
148.7, 130.2, 128.4, 127.0, 122.9, 115.5, 104.7, 43.0, 31.6, 29.5, 29.0, 28.9, 26.4, 
22.5, 14.0. HRMS (EI): C17H24N4O2, calcd 316.3981, found: 316.3993. 
 
5-(4'-Nitrobiphenyl-4-yl)-1-octyl-1H-imidazol-2-amine (BS-205) 
N
NH2N
C8H17 NO2  
Yield: 52 %. 1H NMR (300 MHz, CDCl3): δ = 8.33 (m, 1H), 7.78-7.35 (m, 6H), 7.13 
(m 1H), 6.77 (s, 1H), 4.07 (br s, 2H), 3.79 (m, 2H), 1.63 (m, 2H), 1.19 (m, 10H), 0.84 
(m, 3H). 13C NMR (75.5 MHz, CDCl3): δ =163.8, 160.5, 148.7, 130.2, 128.4, 127.0, 
122.9, 115.5, 104.7, 43.0, 31.6, 29.5, 29.0, 28.9, 26.4, 22.5, 14.0. HRMS (EI): 
C23H28N4O2, calcd 392.4940, found:392.4928. 
 
5-(4-(Methylsulfonyl)phenyl)-1-octyl-1H-imidazol-2-amine (BS-206) 
N
NH2N
C8H17
SO2Me  
Yield: 61 %. 1H NMR (300 MHz, CDCl3): δ = 7.97 (d, J = 8.1 Hz, 2H), 7.51 (d, J = 
7.98 Hz, 2H), 6.83 (s, 1H), 4.09 (br s, 2H), 3.82 (t, J = 7.68 Hz, 2H), 3.09 (s 3H), 1.62 
(m, 2H), 1.21 (m, 10H), 0.86 (t, J = 7.05 Hz, 3H). 13C NMR (75.5 MHz, CDCl3): δ 
=150.7, 138.1, 136.6, 127.9 (×2), 127.6, 127.4 (×2), 126.0, 44.5, 43.6, 31.6, 29.6, 
29.0, 28.9, 26.5, 22.5, 14.0. HRMS (EI): C18H27N3O2S, calcd 349.4909, found: 
349.4920. 
 
5-(4-(Methylthio)phenyl)-1-octyl-1H-imidazol-2-amine (BS-207) 
N
NH2N
C8H17
SMe
 
Yield: 40 %. 1H NMR (300 MHz, CDCl3): δ = 7.33-7.22 (m, 4H), 6.65 (s, 1H), 4.00 
(br s, 2H), 3.73 (t, J = 7.98 Hz, 2H), 2.51 (s, 3H), 1.58 (m, 2H), 1.18 (m, 10H), 0.86 
(t, J = 6.99 Hz, 3H). 13C NMR (75.5 MHz, CDCl3): δ =163.8, 160.5, 148.7, 130.2, 
128.4, 127.0, 122.9, 115.5, 104.7, 43.0, 31.6, 29.5, 29.0, 28.9, 26.4, 22.5, 14.0. HRMS 
(EI): C18H27N3S, calcd 317.4921, found: 317.4935. 
 
5-(Triphenyl-4-yl)-1-octyl-1H-imidazol-2-amine (BS-208) 
N
NH2N
C8H17
 
Yield: 31 %. 1H NMR (300 MHz, CDCl3): δ = 7.70-7.64 (m, 7H), 7.46-7.40 (m 5H), 
6.74 (s, 1H), 4.03 (br s, 2H), 3.80 (m, 2H), 1.63 (m, 2H), 1.20 (m, 10H), 0.86 (m, 3H). 
13C NMR (75.5 MHz, CDCl3): δ =148.9, 140.5, 140.2, 139.2 (×2), 130.0, 129.2, 128.8 
(×2), 128.5, 127.5 (×2), 127.4, 127.3, 127.2 (×4), 127.0, 126.9, 123.1, 43.2, 31.7, 
29.6, 29.0, 28.9, 26.5, 22.5, 14.0. HRMS (EI): C29H33N3, calcd 423.5924, found: 
423.5941. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.10 Representative NMR spectra    
3.10.1 1H and 13C NMR spectra of bs-063 
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3.10.2 1H and 13C NMR spectra of bs-125 
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A microwave assisted one-pot Cu(II)-catalyzed protocol was developed for the 
construction of 2-AI-T framework. This process combining two consecutive steps of 
dimorth rearrangement and click reaction represents a useful protocol for the smooth 
synthesis of novel 2-aminoimidazole-triazole derivatives. 
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4.1 Introduction 
 
There are only a few approaches that describe the direct synthesis of 2-
aminoimidazoles and their biological activity1-5. The earliest method involves 
condensation of α-aminocarbonyl compounds with cyanamide or their synthetic 
equivalents6,7. This method is most commonly used for the direct construction of the 
2-aminoimidazole ring. Other general applicable strategies are cyclocondensation of 
α-bromoketone with N-acetylguanidine in acetonitrile8, iminophosphorane-mediated 
cyclization of α –azido esters9, ammonolysis of 2-amino-1,3-oxazol-3-iumsalts10, 
sequential functionalization of 1,2-diprotected imidazole ring with different 
electrophiles11. Most of them involve long experimental procedures, the use of 
unstable precursors and tiresome workup process. Accordingly, the development of 
straightforward and general procedures for the synthesis of diversely substituted 2-
aminoimidazoles from readily available precursors is highly warranted. Herein, we 
report a rapid and highly efficient Cu-mediated synthesis of 2-aminoimidazole-
triazole framework via click reaction and dimorth rearrangement. 
 
“Click chemistry” has emerged as a fast and efficient approach to synthesis of novel 
compounds with desired function making use of selected “near perfect” reactions.12 
(very fast, selective, high-yield, and wide scope). 
 
The Dimroth rearrangement13 is an isomerization of heterocycles that consists in a 
translocation of endo- or exocyclic heteroatoms through a ring-opening-ring-closure 
sequence. It can be catalyzed by acids, bases, heat or light.  
 
Recently group of Erik14 reported a new one pot microwave assisted synthesis of 
substituted 2-amino-1H- imidazoles from readily available 2-aminopyrimidine (1) and 
α-bromoketone (2). The first step was performed by heating N-(3-
azidopropyl)pyrimidin-2-amine (1) and 2-bromo-1-phenylethanone (2) at 75 oC for 3 
h resulting in the formation of hydroxyl salt (3) which undergoes dimorth type 
rearrangement by 7 equiv of NH2NH2.H2O resulting in the formation of N-(2-azido)-
1H-imidazol-2-amine. Final step of click reaction was performed under microwave-
irradiation using phenylacetylene (1.5.equiv), Cu(Oac)2 (10 mol %)as catalyst at 100 
oC 10 min with a maximum power of 40W to obtain 2-AI-T scaffold (5). (Scheme 1) 
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Scheme-1 Sequential Synthesis of 2-AI-T Framework  
 
In continuation of earlier work on two step synthesis of 2-AI-T scaffold with excellent 
yield. now an ameliorated and convenient one-pot protocol for the synthesis of 2-AI-T 
scaffold under microwave conditions has been reported. 
 
4.2 Optimization Study 
 
Looking to the current exploration in the synthesis and microwave-assisted decoration 
of the 2-aminoimidazole14 and click reaction15 and preliminary success of the 
sequence, it was very interesting to investigate whether one-pot protocol for the 
construction of 2-AI-T scaffold should be possible. The test reaction was performed 
with hydroxy salt {3} and phenyl acetylene as a model system. Different Cu catalyst, 
equiv of NH2NH2.H2O, temperature and reaction time were screened to derive an 
optimized protocol (Table 1). 
 
First, the application of Cu(OAc)2 as catalyst for click reaction and different 
equivalents of aqueous NH2NH2.H2O for simultaneous dimorth rearrangement (Table-
1, No-1-3) was evaluated. However in case of 1 equiv. of hydrazine used, yield was 
only 51 %. (Table-1, No-1). Next study of different reaction time (Table-1, No-3-7) 
performed. It was observed that reaction could complete even in very short time 
(Table-1, No- 6). Next reaction temperature (Table-1, No-8-9) was investigated. 
Decrease of the reaction temperature resulted in lover yield (Table-1, No-9). Then the 
examination the catalyst effect on a reaction (Table-1, No-7-13) was done. However 
replacement of Cu(Oac)2 with CuSO4 resulted in lower yield (Table-1, No-11). While 
in case of Cu Powder (200 mesh) used only traces amount of desire product observed 
(Table-1, No-13). Moreover it was observed that the catalyst was mandatory for 
successfully performing the reaction, as no product was formed in the absence of the 
catalyst (Table-1, No-12). Finally optimum reaction conditions were achieved when a 
mixture of hydroxy salt, 1.2 equiv of phenyl acetylene, 5 mol % of Cu(Oac)2 in 1 ml 
of Ethenol : water (4: 1) was irradiated for 2 min at a ceiling temperature of 100 oC  
applying a maximum power of 36 W, affording the desired compound  in 90 % yield 
(Table 1 No-8). The protocol was checked with conventional condition providing 
lower yield of 24 % of after 24 hrs. 
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No. 
time 
(min) 
temp (oC) Cu salt (mol %) yield (%)b 
1c 20  100 °C Cu(Oac)2, 10 51 
2d 20 100 °C Cu(Oac)2, 10 84 
3 20 100 °C Cu(Oac)2, 10 86 
4 10 100 °C Cu(Oac)2, 10 80 
5 5 100 °C Cu(Oac)2, 10 90 
6 2 100 °C Cu(Oac)2, 10 90 
7 1 100 °C Cu(Oac)2, 10 53 
8 2 100 °C Cu(Oac)2, 5 90 
9 2 90 °C Cu(Oac)2, 5 73 
10 2 100 °C Cu(Oac)2, 2 57 
11 2 100 °C CuSO4.5H2O, 5 67 
12 2 100 °C - - 
13 2 100 °C Cu Powder (200 mesh) Traces  
14e -f 25 °C Cu(Oac)2, 5 24 
 
a All reactions were run on a 0.7 mmol scale of 3, applying phenyl acetylene (1.2 
equiv) in ethanol: water (4:1, 1 mL) under microwave irradiation. The mixture was 
irradiated in a sealed tube (CEM Discover@) at a ceiling temperature of 100 oC and 35 
W maximum power for the stipulated time. b isolated yields. c 1.0 equiv of 
NH2NH2.H2O used. d 5.0 equiv of NH2NH2.H2O used. e reaction carried out at room 
temperature. f time 24 h.  
Table-1: Copper Catalyzed One-Pot protocol: Catalyst, equiv of hydrazine, reaction 
time and Temperature Effects on the model reaction to obtain 2-AI-T scaffolda.  
 
4.3 Results and Discussion 
 
Encouraged by these findings, the scope of this protocol was further explored. An 
array of hydroxy salts 3 (a-j) (Table-2) were reacted with various acetylene using our 
optimized conditions. In most cases, the reactions proceeded well affording the one 
pot product in good to excellent yield (Table-2)    
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a All reactions were run on a 0.7 mmol scale of 3 {a-j} ethanol: water (4:1) (1 ml) with 
phenyl acetylene (1.2 equiv), Cu(OAc)2 (5 mol % ) and hydrazine hydride (2 equiv). 
The mixture was irradiated in a sealed tube (CEM Discover@) at a ceiling temperature 
of 100 oC and 35 maximum power for the stipulated time. b isolated yields. Yields are 
shown in (). 
 
Table-2: Microwave assisted one pot decoration of 2-AI-T Frameworka. 
 
A diverse set of 2-AI-T scaffold were synthesized with these optimized conditions. 
Ten different hydroxy salt 3 {a-j} (n = 1 or 2) were reacted with different (hetero) 
aromatic or alkyl acetylenes (Table-2) to test the generality of this new microwave-
assisted one pot method (Table 2). All reactions were completed within 5 min using 
microwave irradiation at ceiling temperature of 100 oC and 35W power. The yields 
varied from good to excellent, although in some cases lower yields were observed 
(Table 2, No-15,16 and 19). However in case of morpholine substitution (table-2, No-
15-16) probably due to decomposition of starting hydroxy salt 3 {h} lower yields 
were observed. Interestingly when 4,5-disubstituted hydroxy salt react with acetylene 
only 16% of desired product 4{s} was observed due to steric hindrance of 4-Me-
phenyl substitution on dimorth rearrangement. Motivated by the importance of the 
final target to develop new general method toward widely functionalized 2-AI-T 
framework, we next examined the extension of this procedure to other acetylene. The 
reaction proceeded effectively with aliphatic and aromatic terminal acetylenes to give 
the corresponding 2-AI-T (Table 2). Thus, a variety of substituted 2-AI-T containing 
aromatic, aliphatic, cyclic and heterocyclic substitution at the C-4 position of the 
triazole ring were obtained. 
 
4.4 Possible Mechanism 
 
Regarding the mechanism of transformation of 2-hydroxy 2,3-dihydro-1H-
imidazo[1,2-a]pyrimidin-4-ium salts 3 into 2-amino-1H-imidazole-triazole 4, we 
presume that the reaction proceeds via an unusual Dimroth type rearrangement 
(Scheme-3). 
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Scheme-3: Proposed mechanism for One-pot reaction: 
 
In the first step the 2-hydroxy-2,3-dihydroimidazo[1,2-a]pyrimidinium salt (3) 
undergoes cleavage of the pyrimidine ring (a), resulting in the generation of pyrazole 
and 2-amino-5-hydroxyimidazolidine (b), meanwhile copper nanoparticle16 generated 
by reduction of Cu(OAc)2 using 1 equiv of NH2NH2.H2O takes part in click reaction. 
This intermediate (b), which is in equilibrium with the open form c can cyclize again 
leading by dehydration upon microwave irradiation, results in the rearranged 2-
amino-1H-imidazoles triazole (4). 
 
 
 
 
 
4.5 Conclusion 
 
In conclusion microwave-assisted Cu-catalyzed one pot protocol for the synthesis of 
2-aminoimidazole-triazole framework via two consecutive steps of dimorth 
rearrangement and click reaction was demonstrated. Library of 22 compounds have 
been synthesized and were subjected to test for antibiofilm activity. However the 
antibiofilm activities of these classes of compounds are under pipeline. 
 
4.6 Experimental 
4.6.1 General Methods 
All chemical reagents were used without further purification. Solvents for column 
chromatography and TLC were laboratory grade and distilled before use. For thin-
layer chromatography (TLC), analytical TLC plates (Alugram SIL G/UV254 (E. M. 
Merk) were used. Column chromatography was performed with flash silica gel (100-
200 mesh) or neutral alumina oxide (50-200 micron). 1H and 13C NMR spectra were 
recorded on a Bruker Avance 300 (300 MHz) or a Bruker AMX-400 (400 MHz) 
spectrometers. NMR samples were run in the indicated solvents and were referenced 
internally. Chemical shift values were quoted in ppm and coupling constants were 
quoted in Hz. Chemical shift multiplicities were reported as s = singlet, d = doublet, t 
= triplet, q = quartet, m = multiplet and br = broad. Low-resolution mass spectra were 
recorded on a HEWLETT-PACKARD instrument (CI or EI) and LCQ Advantage 
instrument (ESI). High-resolution mass spectra (EI) were recorded on a KRATOS 
MS50TC instrument. Melting points were determined using Reichert-Jung Thermovar 
apparatus and were uncorrected. 
4.6.2 Microwave Irradiation Experiments 
Microwave irradiation experiments were carried out in a dedicated CEM-Discover 
mono-mode microwave apparatus or Microwave apparatuses were used in the 
standard configuration as delivered, operating at a frequency 2.45 GHz with 
continuous irradiation power from 0 to 400 W. The reactions were carried out in 10, 
20, 30 and 50 mL glass tubes. The temperature was measured with an IR sensor on 
the outer surface of the process vial or fibre optic sensor inside the process vial. After 
the irradiation period, the reaction vessel was cooled rapidly (2-5 min) to ambient 
temperature by air jet cooling. 
4.7 Experimental protocols 
 
4.7.1 General Procedure for the Preparation 3-Azido-propylamine 
To a solution of 3-chloropropan-1-amine hydrochloride (3.2 g, 14.6 mmol) in water 
(10 mL) was slowly added NaN3 (3.2 g, 49.2 mmol) as a solution in water (15 mL).  
The resulting solution was allowed to stir at reflux overnight.  After cooling to room 
temperature, about 2/3 of the water was removed by evaporation and the remaining 
residue diluted with ether (50 mL).  This biphasic mixture was cooled to 0 °C and 
KOH pellets (4.0 g) were slowly added.  The phases separated and the aqueous layer 
extracted with ether (2 x 30 mL).  All organics combined, dried over Na2SO4, and 
concentrated to afford 3-Azido-propylamine (1.17 g, 80%) as yellow oil 
 
4.7.2 General Procedure for the Preparation of N-(3-azidopropyl)pyrimidin-2-
amine:  
In a 50 mL microwave vial were successively dissolved in EtOH (20 mL) 2-
chloropyrimidine (3.43 g, 30 mmol), 3-Azido-propylamine (48 mmol, 1.6 equiv) and 
triethylamine (6.2 mL, 45 mmol, 1.5 equiv). The reaction tube was sealed, and 
irradiated in the cavity of a Milestone MicroSYNTH microwave reactor at a ceiling 
temperature of 120 °C at 100 W maximum power for 60 min. After the reaction 
mixture was cooled with an air flow for 15 min, it was diluted with water (100 mL), 
extracted with DCM (2×150 mL) and dried over Na2SO4. The solvent was evaporated 
in vaccuo, and the crude mixture was purified by silica gel flash chromatography 
using 0-5% MeOH−DCM as the eluent. 
 
4.7.3 General Procedure for the Preparation of Salts. 
 
To a solution of N-(3-azidopropyl)pyrimidin-2-amine (6 mmol) and α-
bromoacetophenone (7.2 mmol, 1.2 equiv) in acetonitrile (12 mL) was added 4-
dimethylaminopyridine (6 mg, 0.05 mmol). After being stirred at 85 °C for 5 h, the 
reaction mixture was diluted with acetone (20 mL) and the precipitate was filtered and 
washed with acetone (2×20 mL), ether (2×20 mL) and dried over P2O5 to give salt as 
a white solid. 
 
 
4.7.4 General Procedure for the preparation of 2-AI-T. 
 
Cool the suspension of hydrazine hydride (2 equiv), in ethanol (0.8 ml.). To the 
suspension were added Cu(OAc)2 (5 mol %) in water (0.2 ml). and stirred it for 2 min 
at 0 oC. To this were added acetylene (1.5 eq) and hydroxyl salt (1 eq.) The reaction 
mixture was irradiated at 100 0 oC at the maximum power 35 W for 2-5 min. After 
completion of the reaction, the solvent was removed under reduce pressure. The crude 
product was purifier by column chromatography over silica gel using DCM / 
methanol / 7N methanolic NH3 (96:3:1) as the eluent.  
 
4.8 Spectral Characterization  
2-Azidoethanamine (BS-167) 
H2N
N3
 
Yield: 41 %. 1H NMR (300 MHz, CDCl3): δ = 3.37 (t, J = 5.61 Hz, 2H), 2.88 (t, J = 
5.50 Hz, 2H), 1.53 (Br s, 2H). 
 
3-Azidopropan-1-amine (BS-220) 
N3H2N  
Yield: 45 %. 1H NMR (300 MHz, CDCl3): δ = 3.38 (t, J = 6.93 Hz, 2H), 2.81 (t, J = 
6.84 Hz, 2H), 1.73 (m, 2H), 1.36 (Br s, 2H). 
 
N-(2-Azidoethyl)pyrimidin-2-amine (BS-168) 
N
N
N
H
N3
 
Yield: 67 %. 1H NMR (300 MHz, CDCl3): δ = 8.30 (d, J = 4.74 Hz, 2H), 6.58 (t, J = 
4.74 Hz, 1H), 5.44 (Br s, 1H), 3.64 (m, 2H), 3.54 (t, J = 5.58 Hz, 2H), 13C NMR  
(75.5 MHz, CDCl3):  δ =162.0, 158.1, 158.0, 111.1, 50.8, 40.7. HRMS (EI) C6H6N6, 
calcd 164.0810, found :. 
 
N-(3-Azidopropyl)pyrimidin-2-amine (BS-221) 
N
N
N
H
N3
 
Yield: 69 %. 1H NMR (300 MHz, CDCl3): δ = 8.28 (d, J = 4.80 Hz, 2H), 6.54 (t, J = 
4.80 Hz, 1H), 5.30 (Br s, 1H), 3.52 (m, 2H), 3.42 (t, J = 6.57 Hz, 2H), 1.90 (m, 2H).  
 
1-(3-Azidopropyl)-2-hydroxy-2-phenyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-
4-ium bromide (BS-230) 
N
N
N
OH
Br
N3
 
Yield: 72 %. 1H NMR (300 MHz, DMSO-d6) : δ = 9.05 (m, 2H), 7.93 (s, 1H), 7.80 
(m, 2H), 7.48 (m, 3H), 7.37 (t, J = 4.86 Hz, 1H), 4.95 (m, 2H), 3.41 (m, 4H), 1.64 (m, 
2H). 13C NMR (75.5 MHz, DMSO-d6): δ = 167.4, 154.6, 148.2, 138.1, 129.3, 128.4 
(×2), 126.9 (×2), 111.4, 90.6, 62.7, 47.9, 38.2, 27.0. 
 
1-(2-Azidoethyl)-2-hydroxy-2-phenyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-4-
ium bromide (BS-227) 
N
N
N
OH
Br
N3
 
Yield:  75 %. 1H NMR (300 MHz, DMSO-d6) : δ = 9.02 (m, 2H), 7.99 (s, 1H), 7.80 
(m, 2H), 7.49 (m, 3H), 7.41 (t, J = 4.92 Hz, 1H), 4.95 (m, 2H), 3.38 (m, 4H).  13C 
NMR (75.5 MHz, DMSO-d6): δ = 167.5, 154.7, 148.4, 137.8, 129.4, 128.4 (×2), 126.9 
(×2), 111.8, 90.6, 62.8, 48.1 (×2). 
 
1-(2-Azidoethyl)-2-hydroxy-2-(naphthalen-1-yl)-2,3-dihydro-1H-imidazo[1,2-
a]pyrimidin-4-ium bromide (BS-271) 
N
N
N
OH
Br
N3
 
Yield:  67 %. 1H NMR (300 MHz, DMSO-d6) : δ = 9.10 (m, 2H), 8.38 (s, 1H), 8.16 
(s, 1H), 8.02 (m, 3H), 7.88 (m, 1H), 7.59 (m, 2H), 7.44 (m, 1H), 5.05 (s, 2H), 3.42 (m, 
4H). 13C NMR (75.5 MHz, DMSO-d6): δ = 167.5, 154.9, 148.5, 135.0, 132.9, 132.1, 
128.4, 128.2, 127.5, 127.1, 126.7 (×2), 124.1, 111.9, 90.8, 62.6, 48.2 (×2). 
 
1-(3-Azidopropyl)-2-(4-bromophenyl)-2-hydroxy-2,3-dihydro-1H-imidazo[1,2-
a]pyrimidin-4-ium bromide (BS-272) 
N
N
N
OH
Br
N3
Br  
Yield:  76 %. 1H NMR (300 MHz, DMSO-d6) : δ = 9.06 (d of d, J = 1.62, 4.60 Hz, 
1H), 8.98 (d of d, J = 1.62, 6.24 Hz,1H)  8.00 (s, 1H), 7.72 (m, 4H), 7.37 (m, 1H), 
4.85 (m, 2H), 3.37 (m, 4H), 1.66 (m, 2H). 13C NMR (75.5 MHz, DMSO-d6): δ = 
167.5, 154.7, 148.2, 137.6, 131.4(×2), 129.3 (×2), 122.9, 111.5, 90.3, 62.5, 47.9, 38.2, 
27.0. 
 
1-(2-Azidoethyl)-2-(3,4-dichlorophenyl)-2-hydroxy-2,3-dihydro-1H-imidazo[1,2-
a]pyrimidin-4-ium bromide (BS-273) 
N
N
N
OH
Br
N3
Cl
Cl
 
Yield:  78 %. 1H NMR (300 MHz, DMSO-d6) : δ = 9.12 (m, 2H), 8.20 (s, 1H), 8.09 
(s, 1H), 7.79 (m, 2H), 7.43 (m, 1H), 4.93 (m, 2H), 3.42 (m, 4H).  13C NMR (75.5 
MHz, DMSO-d6): δ = 167.5, 154.9, 148.3, 139.0, 132.2, 131.3, 130.5, 129.5, 127.4, 
112.1, 89.8, 62.5, 48.0 (×2). 
 
 
 
1-(3-Azidopropyl)-2-(3,4-dichlorophenyl)-2-hydroxy-2,3-dihydro-1H-
imidazo[1,2-a]pyrimidin-4-ium bromide (BS-274) 
N
N
N
OH
Br
N3
Cl
Cl
 
Yield: 81 %. 1H NMR (300 MHz, DMSO-d6) : δ = 9.07 (m, 1H), 8.97 (m,1H)  8.12 (s, 
1H), 8.08 (Br s, 1H), 7.97 (m, 2H), 7.38 (t, J = 4.92 Hz, 1H), 4.86 (m, 2H), 3.37 (m, 
4H), 1.68 (m, 2H). 13C NMR (75.5 MHz, DMSO-d6): δ = 167.5, 154.7, 148.1, 139.2, 
132.2, 131.3, 130.6, 129.3, 127.4, 111.6, 89.8, 62.4, 47.8, 38.3, 26.9. 
 
1-(2-Azidoethyl)-2-(4-chlorophenyl)-2-hydroxy-3-p-tolyl-2,3-dihydro-1H-
imidazo[1,2-a]pyrimidin-4-ium bromide (BS-299) 
N
N
N
OH
Br
N3
Cl  
Yield: 42 %. 1H NMR (300 MHz, DMSO-d6) : δ = 9.19 (d, J = 3.06 Hz, 1H), 8.55 (d, 
J = 5.43 Hz, 1H), 7.71 (d, J = 8.52 Hz, 2H), 7.70 (s, 1H), 7.55 (d, J = 8.49 Hz, 2H), 
7.38 (m, 1H), 7.42 (d, J = 7.80 Hz, 2H), 7.08 (d, J = 7.80 Hz, 2H), 6.10 (s, 1H), 3.36 
(m, 4H), 2.33 (s, 3H) 13C NMR (75.5 MHz, DMSO-d6): δ = 168.2, 156.1, 146.9, 
139.5, 135.9, 134.4, 129.4 (×6), 128.4 (×2), 124.4, 112.8, 93.5, 74.9, 47.9, 41.0, 20.7. 
 
1-(2-Azidoethyl)-2-(4-fluorophenyl)-2-hydroxy-2,3-dihydro-1H-imidazo[1,2-
a]pyrimidin-4-ium bromide (BS-300) 
N
N
N
OH
Br
N3
F  
Yield: 79 %. 1H NMR (300 MHz, DMSO-d6) : δ = 9.09 (d, J = 4.53 Hz, 1H), 9.01 (d, 
J = 6.00 Hz, 1H), 8.04 (s, 1H), 7.85 (m, 2H), 7.37 (m, 3H), 4.92 (m, 2H), 3.38 (m, 
4H).  13C NMR (75.5 MHz, DMSO-d6): δ = 167.5, 164.1, 160.9, 154.7, 148.4, 134.0 
(d), 129.4 (d), 115.4, 115.1, 111.9, 90.3, 62.7, 48.1 (×2).  
 
5-(4-Bromophenyl)-N-(2-(4-(4-methoxyphenyl)-1H-1,2,3-triazol-1-yl)ethyl)-1H-
imidazol-2-amine (BS-219) 
N
H
N
N
H
N
NN
Br
O
 
Yield: 66 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.62 (br s, 1H), 8.45 (s, 1H), 7.43 
(d, J = 8.8 Hz, 2H), 7.57 (d, J = 7.9 Hz, 2H), 7.43 (d, J = 8.8 Hz, 2H), 7.10 (s, 1H), 
6.98 (d, J = 8.8 Hz, 2H), 6.02 (m, 1H), 4.60 (t, J = 5.90 Hz, 2H), 3.78 (s, 3H), 3.68 
(m, 2H). 13C NMR  (75.5 MHz, DMSO-d6):  δ =158.8, 150.0, 146.0, 131.0, 126.4 
(×4), 125.5 (×2), 123.4, 120.7, 117.5, 114.2 (×4), 55.0, 49.2. 42.8.  HRMS (EI) 
C20H19BrN6O, calcd 438.0804, found :438.0811.  
 
5-Phenyl-N-(3-(4-phenyl-1H-1,2,3-triazol-1-yl)propyl)-1H-imidazol-2-amine (BS-
238) 
N
H
N
N
H
N N
N
 
Yield: 90 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.91 (br s, 1H), 8.63 (s, 1H), 7.88 
(d, J = 7.2 Hz, 2H), 7.59 (d, J = 7.2 Hz, 2H), 7.44 (t, J = 7.7 Hz, 2H), 7.27 (m, 3H), 
7.08 (m, 2H), 6.09 (br s, 1H), 4.50 (t, J = 7.1 Hz, 2H), 3.21 (m, 2H), 2.21 (m, 2H). 13C 
NMR  (75.5 MHz, DMSO-d6):  δ = 150.3, 146.2, 133.0, 132.3, 130.8, 128.8 (×2), 
128.3, 127.7, 125.6, 125.0 (×2), 123.6 (×2), 121.4, 110.4, 104.1, 47.3, 28.8 (×2). 
HRMS (EI) C20H20N6, calcd 344.1749, found : 344.1734.  
5-Phenyl-N-(2-(4-phenyl-1H-1,2,3-triazol-1-yl)ethyl)-1H-imidazol-2-amine (BS-
228) 
N
H
N
N
H
N
NN
 
Yield: 84 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.68 (br s, 1H), 8.57 (s, 1H), 7.82 
(d, J = 7.3 Hz, 2H), 7.61 (m, 2H), 7.43 (t, J = 7.6 Hz, 2H), 7.28 (m, 3H), 7.06 (m, 
2H), 6.01 (br s, 1H), 4.63 (t, J = 6.1 Hz, 2H), 3.70 (m, 2H). 13C NMR  (75.5 MHz, 
DMSO-d6):  δ = 150.3, 146.1, 130.4, 128.8 (×4), 128.2, 127.7, 125.1, 125.0 (×4), 
123.4, 121.7, 104.1, 49.3. 42.9. HRMS (EI) C19H18N6, calcd 330.1593, found : 
330.1582.  
 
5-(4-Bromophenyl)-N-(2-(4-p-tolyl-1H-1,2,3-triazol-1-yl)ethyl)-1H-imidazol-2-
amine (BS-231) 
N
H
N
N
H
N
NN
Br  
Yield: 73 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.66 (br s, 1H), 8.50 (s, 1H), 7.70 
(d, J = 8.07 Hz, 2H), 7.57 (d, J = 8.31 Hz, 2H), 7.43 (d, J = 8.56 Hz, 2H), 7.22 (d, J = 
8.07 Hz, 2H), 7.13 (s, 1H), 6.03 (br s, 1H), 4.61 (t, J = 5.80 Hz, 2H), 3.68 (m, 2H), 
2.32 (s, 3H). 13C NMR  (75.5 MHz, DMSO-d6):  δ = 150.4, 146.1, 136.9 (×2), 130.9 
(×2), 129.3 (×4), 128.0, 125.3, 124.9 (×3), 121.2, 117.4, 49.2, 42,8, 20.7.  HRMS (EI) 
C20H19BrN6, calcd 422.0855, found : 422.0863.  
 
N-(2-(4-(4-Butylphenyl)-1H-1,2,3-triazol-1-yl)ethyl)-5-(naphthalen-1-yl)-1H-
imidazol-2-amine (BS-275) 
N
H
N
N
H
N
NN C4H9
 
Yield: 64 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.9 (br s, 1H), 8.54 (s, 1H), 8.14 
(s, 1H), 7.73 (m, 6H), 7.37 (m, 2H), 7.23 (m, 3H), 6.01 (m, 1H), 4.68 (m, 2H), 3.74 
(m, 2H), 2.58 (t, J = 7.4 Hz, 2H), 1.56 (m, 2H), 1.32 (m, 2H), 0.89 (t, J = 7.4 Hz, 3H). 
13C NMR (75.5 MHz, DMSO-d6):  δ = 150.7, 146.2, 141.8, 133.5, 131.3, 128.7 (×3), 
128.3, 127.5, 127.3 (×3), 126.0, 125.0 (×3), 124.6, 123.2, 121.3, 120.2, 49.3, 42.9, 
34.5, 32.9, 21.7, 13.7.  HRMS (EI) C27H28N6, calcd 436.2375, found : 436. 2349. 
 
 
5-(4-Bromophenyl)-N-(2-(4-heptyl-1H-1,2,3-triazol-1-yl)ethyl)-1H-imidazol-2-
amine (BS-277) 
N
H
N
N
H
N
NN C7H15
Br  
Yield: 73 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.56 (br s, 1H), 7.82 (s, 1H), 7.59 
(d, J = 8.2 Hz, 2H), 7.42 (d, J = 7.9 Hz, 2H), 7.13 (s, 1H), 5.93 (br s, 1H), 4.51 (t, J = 
5.90 Hz, 2H), 3.60 (m, 2H), 2.57 (d, J = 7.7 Hz, 2H), 1.57 (m, 2H), 1.25 (m, 8H), 0.85 
(t, J = 6.9 Hz, 3H). 13C NMR  (75.5 MHz, DMSO-d6):  δ = 150.5, 146.7 (×2), 131.0 
(×3 ), 125.3, 121.9 (×2), 117.4, 104.1, 48.9, 42.9, 31.1, 28.9, 28.5, 28.4, 25.0, 22.0, 
13.9.  HRMS (EI) C20H27BrN6, calcd 430.1481, found : 430.1488. 
 
5-(4-Bromophenyl)-N-(3-(4-(4-pentylphenyl)-1H-1,2,3-triazol-1-yl)propyl)-1H-
imidazol-2-amine (BS-278) 
N
H
N
N
H
N N
N
Br
C5H11  
Yield: 80 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.58 (br s, 1H), 8.55 (s, 1H), 7.72 
(d, J = 8.06 Hz, 2H), 7.53 (d, J = 8.06 Hz, 2H), 7.38 (d, J = 8.27 Hz, 2H), 7.23 (d, J = 
8.06 Hz, 2H), 7.11 (s, 1H), 5.96 (m, 1H), 4.47 (t, J = 6.57 Hz, 2H), 3.19 (m, 2H), 2.59 
(t, J = 7.63 Hz, 2H), 2.14 (m, 2H), 1.59 (m, 2H), 1.30 (m, 4H), 0.86 (t, J = 6.78 Hz, 
3H). 13C NMR  (75.5 MHz, DMSO-d6):  δ = 146.3, 142.9, 131.0 (×2), 128.7 (×4), 
128.3, 125.4, 124.0 (×4), 121.0, 117.3 (×2), 47.3, 39.9, 34.8, 30.8, 30.5, 30.6, 21.9, 
13.8. HRMS (EI) C25H29BrN6. calcd.492.1637, found: 492. 1621. 
 
5-(3,4-Dichlorophenyl)-N-(2-(4-(4-heptylphenyl)-1H-1,2,3-triazol-1-yl)ethyl)-1H-
imidazol-2-amine ( BS-279) 
N
H
N
N
H
N
NN
Cl
Cl
C7H15
 
Yield: 80 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.66 (br s, 1H), 8.50 (s, 1H), 7.86 
(s, 1H), 7.71 (d, J = 8.3 Hz, 2H), 7.62 (m, 1H), 7.48 (d, J = 8.3 Hz, 1H), 7.22 (d, J = 
8.3 Hz, 3H), 6.06 (m, 1H), 4.61 (t, J = 5.77 Hz, 2H), 3.69 (m, 2H), 2.58 (t, J = 
7.58Hz, 2H), 1.57 (m, 2H), 1.28 (m, 8H), 0.86 (m, 3H). 13C NMR  (75.5 MHz, 
DMSO-d6):  δ = 146.1, 141.8, 130.9 (×2), 130.3, 128.6 (×3), 128.2 (×2),  126.5,124.9 
(×3), 124.8, 124.7, 121.2, 49.2, 42.8, 34.8, 31.1, 30.7, 28.5, 28.4, 22.0, 13.8. HRMS 
(EI) C26H30Cl2N6, calcd 496.1909, found : 496.1919. 
 
5-(3,4-Dichlorophenyl)-N-(3-(4-((methylamino)methyl)-1H-1,2,3-triazol-1-
yl)propyl)-1H-imidazol-2-amine (BS-283) 
N
H
N
N
H
N N
N
H
N
Cl
Cl  
Yield: 81 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.70 (br s, 1H), 7.99 (s, 1H), 7.82 
(s, 1H), 7.58 (d, J = 8.7 Hz, 1H), 7.48 (d, J = 8.2 Hz, 1H), 7.23 (s, 1H), 6.01 (m, 1H), 
4.41 (t, J = 6.95 Hz, 2H), 3.67 (m, 2H), 3.14 (m, 2H), 2.26 (s, 3H), 2.07 (t, J = 6.5 Hz, 
2H), 1.86 (s,1H) 13C NMR  (75.5 MHz, DMSO-d6):  δ = 151.4, 145.9, 135.9, 130.9 
(×2), 130.3, 126.4 (×2), 124.6, 123.4, 122.6, 47.0 (×2), 41.0, 35.4, 30.3. HRMS (EI) 
C16H19Cl2N7, calcd 389.1079, found: 389.1064. 
 
N-(3-(4-(2-Aminopropan-2-yl)-1H-1,2,3-triazol-1-yl)propyl)-5-(4-bromophenyl)-
1H-imidazol-2-amine (BS-287) 
N
H
N
N
H
N N
N
Br
H2N  
Yield: 75 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.57 (br s, 1H), 7.92 (s, 1H), 7.55 
(d, J = 8.3 Hz, 2H), 7.42 (d, J = 8.3 Hz, 2H), 7.11 (s, 1H), 5.94 (t, J = 5.6 Hz, 1H), 
4.38 (t, J = 7.0 Hz, 2H), 4.10 (m, 2H), 3.16 (m, 2H), 2.07 (m, 2H), 1.37 (s, 6H). 13C 
NMR  (75.5 MHz, DMSO-d6):  δ = 156.0, 151.3, 134.0, 131.0 (×3), 125.3 (×2), 120.1 
(×2), 117.3, 54.8, 48.5, 47.1, 30.8 (×2), 30.1. HRMS (EI) C17H22BrN7, calcd 
403.1120, found: 403.1131. 
5-(3,4-Dichlorophenyl)-N-(2-(4-cyclohexyl-1H-1,2,3-triazol-1-yl)ethyl)-1H-
imidazol-2-amine (BS-301) 
N
H
N
N
H
N
NN
Cl
Cl  
Yield: 85 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.64 (br s, 1H), 7.58 (s, 1H), 7.80 
(s, 1H), 7.60 (m, 1H), 7.48 (d, J = 8.3 Hz, 1H), 7.24 (s, 1H), 6.00 (m, 1H), 4.50 (t, J = 
5.76 Hz, 2H), 3.61 (m, 2H), 2.61 (m, 1H), 1.91 (m, 2H), 1.69 (m, 3H), 1.32 (m,5H). 
13C NMR  (75.5 MHz, DMSO-d6):  δ = 151.9, 150.6, 131.0 (×2), 130.3, 126.6 (×2), 
124.7, 123.4, 120.7, 104.1, 54.8, 49.0, 42.8, 34.5, 32.4 (×2), 25.5 (×2).HRMS (EI) 
C19H22Cl2N6, calcd 404.1283., found: 404.1278. 
 
5-(3,4-Dichlorophenyl)-N-(2-(4-propyl-1H-1,2,3-triazol-1-yl)ethyl)-1H-imidazol-
2-amine (BS-302) 
N
H
N
N
H
N
NN C3H7
Cl
Cl  
Yield: 90 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.80 (br s, 1H), 7.84 (d, J = 1.7 
Hz, 1H), 7.82 (s, 1H), 7.59 (d of d, J = 8.4, 1.7 Hz, 1H), 7.53 (d, J = 8.4 Hz, 1H), 7.26 
(s, 1H), 6.14 (br s, 1H), 4.51 (t, J = 6.04 Hz, 2H), 3.62(m, 2H), 2.56 (t, J = 7.49 Hz, 
2H), 1.57 (m, 2H), 0.89 (t, J = 7.25 Hz, 3H). 13C NMR  (75.5 MHz, DMSO-d6):  δ = 
150.4, 146.5, 135.0, 131.0 (×2), 130.4 126.8 (×2), 124.8, 123.5, 122.0, 48.8, 42.8, 
27.0, 22.0, 13.6. HRMS (EI) C16H18Cl2N6, calcd 364.0970., found: 364.0980. 
 
5-(3,4-Dichlorophenyl)-N-(3-(4-propyl-1H-1,2,3-triazol-1-yl)propyl)-1H-
imidazol-2-amine (BS-303) 
N
H
N
N
H
N N
N
C3H7
Cl
Cl  
Yield: 83 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.80 (br s, 1H), 7.88 (s, 1H), 7.83 
(d, J = 1.7 Hz 1H), 7.58 (d of d, J = 8.3, 1.7 Hz, 1H), 7.52 (s, 1H), 7.49 (s, 1H), 6.13 
(br s, 1H), 4.38 (t, J = 6.98 Hz, 2H), 3.15 (m, 2H), 2.57 (t, J = 7.51 Hz, 2H), 2.06 (m, 
2H), 1.58 (m, 2H), 0.89 (t, J = 7.51 Hz, 3H). 13C NMR  (75.5 MHz, DMSO-d6):  δ = 
150.0, 146.6, 135.1, 131.0 (×2), 130.3 126.8 (×2), 124.8, 123.5, 121.7, 54.8, 46.9, 
30.0, 27.0, 22.2, 13.5. HRMS (EI) C17H20Cl2N6, calcd 378.1127., found : 378.1114. 
 
5-(4-Bromophenyl)-N-(2-(4-propyl-1H-1,2,3-triazol-1-yl)ethyl)-1H-imidazol-2-
amine (BS-304) 
N
H
N
N
H
N
NN C3H7
Br  
Yield: 95  %.  1H NMR (300 MHz, DMSO-d6): δ = 10.63 (br s, 1H), 7.87(s, 1H), 7.62 
(m, 2H), 7.48 (d , J = 8.6 Hz, 2H), 7.17 (s, 1H), 5.98 (t, J = 5.3 Hz, 1H), 4.59 (t, J = 
6.04 Hz, 2H), 3.66 (m, 2H), 2.61 (t, J = 7.44 Hz, 2H), 1.62 (m, 2H), 0.94 (t, J = 7.21 
Hz, 3H). 13C NMR  (75.5 MHz, DMSO-d6):  δ = 150.5, 146.5, 134.6, 131.0 (×3), 
125.4 (×2), 122.0 (×2), 117.4, 48.9, 42.9, 27.0, 22.2, 13.6. HRMS (EI) C16H19BrN6, 
calcd 374.0855., found: 374.0844. 
 
5-(4-Bromophenyl)-N-(3-(4-propyl-1H-1,2,3-triazol-1-yl)propyl)-1H-imidazol-2-
amine (BS-305) 
N
H
N
N
H
N N
N
C3H7
Br  
Yield: 74 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.59 (br s, 1H), 7.89 (s, 1H), 7.55 
(d , J = 8.1 Hz, 2H), 7.42 (d , J = 8.4 Hz, 2H), 7.11 (s, 1H), 5.93 (t, J = 5.25 Hz, 1H), 
4.38 (t, J = 6.83 Hz, 2H), 3.14 (m, 2H), 2.48 (t, J = 7.62 Hz, 2H), 2.06 (m, 2H), 1.58 
(m, 2H), 0.90 (t, J = 7.35 Hz, 3H). 13C NMR  (75.5 MHz, DMSO-d6):  δ = 151.1, 
146.6, 134.6, 131.0 (×3), 125.4 (×2), 121.7 (×2), 117.4, 47.9, 30.0, 27.0 (×2), 22.2, 
13.5. HRMS (EI) C17H21BrN6, calcd 388.1011., found: 388.1023. 
 
 
(2-(3-(4-Propyl-1H-1,2,3-triazol-1-yl)propylamino)-1H-imidazol-5-
yl)(morpholino)methanone (BS-306) 
N
H
N
N
H
O
N
N N
N
C3H7
O  
Yield: 29 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.02 (br s, 1H), 7.85 (s, 1H), 7.10 
(s, 1H), 6.05 (m, 1H), 4.35 (t, J = 6.8 Hz, 2H), 3.75 (m, 4H), 3.57 (t, J = 4.31 Hz, 4H), 
3.10 (m, 2H), 2.57 (t, J = 7.42 Hz, 2H), 2.05 (m, 2H), 1.60 (m, 2H), 0.90 (t, J = 7.42 
Hz, 3H). 13C NMR  (75.5 MHz, DMSO-d6):  δ = 161.2, 150.1, 146.6, 122.8, 121.7 
(×2), 66.3 (×2), 54.8 (×2), 46.9, 44.4, 29.9, 27.0, 22.2, 13.5. HRMS (EI) C16H25N7O2, 
calcd 347.2070., found: 347.2085. 
 
(2-(2-(4-Propyl-1H-1,2,3-triazol-1-yl)ethylamino)-1H-imidazol-5-
yl)(morpholino)methanone (BS-307) 
N
H
N
N
H
N
NN
O
N
C3H7
O  
Yield: 29 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.89 (br s, 1H), 7.78 (s, 1H), 7.08 
(s, 1H), 5.98 (m, 1H), 4.45 (m, 2H), 3.74 (m, 3H), 3.58 (m, 6H), 3.16 (m, 1H), 2.56 
(m, 2H), 1.57 (m, 2H), 0.89 (t, J = 7.25 Hz, 3H). 13C NMR  (75.5 MHz, DMSO-d6):  δ 
= 161.4, 149.7, 146.5 (×2), 121.9 (×2), 66.3 (×2), 48.7 (×2), 44.4, 44.7,  27.0, 22.2, 
13.6. HRMS (EI) C15H23N7O2, calcd 333.1913., found: 333.1920. 
 
N-(2-(4-(Cyclopentylmethyl)-1H-1,2,3-triazol-1-yl)ethyl)-5-(4-fluorophenyl)-1H-
imidazol-2-amine (BS-308) 
N
H
N
N
H
N
NN
F  
Yield: 68  %.  1H NMR (300 MHz, DMSO-d6): δ = 10.63 (br s, 1H), 7.82 (s, 1H), 
7.63 (q, J = 2.9, 5.7 Hz, 2H), 7.11 (t , J = 8.7 Hz, 2H), 7.03 (s, 1H), 5.96 (t, J = 5.4 
Hz, 1H), 4.51 (t, J = 5.99 Hz, 2H), 3.61 (m, 2H), 2.59 (d, J = 7.08 Hz, 2H), 2.07 (m, 
1H), 1.66 (m, 6H), 1.70 (m, 2H). 13C NMR  (75.5 MHz, DMSO-d6):  δ = 161.8, 158.6, 
150.3, 146.2, 146.1, 130.9, 125.2, 125.1, 122.2, 115.1, 114.8, 48.9, 42.9, 31.8 (×3), 
31.0, 24.5 (×2). HRMS (EI) C19H23FN6, calcd 354.1968., found: 354.1974. 
 
N-(2-(4-Cyclopropyl-1H-1,2,3-triazol-1-yl)ethyl)-5-(4-fluorophenyl)-1H-imidazol-
2-amine (BS-309) 
N
H
N
N
H
N
NN
F  
Yield: 80  %.  1H NMR (300 MHz, DMSO-d6): δ = 10.55 (br s, 1H), 7.79 (s, 1H), 
7.64 (m, 2H), 7.10 (t , J = 8.7 Hz, 2H), 7.02 (s, 1H), 5.90 (m, 1H), 4.99 (t, J = 5.85 
Hz, 2H), 3.61 (m, 2H), 1.91 (m, 1H), 0.85 (m, 2H), 0.69 (m, 2H). 13C NMR  (75.5 
MHz, DMSO-d6):  δ = 161.8, 158.6, 150.4, 148.6 (×2), 131.1, 125.1, 125.0, 120.9, 
115.1, 114.8, 48.9, 42.9, 7.6(×2), 6.5. HRMS (EI) C16H17FN6, calcd 312.1499., found: 
312.1487. 
  
5-(4-Chlorophenyl)-N-(2-(4-cyclopentyl-1H-1,2,3-triazol-1-yl)ethyl)-4-p-tolyl-1H-
imidazol-2-amine(BS-310-B) 
N
H
N
N
H
N
NN
Cl  
Yield: 16 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.89 (br s, 1H), 7.84 (s, 1H), 7.40 
(m, 2H), 7.29 (m, 4H), 7.14 (m, 2H), 5.87 (m, 1H), 4.52 (t, J = 5.87 Hz, 2H), 3.64 (m, 
2H), 3.06 (m, 1H), 2.29 (s, 3H), 1.95 (m, 2H), 1.60 (m, 6H). 13C NMR  (75.5 MHz, 
DMSO-d6):  δ = 150.9, 150.1, 135.7, 130.0, 128.9 (×3), 128.1 (×3), 128.0 (×2), 127.2 
(×3), 121.1, 104.1, 49.0, 42.7, 36.1, 32.7 (×2), 24.6 (×2), 20.7. HRMS (EI) 
C25H27ClN6.  calcd.446.1986, found: 446.1990. 
 
 
 
 
N-(3-(4-(4-Tert-butylphenyl)-1H-1,2,3-triazol-1-yl)propyl)-5-(3,4-
dichlorophenyl)-1H-imidazol-2-amine (BS-340): 
N
H
N
N
H
N N
N
Cl
Cl  
Yield: 91 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.68 (br s, 1H), 8.53 (s, 1H), 7.82 
(s, 1H), 7.73 (d, J = 7.9 Hz, 2H), 7.57 (m, 1H), 7.43 (m, 3H), 7.25 (s, 1H) 6.02 (m, 
1H), 4.48 (t, J = 6.73 Hz, 2H), 3.20 (m, 2H), 2.14 (m, 2H), 1.30 (s, 9H). 13C NMR 
(75.5 MHz, DMSO-d6):  δ = 150.2, 146.2, 131.0, 130.3, 128.0, 126.6, 125.5 (×3), 
124.8 (×3), 124.7, 123.4, 121.0 (×2), 104.1, 47.3, 39.6, 34.2, 31.0 (×3), 29.9.HRMS 
(EI) C24H26Cl2N6, calcd 468.1596, found: 468.1602. 
 
5-(3,4-Dichlorophenyl)-N-(3-(4-(thiophen-3-yl)-1H-1,2,3-triazol-1-yl)propyl)-1H-
imidazol-2-amine (BS-341): 
N
H
N
N
H
N N
N
Cl
Cl
S
 
Yield: 80 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.67 (br s, 1H), 8.46 (s, 1H), 7.82 
(m, 2H), 7.63 (m, 1H), 7.58 (m, 1H), 7.51 (m, 2H), 7.26 (s, 1H) 6.02 (m, 1H), 4.47 (t, 
J = 6.8 Hz, 2H), 3.19 (m, 2H), 2.14 (m, 2H). 13C NMR (75.5 MHz, DMSO-d6):  δ = 
151.3, 142.8, 132.1 (×2), 131.0, 130.0, 127.0, 126.5, 125.7, 124.7, 123.4, 121.1, 120.6 
(×2), 104.1, 47.3, 39.5, 29.9. HRMS (EI) C18H16Cl2N6S, calcd 418.0534, found: 
418.0522. 
 
5-(4-Bromophenyl)-N-(2-(4-cyclopropyl-1H-1,2,3-triazol-1-yl)ethyl)-1H-imidazol-
2-amine(BS-342): 
N
H
N
N
H
N
NN
Br  
Yield: 78 %.  1H NMR (300 MHz, DMSO-d6): δ = 10.56 (br s, 1H), 7.80 (s, 1H), 7.60 
(d, J = 7.3 Hz, 2H), 7.43 (d, J = 7.3 Hz, 2H), 7.14 (s, 1H), 5.93 (m, 1H), 4.49 (t, J = 
5.48 Hz, 2H), 3.59 (m, 2H), 3.16 (d of d, J = 5.2, 1.4 Hz, 1 H), 0.87 (m, 2H), 0.69 (m, 
2H). 13C NMR  (75.5 MHz, DMSO-d6):  δ = 150.4, 148.7 (×3), 131.0, 130.9, 125.3, 
120.9 (×3), 117.4, 48.9, 42.8, 7.5 (×2), 6.5. HRMS (EI) C16H17BrN6, calcd 372. 0698, 
found: 372.0689. 
 
4.9 Representative NMR spectra    
4.9.1 1H and 13C NMR spectra of bs-272 
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4.9.2 1H and 13C NMR spectra of bs-304 
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Chapter-5 
“Crystal and Molecular Structure Analysis of DP-7: A New 
Multi Drug Resistance Reverter Lead Molecule” 
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The synthesis of this 3,5-Dibenzoyl-4-(3-methoxyphenyl)-1,4-dihydro-2,6-dimethyl 
pyridine DP7, bearing dibenzoyl groups at C(3) and C(5), respectively, has been 
achieved by applying the modified Hantzsch-type condensation of 1,3-Diketone (2 
equiv) and aromatic aldehydes (1 equiv) using ammonium carbonate as nitrogen 
source. The product obtained was characterized by spectroscopic techniques & in 
order to correlate structure activity relationship, the X-ray crystallographic study of 
DP-7 has been carried out. 
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5.1 Introduction 
 
The membrane efflux protein P-glycoprotein, a member of the ATP binding cassette 
(ABC) family, recognizes and transports structurally, chemically, and  
armacologically diverse hydrophobic compounds, giving rise to a phenomenon known 
as multidrug resistance (MDR). Development of MDR is one of the main reasons of 
failure in cancer chemotherapy, as tumour cells, by increasing drug efflux, acquire 
cross-resistance to many structurally and functionally unrelated anticancer agents, 
which therefore never achieve effective intracellular concentrations1. In the past few 
years, extensive studies have been performed with the aim of developing effective 
chemo sensitizers to overcome MDR of human cancer cells. Potent P-glycoprotein 
inhibitors have been tested in clinical trials so far, including Ca2+ channel blockers 
such as verapamil and dihydropyridines2,3. However, clinical application of these 
agents has not been extensively pursued to date, owing to their unwanted and 
sometimes life threatening cardiovascular side effects such as atria-ventricular block 
and hypotension. As a consequence, in the last few years, much attention has been 
focused on congeners of these first generation-MDR inhibitors, in order to develop 
compounds characterized by appropriate potency and selectivity but also by reduced 
cardiovascular toxicity. 
 
Very recently, 3,5-Dibenzoyl-4-(3-phenoxyphenyl)-1,4-dihydro-2,6-dimethylpyridine 
(DP7) was proposed as a new MDR reverter. It was found that DP7, at a 
concentration two order of magnitude higher than its IC50 as a P-glycoprotein 
inhibitor, was devoid of cardiovascular effects in in vitro rat preparations4,5. These 
data were not considered sufficient evidence of DP7 safety before this drug could be 
subjected to clinical investigation. Several 1,4 dihydropyridine calcium antagonists 
are substrate of CYP enzymes. In particular, CYP3A4 metabolizes dihydropyridines 
into the corresponding pyridines6. The dihydropyridine can also inhibit the activity of 
CYP3A4. For example, Katoh7 reported that nicardipine, benidipine, maidipine and 
barnidipine strongly inhibited human CYP3A4 activity, while nivaldipine, nifedipine, 
nitrendepine and amlodipine exhibited a weak inhibition. 
 
The DP-7 was very well explored for variety of biological activity8. It was very 
important to study the X-ray Crystal structure of this molecule which was not studied 
so far and therefore development of single crystal was taken up in the current work. 
Thus the synthesis was optimized and studied. 
 
5.2 Reaction Scheme 
5.2.1 Scheme-1 1-phenylbutane-1,3-dione 
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5.2.2 Scheme-2 DP-7 
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5.3 Method of Crystallization 
 
0.1gm of DP-7 was taken in 25 ml of methanol into 50ml single neck RBF and 
Charcoal (2 g) was added. The solution was heated up to reflux temperature on a 
water bath for 45 min. The solution was filtered, while hot through Whatmann 42 
filter paper. The resulting solution was kept in a stopper conical flask slightly opened. 
After 10 days, crystals grew in cubic shape due to thin layer evaporation. They were 
filtered and washed with chilled methanol. 
5.4 Crystal structure determination: 
 
A single crystal of suitable size was chosen for X-ray diffraction studies. The data 
were collected at room temperature on a DIPLabo Image Plate system with graphite 
monochromated radiation MoKα. Each exposure of the image plate was set to a period 
of 400 s. Thirty-six frames of data were collected in the oscillation mode with an 
oscillation range of 5˚ and processed using Denzo9. The reflections were merged with 
Scalepack. All the frames could be indexed using a primitive trilinic lattice. The 
structure was solved by direct methods using SHELXS-9710. Least-squares refinement 
using SHELXL-9710with isotropic displacement parameters for all the non-hydrogen 
atoms converged the residual to 0.1999. Subsequent refinements were carried out with 
anisotropic thermal parameters for the non-hydrogen atoms. After eight cycles of 
refinement the residuals converged to 0.0578. The hydrogen atoms were fixed at 
chemically acceptable positions, and were allowed to ride on their parent atoms.  
 
5.5 Results and discussion: 
 
The details of crystal data and refinement are given in Table 1. The bond lengths and 
bond angles of all the non-hydrogen atoms (Table 2 and 3.) and are in good agreement 
with the standard values10. Figure 1 represents the ORTEP12 diagram of the molecule 
with thermal ellipsoids drawn at 50% probability.  
 
In the title compound C33H27NO3, the 1,4-dihydropyridine ring is in boat 
conformation, with atoms N1 and C4 deviating from the plane13 (Cremer and Pople, 
1975) defined by the atoms N1/C2/C3/C4/C5/C6 by 0.1793(2)Å and 0.271(2)Å, 
respectively. The 1,4-dihydropyridine ring is puckered. The puckering parameters are 
Q = 0.406(2)Å, θ =106.0(3)˚ and Φ =2.4(3)˚. The dihedral angle between the least 
squares planes of the ring 1 and 2 is 87.70(1)˚, indicating that the ring 2 is nearly 
orthogonal to the dihydropyridine ring. The dihedral angles between the plane (1,3), 
(1,4) and (3,4) are 60.74(1)˚, 53.54˚ and 79.49˚, respectively. The structural 
conformation of carbomyl groups at C3 and C5 position is described by the torsion 
angle values of 50.09˚ and 161.10˚ and have -syn-periplanar and -anti-periplanr 
conformations. The structure exhibits coplanarity of the carbomyl group (C=O) with 
the conjugated double bond of the 1,4-dihydropyridine ring. The structure exhibit 
both inter and intramolecular hydrogen bonds of the type N–H. . .O and C–H. . .O, the 
hydrogen bonds bind the molecules into infinite one- dimensional chain. The 
observed hydrogen bonds are listed in Table 4. The packing of the molecules down b 
axis is shown in the Figure 2. 
 
 
Empirical formula C33H27NO3 
Formula weight 485.56 
Temperature 293 k 
Wavelength 0.71073 Å 
Crystal system Triclinic 
Space group Pī 
Cell dimensions 
a = 7.4310(6Å), b =12.2580(16)Å, c = 
14.4180(17)Å, α = 92.066(3)˚, β=95.319(7)˚, γ= 
96.235(7)˚ 
Volume 1298.5(3)Å3 
Z 2 
Density(calculated) 1.242Mg/m3 
Absorption coefficient 0.079 mm-1 
F000 512 
Crystal size 0.30 x 0.27 x 0.25 mm 
Theta range for data collection 3.07˚ to 25.02˚ 
Index ranges -8<=h<=8, -14<=k<=14, -17<=l<=17 
Reflections collected 6548 
Independent reflections 4085 
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4085 / 0 / 337 
Goodness-of-fit on F2 1.035 
Final R indices [I > 2σ(I)] R1 = 0.0578, wR2 = 0.1493 
R indices (all data) R1 = 0.0728, wR2 = 0.1624 
Extinction coefficient 0.045(8) 
Largest diff. peak and hole 0.446 and -0.315e.Å-3 
Deposition number CCDC 
 
Table-1: Experimental crystallographic data 
 
 
Atoms Length(Å) Atoms Length (Å) 
N1-C2 1.374(2) C17-C18 1.369(5) 
N1-C6 1.392(3) C18-C19 1.354(6) 
C2-C3 1.377(3) C19-C20 1.331(7) 
C2-C8 1.495(3) C20-C21 1.334(6) 
C3-C30 1.456(3) C22-O23 1.217(3) 
C3-C4 1.509(3) C22-C24 1.502(3) 
C4-C5 1.524(3) C24-C25 1.385(3) 
C4-C9 1.535(3) C24-C29 1.390(3) 
C5-C6 1.343(3) C25-C26 1.383(4) 
C5-C22 1.480(3) C26-C27 1.365(5) 
C6-C7 1.497(3) C27-C28 1.370(6) 
C9-C10 1.377(3) C28-C29 1.376(5) 
C9-C14 1.390(3) C30-O31 1.241(2) 
C10-C11 1.388(3) C30-C32 1.493(3) 
C11-C12 1.358(4) C32-C33 1.388(3) 
C12-C13 1.372(4) C32-C37 1.390(3) 
C13-C14 1.383(4) C33-C34 1.382(3) 
C13-O15 1.392(3) C34-C35 1.372(4) 
O15-C16 1.387(3) C35-C36 1.379(4) 
C16-C17 1.353(4) C36-C37 1.378(3) 
C16-C21 1.362(5)   
 
Table-2:  Bond lengths (Å)  
 
Atoms Angle(˚) Atoms Angle(˚) 
C2-N1-C6 122.62(2) C21-C16-O15 117.5(3) 
N1-C2-C3 118.10(2) C16-C17-C18 118.2(3) 
N1-C2-C8 113.33(2) C19-C18-C17 119.5(4) 
C3-C2-C8 128.53(2) C20-C19-C18 121.0(4) 
C2-C3-C30 126.66(2) C19-C20-C21 120.7(4) 
C2-C3-C4 118.06(2) C20-C21-C16 119.1(3) 
C30-C3-C4 115.09(2) O23-C22-C5 123.7(2) 
C3-C4-C5 108.93(1) O23-C22-C24 119.5(2) 
C3-C4-C9 114.15(2) C5-C22-C24 116.65(2) 
C5-C4-C9 109.54(2) C25-C24-C29 118.8(3) 
C6-C5-C22 122.16(2) C25-C24-C22 121.4(2) 
C6-C5-C4 118.62(2) C29-C24-C22 119.7(2) 
C22-C5-C4 119.04(2) C26-C25-C24 120.6(3) 
C5-C6-N1 117.99(2) C27-C26-C25 119.9(3) 
C5-C6-C7 127.0(2) C26-C27-C28 120.0(3) 
N1-C6-C7 114.96(2) C27-C28-C29 120.9(3) 
C10-C9-C14 117.8(2) C28-C29-C24 119.8(3) 
C10-C9-C4 123.18(2) O31-C30-C3 118.58(2) 
C14-C9-C4 118.97(2) O31-C30-C32 117.36(2) 
C9-C10-C11 120.7(2) C3-C30-C32 123.99(2) 
C12-C11-C10 121.3(3) C33-C32-C37 119.10(2) 
C11-C12-C13 118.6(2) C33-C32-C30 118.92(2) 
C12-C13-C14 121.0(2) C37-C32-C30 121.67(2) 
C12-C13-O15 116.8(2) C34-C33-C32 120.4(2) 
C14-C13-O15 122.0(3) C35-C34-C33 120.1(2) 
C13-C14-C9 120.5(2) C34-C35-C36 119.9(2) 
C16-O15-C13 119.0(2) C37-C36-C35 120.6(2) 
C17-C16-C21 121.5(3) C36-C37-C32 119.9(2) 
C17-C16-O15 120.8(3)   
Table-3:  Bond angles (˚) 
 
 
 
Atoms Length (Å) Angle(˚) Symmetry codes 
N1–H1. . .O31 2.999(2) 156 1 + x, y, z 
 
Table-4:  Hydrogen bonding geometry 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.-1:  ORTEP of the molecule with thermal ellipsoids drawn at 50% 
probability. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.-2: Packing of the molecules when viewed down the a axis. The dashed line 
represents the hydrogen bond. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.-3: Packing of the molecules when viewed down the b axis. The dashed line 
represents the hydrogen bond. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.-4: Packing of the molecules when viewed down the c axis. The dashed line 
represents the hydrogen bond. 
 
5.6 Conclusion: 
 
3,5-Dibenzoyl-4-(3-methoxyphenyl)-1,4-dihydro-2,6-dimethyl pyridine (DP-7) has 
been shown to be a powerful P-gp inhibitor, almost devoid of cardiovascular effects, 
but capable of inhibiting liver CYP3A, thus it can be conclude that DP-7 is a good 
lead compound for the synthesis of new dihydropyridines. As DP-7 shown promising 
MDR activity and looking to the scientific publications of DP-7, studied of X-ray 
crystal structure of DP-7 performed.   
 
5.7 Experimental: 
 
5.7.1 Preparation of 1-phenylbutane-1,3-dione 
 
Cool peaces of freshly prepared sodium methoxide (6 gm) at 0 oC using ice cold 
water. To that added ethyl acetate (100 ml) slowly and stirred at 0 oC for 10 min. to 
that solution added acetophenone (30 ml) drop wise over 45 min and stirred for 
another 12 hrs. After completion of reaction filtered the reaction mass, washed with 
diethyl ether and dried in rotavap. After that dissolved the crude product in to water 
and filter it to removed unwanted crude material. To that filtrate added gl. acetic acid 
to set Ph 3. Solid formed was filtered and dried to give titled compound as white 
powder (mp. 61 oC). 
5.7.2 Synthesis of 3,5-Dibenzoyl-4-(3-methoxyphenyl)-1,4-dihydro-2,6-dimethyl 
pyridine(DP-7) 
 
To a solution of 1-phenylbutane-1,3-dione (20mmol) in dry methanol (25ml), 3-
phenoxybenzaldehyde (10mmol) and  ammonium carbonate (1.5g) was added and the 
reaction mixture was refluxed for 18hrs with vigorous stirring. After completion of 
the reaction, reaction mixture was cooled to RT and was poured on to ice-water 
mixture (100ml) and extracted with dichloromethane (2 x 100ml). The organic 
extracts were combined and dried over sodium sulfate and the solvent was removed at 
reduced pressure. The residue was subjected to the column chromatography (silica 
gel; Hexane-Ethyl acetate, 5:5 v/v) to give titled compound as light yellow crystals 
(M.P. 190-192°C). 
 
5.8 Characterization 
3,5-Dibenzoyl-4-(3-methoxyphenyl)-1,4-dihydro-2,6-dimethyl pyridine(DP-7) 
N
H
Ph
O
Ph
O
O
Ph
 
1H NMR (400 MHz CDCl3): δ = 7.57-7.53 (m 4H), 7.46-7.42 (m 2H), 7.36-7.31 (m 
4H), 7.28-7.24 (m 2H), 7.10-7.02 (m 2H), 6.86-6.84 (m 2H), 6.72-6.70 (d of d 2H, J = 
2,2), 6.67 (t 1H, J =2), 5.68 (s 1H), 5.15 (s 1H), 1.92 (s 6H). 13C NMR (400 MHz 
CDCl3): δ = 197.8 (×2), 157.2 (×2), 147.8 (×2), 140.3 (×2), 131.5, 129.8 (×3), 129.2 
(×2), 128.4 (×4), 128.2 (×4), 122.8, 122.3, 118.5, 117.9 (×2), 117.1, 112.6 (×2), 43.7, 
19.0 (×2).    MS (m/z): 485 (M+, 62%), 316 (100%). IR (KBr, cm-1): 3396(N–H 
stretching), 3030(C-H stretching, Asymmetric), 2930(C–H stretching, Symmetric), 
1703(C=O stretching, ester), 1670(C=O stretching, ketone), 1589(N–H deformation).  
 
5.9 Representative NMR spectra    
5.9.1 1H NMR spectra of bs-DP-7 
 
 
 
 
 
 
 
5.9.2 13C spectra of bs-DP-7 
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SUMMARY 
 
The work represented in the thesis entitled “Synthesis and Characterization of New 
heterocyclic compounds & their application” is divided into five chapters which can 
be summarized as under. 
 
Chapter-1 covers basic introduction to Microwave assisted organic synthesis 
including comparison of conventional vs microwave assisted reaction and 
introduction of 2-aminoimidazole and their presence as naturally occurring marine 
alkaloids described. In this part various synthetic approaches toward 2-
aminoimidazole and short review on 2-aminoimidazole as pharmacophores also 
presented. Finally basic concept of anti biofilm activity described.   
 
Chapter-2 deals with microwave assisted one pot synthesis and Structure Activity 
Relationship of 2-Hydroxy-2-phenyl-2,3-dihydro-imidazo[1,2-a] pyrimidinium Salts 
and 2N-Substituted 4(5)-Phenyl-2-Amino-1H-imidazoles as Inhibitors of the Biofilm 
Formation by Salmonella Typhimurium and Pseudomonas aeruginosa. 
 
Chapter-3 entitled “Structure Activity Relationship of N1-Substituted 2-
Aminoimidazoles as Inhibitors of Biofilm Formation by Salmonella Typhimurium 
and Pseudomonas aeruginosa.” In this chapter a library of N1-substituted 4(5)-phenyl-
2-aminoimidazoles was synthesized and tested for the antagonistic effect against 
biofilm formation by Salmonella Typhimurium and Pseudomonas aeruginosa. The 
substitution pattern of the 4(5)-phenyl group and the nature of the N1-substituent were 
found to have a major effect on the biofilm inhibitory activity. The most active 
compounds of this series were shown to inhibit the biofilm formation at low 
micromolar concentrations.   
 
Chapter-4 deals with microwave-assisted Cu-catalyzed one pot protocol for the 
synthesis of 2-aminoimidazole-triazole framework via two consecutive steps of 
dimorth rearrangement and click reaction was demonstrated. Library of 22 
compounds have been synthesized and were subjected to test for antibiofilm activity. 
However, the antibiofilm activities of these classes of compounds are under pipeline. 
 
After careful study of Structure Activity Relationship, a fresh libraries of N1-
substituted 2-aminoimidazoles and N1-unsubstituted 2-aminoimidazoles have been 
synthesized and tested for anti biofilm activity. In Chapter-4 microwave assisted one 
pot protocol for synthesis of 2-aminoimidazole-triazoel framework has been described 
and all newly synthesized compounds were tested for antibiofilm activity. However 
activities of these calls of compounds are under pipeline.  
 
Chapter-5 entitled “Crystal and molecular structure analysis of DP-7: A new Multi 
Drug Resistance Reverter Lead Molecule” deal with crystal and molecular structure 
analysis. 3,5-Dibenzoyl-4-(3-methoxyphenyl)-1,4-dihydro-2,6-dimethyl pyridine 
(DP-7) has been shown to be a powerful P-gp inhibitor, almost devoid of 
cardiovascular effects, but capable of inhibiting liver CYP3A, thus it can be conclude 
that DP-7 is a good lead compound for the synthesis of new dihydropyridines. As DP-
7 demonstrated promising MDR activity, several scientific publications on this 
molecule appeared. However study of X-ray crystallography was done first time and 
presented in the current work.   
 
All newly synthesized compounds have been characterized by 1H NMR, 13C NMR 
and HRMS. Some representative copy of 1H and 13C NMR spectra also presented. 
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Abstract An efficient microwave-assisted one-pot two-step
protocol was developed for the construction of disubstituted
2-amino-1H -imidazoles. This process involves the sequen-
tial formation of 2,3-dihydro-2-hydroxyimidazo[1,2-a]pyri-
midinium salts from readily available 2-aminopyrimidines
and α-bromoketones, followed by cleavage of the pyrimi-
dine ring with hydrazine.
Keywords Heterocycles · 2-Aminoimidazoles ·
Microwave-assisted synthesis · Ring opening ·
Rearrangement
Introduction
The class of 2-aminoimidazoles has recently attracted partic-
ular interest due to various biological properties of these com-
pounds. 2-Aminoimidazole alkaloids and their metabolites,
isolated from the marine sponges Hymeniacidon sp., have
been described as potent antagonists of serotonergic [1] and
histaminergic receptors [2]. Naamine and isonaamine alka-
loids from the marine sponges Leucetta sp. exhibit antiviral
and anticancer activity [3–10]. Because of these interesting
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Scheme 1 Synthesis of substituted 2-amino-1H -imidazoles
biological activities, numerous synthetic routes to 1-substi-
tuted and 1-unsubstituted 2-aminoimidazoles have been
reported. Modern synthetic methods for accessing 1-unsub-
stituted 2-amino-1H -imidazoles can be roughly classified
as heterocyclization of substituted or protected guanidines
with 1,2-dielectrophiles [11,12], heteroaromatic nucleophilic
substitution, and recyclization of 2-aminooxazoles [13].
Although different substituted guanidines are readily avail-
able and can be prepared in situ (e.g., from cyanamides [14]),
the high basicity of guanidines together with non-regioselec-
tivity often leads to multiple products. Protection by acetyl
[11] and Boc-groups [12] requires, in turn, acidic deprotec-
tion conditions.
Recently, we have described two new approaches to the
synthesis of substituted 2-amino-1H -imidazoles 1. The first
approach is based on the cleavage of imidazo[1,2-a]pyrimi-
dines [15] 2 with hydrazine (Scheme 1, route A) [16]. In the
second approach, the hydrazinolysis of 2-hydroxy-2,
3-dihydroimidazo[1,2-a]pyrimidinium salts 3 followed
by Dimroth-type rearrangement afforded trisubstituted
2-amino-1H -imidazoles 1 (Scheme 1, route B) [17].
2-Hydroxy-2,3-dihydroimidazo[1,2-a]pyrimidinium salts
3 can be easily prepared from 2-aminopyrimidines 4 with
α-bromoketones 5 under microwave irradiation (Scheme 2).
We found that the outcome of this reaction strongly depends
on the temperature [18]. The microwave-assisted reaction
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Scheme 2 Competitive
formation of 1-unsubstituted
and 1-substituted
2-amino-1H -imidazoles upon
microwave irradiation
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Table 1 Investigation of the
condensation under
conventional heating and
microwave irradiation
All reactions were carried out on
a 1 mmol scale of
2-methylaminopyrimidine
(1, R1 = Me) with 1.35 equiv. of
α-phenacylbromide (2, R2 = Ph)
in MeCN (5 mL)
a Isolated yield after
recrystallization from MeCN
N
N
N
Ph
OH
Me
Br
3
N
N
N
Ph
Me
6
+
N
N
NHMe
+ Br
Ph
O
4 (R1 = Me) 5 (R2 = Ph)
Conditions Br
Entry Conditions Time (min) T ( ◦C) 3 (Yield %)a 6 (Yield %)a
1  30 80 64 0
2 60 80 77 0
3 30 100 81 Traces
4 60 100 85 Traces
5 30 120 68 17
6 60 120 53 28
7 MW 30 80 88 0
8 60 80 85 0
9 30 100 48 33
10 60 100 45 35
11 30 120 12 79
12 60 120 Traces 84
between 2-aminopyrimidines 4 and α-bromoketones 5 per-
formed at 80–100 ◦C gave 2-hydroxy-2,3-dihydroimi-
dazo [1,2-a]pyrimidinium salts 3, while irradiation of the
reaction mixture at temperatures above 100 ◦C provided
aromatic 1-substituted imidazo[1,2-a ]pyrimidinium salts
6 (Scheme 2). The hydrazinolysis of the salts 3 and 6 leads to
the corresponding 1-unsubstituted and 1-substituted
2-amino-1H -imidazoles 1 and 7. Thus, by performing the
reaction at 130−150 ◦C, we were able to prepare a library of
1,4,5-trisubstituted 2-aminoimidazoles 7 via a one-pot two-
step protocol [18].
In continuation of our ongoing studies, herein we report
a simple one-pot procedure for the synthesis of 1-unsubsti-
tuted 2-amino-1H -imidazoles 1 from 2-aminopyrimidines 4
and α-bromoketones 5 under microwave irradiation.
Results and discussion
We carefully investigated the formation and dehydratation of
salt 3 resulting in the formation of salt 6 under conventional
heating conditions as well as upon microwave irradiation.
As a proof of concept, the condensation of 2-methylamino-
pyrimidine (4, R1 = Me) and α-phenacylbromide (5, R2 = Ph)
was studied (Table 1). A sealed vial containing a solution of
the starting compounds in acetonitrile was conventionally
heated with an oil bath (Table 1, entries 1–6) or irradiated
with microwaves (Table 1, entries 7–12) at different tem-
peratures for 30–60 min. The formation of the 2-hydroxy
salt 3 was faster under microwave irradiation, and this com-
pound was obtained in 88% yield within 30 min. Further
increase of the temperature up to 120 ◦C using conventional
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Table 2 Microwave-assisted
synthesis of substituted
2-amino-1H -imidazoles 1
N
H
R1HN
N R2N
N
NHR1
O
R2
Br +
1. MW  80 °C
    MeCN 30 min
2. N2H4, MW  90 °C
    MeCN 10 minN
N
N
R2
OH
R1
13
4
5
Br
entry 2-aminopyrymidine 4 α–bromoketone 5 product 1 yield 
(%)a 
1 
N
N
NH2
 
Br
O
Ph
N
N
H
H2N
Ph
1{1}
 
75 
2 
N
N
NH2
 
Br
O
F
N
N
H
H2N
F
1{2}
 
79 
3 
N
N
NH2
 
Br
O
Cl
N
N
H
H2N
Cl
1{3}
 
88 
4 
N
N
N
H
Me
 
Br
O
OMe
OMe
N
N
H
HN
OMe
1{4}
MeO
Me
 
48 
5 
N
N
N
H
Piperonyl
 
Br
O
 
N
N
H
HN
1{5}
Piperonyl
 
72 
6 
N
N
N
H
Pr
 
Br
O
Cl
Cl
N
N
H
HN
Cl
1{6}
ClPr
 
70 
heating or microwave irradiation led to a mixture of salts 3
and 6 (Table 1). Interestingly, using microwave irradiation at
120 ◦C for 60 min, we were able to drive the reaction com-
pletely to the formation of the imidazo[1,2-a]pyrimidinium
salt 6 (Table 1, entry 12).
As the transformation of salts 3 into salts 6 is relatively
rapid at the temperatures above 100 ◦C, the synthesis of
salts 3 was conducted at 80 ◦C. Treatment of substituted
2-aminopyrimidines 4 with 15 mol% excess of α-bromok-
etones 5 in MeCN under microwave irradiation for 30 min
generated the intermediate salts 3 which, in most cases, pre-
cipitated from the reaction mixture upon cooling (Table 2).
Reaction progress was monitored by mass-spectrometry.
In all the cases examined, the reaction appeared to be com-
plete after 30 min. The cleavage step was performed under
microwave irradiation at 90 ◦C, using seven equivalents of
123
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Table 2 continued
9 
N
N
N
H
Pentyl
Br
O
Cl
N
N
H
HN
1{9}
Cl
Pentyl 61 
10 
N
N
N
H
Hexyl
Br
O
F
N
N
H
HN
1{10}
Hexyl
F
69 
11 
N
N
N
H
PMB
Br
O
Br
N
N
H
HN
1{11}
PMB Br 44 
12 N
N
N
H
Cyclooctyl Br
O
SO2Me
N
N
H
HN
1{12}
SO2Me
Cyclooctyl 66 
13 
N
N
N
H
Bu
Br
O
N
N
H
HN
1{13}
Bu 83 
14 
N
N
N
H
PMB
Br
O
NO2
N
N
H
HN
1{14}
NO2
PMB 89 
7 
N
N
N
H
 
Br
O
SO2Me
N
N
H
HN
1{7}
SO2Me
 
73 
8 
N
N
N
H
Octyl
Br
O
Cl
N
N
H
HN
1{8}
Cl
Octyl 79 
hydrazine hydrate. Based on the data given in Table 2, the
reaction appears to be compatible with both aryl and alkyl
substitutions. All the reactions were clean, smooth, and pro-
vided the products 1{1–18} in good and high yields. The
compounds were purified by column chromatography using
5–10% MeOH in CH2Cl2 as the eluent. All the final 2-amino-
1H -imidazoles 1{1–18} were characterized by 1H and 13C
NMR spectroscopy. Their compositions were also confirmed
by HRMS.
In conclusion, we have developed a simple and practical
microwave-assisted procedure for the preparation of substi-
tuted 2-amino-1H -imidazoles. We have investigated a one-
pot synthesis and cleavage of 2-hydroxy-2,3-dihydroimidazo
[1,2-a]pyrimidinyl-4-ium bromides by hydrazine hydrate and
found microwave irradiation to be very effective in this regard.
A small library of 2-amino-1H -imidazoles was synthesized
for screening for potential antiviral and antibacterial
activities.
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Table 2 continued
All the reactions were carried
out on a 4 mmol scale of
2-alkylaminopyrimidine 4 with
1.15 equiv of α-bromoketone 5
in MeCN (3 mL)
a Isolated yield after column
chromatography
15 
N
N
N
H
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Br
O
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N
N
H
HN
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16 
N
N
N
H
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SMe
1{16}
53 
17 N
N
N
H
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Br
O
NO2
1{17}
N
N
H
HN
OMe
NO2
61 
18 
N
N
N
H
Br
O
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1{18}
N
N
H
HN
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60 
Experimental section
Microwave irradiation experiments
A monomode CEM-Discover microwave reactor (CEM Cor-
poration, P.O. Box 200, Matthews, NC 28106) was used
in the standard configuration as delivered, including propri-
etary software. All the experiments were carried out in sealed
microwave process vials (10 mL) at the maximum power and
temperature, as indicated in the tables. After completion of
the reaction, the vial was cooled to 50 ◦C via air-jet cooling
before it was opened.
General procedure for the one-pot two-step microwave-
assisted synthesis of 2-amino-1H -imidazoles 1{1–18}
In a microwave, vial (10 mL) was successively dissolved
in dry MeCN (3 mL), the corresponding 2-aminopyrimidine
(4 mmol) and α-bromoketone (4.6 mmol). The reaction tube
was sealed and irradiated in a microwave reactor at a ceiling
temperature of 80 ◦C and a maximum power of 50 W for
30 min. After the reaction mixture was cooled with an air
flow for 15 min, hydrazine hydrate (0.9 mL, 28 mmol of a
64% solution, 7 equiv.) was added, and the mixture was irra-
diated at a ceiling temperature of 90 ◦C and a maximum
power of 50 W for another 10 min. After the reaction mixture
was cooled, hydrazine hydrate was removed by distillation
with toluene (3×20 mL). The resulting residue was purified
by column chromatography (silica gel; MeOH-DCM 1:9 v/v
with 0.5% of 6 N ammonia in MeOH) to afford 1 as amor-
phous solid.
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